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New Ant i mu s c ar i n i c  Agent s  for I mproved Treatment of  Po i son i ng by 
Cho l i nesterase  I n h i b i tors  
ABSTRACT 
A d i s s e rt at i on subm i tted i n  part i a l ful f i l l ment  of  the requ i re ­
men t s  for t h e  degree of  Doctor o f  Ph i l o sophy i n  Med i c i na l  Chem i s try 
at t he  Med i ca l  Co l l ege  of  V i rg i n i a ,  V i rg i n i a  Commonwea l t h  Un i vers i ty .  
Robert Lee Hud ki n s ,  Ph . D .  
Med i ca l  Co l l ege  o f  V i rg i n i a/V i rg i n i a  Commonwea l th  U n i vers i ty 
Adv i sor : J ames F .  Stubb i n s ,  Ph . D .  
Po i so n i ng by org anophosphate  cho l i nesterase  i n h i b i tors  re s u l t s  
i n  a rap i d  r i s e  i n  acetyl cho l i ne ( AC h )  i n  t he  synapse  and many 
p ronounced p harmacol og i ca l  effec t s  i n  n umero u s  t i s s ues  i n  the body . 
The  t reatment for org anophosphorus  po i son i ng i nvol ves  admi n i strat i on 
o f  a cho l i nestera se - react i vat i ng ox i me to restore t he  act i v i ty o f  the  
cho l i n e s terase  and an ant i mu s c ar i n i c  agent  to bl oc k the  response  to  
the  exc e s s  ACh . Pre sent l y  atrop i ne i s  the  s tandard ant i muscar i n i c  
agent u sed c l i n i ca l l y  a s  a n  ant i dote . Th i s  research  was  d i rected 
toward f i nd i ng an ant i mu s c ar i n i c  agent better than  atrop i ne a s  an  
a n t i dote . 
S i nce  caram i phen  and  aprophen have been reported to be effec t i ve 
ant i dotes  we synthes i zed n umerous  structural  var i at i on s  of  these  
mol ecu l e s  w i t h the  a i m  o f  enh anc i ng the  ant i mu s c a r i n i c  and a nt i dotal  
propert i e s .  Many of  these  compounds  showed enhanced ant i mu scar i n i c  
xi i i 
propert i es .  We syn the s i zed ana l og s of  c arami phen  wh i ch have d i f ­
ferent subst  i tuen t s  i n  t he  para pos  i t  i on of  the  p henyl r i  ng . The  
purpose o f  t he  set  was  to  test  the  e ffect o f  d i fferent  s u bs t i tuents  
on  t he  ant i mu s c ar i n i c  and ant i dota l  act i v i ty and to  l ook  for any 
pos s i bl e  rel a t i on s h i p  o f  act i v i ty w i t h  s ub st i tuent parameters  such  a s  
H a nvnett ' s  s i gma ( 0') o r  Han s c h ' s  p i  ('iT') va l ues . F our  s ubs t i tuents  
were s e l ected wh i ch have extreme va l ues  for s i gma and  p i  i n  a 
pos i t i ve o r  negat i ve d i rect i on ,  i n  a l l comb i nat i on s .  The  s ubst i t u ­
ent s  chosen  for u s e  i n  t h  i s  approach were t h e  ami  no  ( - 0', -/l); 1 - '  
tetrazol yl  ( +0', -'il); 1 - pyrrol i d i nyl  (-0', + iT') ;  and the  t r i fl uoro ­
methyl ( +0', +71) . 
Some N - s u b s t i tuted - 1 , 6 - hexaned i am i nes  were synthes i zed to 
exam i ne the  SAR for ant i mu s c ar i n i c  and ant i dotal  propert i es o f  t h i s  
s er i e s . I n  a b i nd i ng a s s ay these  compounds s howed moderate aff i n i ty 
w i t h  a preference for the  M2 receptor s ubtype . I t  was  determ i ned the  
b i s -quatern a ry s t ructure was  not mandatory for muscar i n i c  act i v i ty .  
The  opt i mum compound o f  t h i s  s er i es was  N , N ' - d i methyl - N , N ' - b i s [ 3 - ( 2 -
phtha l i mi do ) propyl ]- 1 , 6 - hexaned i am i n e .  
Al s o ,  a n umber of  l i terature and curren t l y  manufactured ant i mu s ­
c ar i n i c s were obt a i ned . Al l of  t h e  compounds  are be i ng s creened i n  a 
n umber o f  in vitro and  in vivo a s s ays des i gned to g i ve i nformat i on on 
the  SAR for the p harmacol og i ca l  propert i e s  wh i ch m i g ht  be i mport ant 
as an  ant i dote . 
Current i n format i on from th i s  research i nd i cates  the  best 
a nt i dotes  are not t he  be st  ant i mu s c ar i n i c s i n  the  pharmacol og i ca l  
a s s ays . Good central  ant i mu scar i n i c  act i v i ty i s  the  p r i mary property 
x iv 
of a good ant i dote , a l though the  ant i dota l  e ffect i vene s s  of  an agent 
can  not be descr i bed so l e l y  based on  i t s ant i mu s c ar i n i c  propert i es .  
I .  I NTRODUCT ION 
A .  H i stor i ca l  Background 
Long before acetyl cho l i ne ( AC h )  was  recogn i zed to be a c h em i ca l  
transmi tter , the  presence i n  the bl ood o f  a n  enzyme capabl e of  
degrad i ng ACh had  been postu l ated by  S i r  . Henry Dal e !. The  f i rst  
ex i stence o f  such  an e s terase  hydro l yz i ng ACh was  demo n s t rated i n  
b l ood p l a sma by Staedman and coworkers  i n  1 93 22 . Exten s i ve s t ud i e s 
d u r i ng t he  fol l ow i ng years  contr i buted i nforma t i on  on d i fferent types  
of  acetyl cho l i nesterases  ( AC h E s ) ,  t he i r  k i ne t i c  propert i e s ,  and 
d i s t r i but i on i n  exc i tabl e t i s s ues . 
Drugs that  i nh i b i t  ACh E  are ca l l ed ant i cho l i nesterase  agen t s . 
They cause  ACh to accumu l ate at chol i nerg i c  receptor s i tes  and t hu s  
are capabl e of  produc i ng effect s  equ i va l ent to  exces s i ve s t i mu l at i on 
of  chol i ne rg i c  receptors  throughout  the  central  and per i pheral  
nervous sy stem . 
Pr i or to  Worl d War I I ,  o n l y  t he  " revers i bl e "  a n t i cho l i ne sterase  
agents  were genera l l y  known , of  wh i c h physos t i gm i ne , a l s o  ca l l ed 
e ser i ne , ( 1) ,  i s  the  mos t  common exampl e .  
1 
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Phy s o st i gm i ne i s  an a l kal o i d  obt a i ned from the Ca l abar  bean , the 
d r i ed r i pe seed o f  Physost igma veneno sum Bal fou r ,  a peren n i a l  p l ant 
found i n  trop i cal  West Afr i c a .  The  Ca l abar bean , a l s o  ca l l ed E s i re 
nut , chop  n u t , or bean of  Etu  E sere ,  was once u sed by n at i ve t r i be s  
o f  W e s t  A fr i ca a s  a n  " ordeal  po i s on "  i n  t r i a l s for w i tchcraft 1 . 
The  Ca l  abar  bean was  f i  r st  brought to Engl  and i n  1 840 by a 
Br i t i s h med i ca l  off i c e r .  The  earl i e s t  i nve s t i gat i on s  of  i t s ph arma­
co l og i ca l  propert i e s were conducted by  C hr i s t i o sen ( 1855)3 , Fraser  
( 1 863 ) 4 , and  Argyl l - Robertson ( 1 863 ) 5 . T he  f i r s t  therapeut i c  u s e  of  
the  d rug was  i n  1 877 i n  t he  treatment of  g l aucoma , one  of  i t s few 
med i ca l  u s e s  today . I t  was  not unt i l  1 930  t h at Engel hart  and Loewi 6 , 
and then  Matthes 7 , f i r st  demo n strated that  i t s act i on was  t hat o f  an 
i n h i b i tor  o f  acetyl cho l i ne sterase . 
Short l y  before and dur i ng Worl d War I I ,  a new c l a s s  of  h i gh l y  
tox i c  compound s ,  t h e  org anophosphates , was  devel oped by Schrader8 o f  
I . G .  Farben i nd u s tr i e ,  f i r st  a s  agr i cu l tura l  i n sect i c i de s  and l ater  a s  
potent i al chem i ca l  warfare agen t s . The  extreme tox i c i ty of  these  
compounds  was  determ i ned to be due  to  t he i r  " i rrevers i bl e " i n act i v a -
t i on of  AChE ,  thereby exert i ng a l ong l a s t i ng i n h i b i t i on .  I t  i s  of  
i mportance  to  note  t h at the  f i  r st  account o f  the  synthes  i s  o f  a 
h i gh l y  potent  compound of  the  organophosphate  ser i e s , tetraethyl ­
pyrophosphate ( TE P P )  ( £) ,  was  i n  1 854 by C l ermont9 , ten years pr i or 
to t he  i s o l at i on o f  physo s t i gm i ne . 
o 0 
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Lange and  Kruegar10 descr i bed the  synthes i s  o f  d i methyl  and 
d i ethyl fl uorophosphate i n  1932 and a l so ment i oned s ome of the i r  
p hys i ol og i ca l  effects ,  mo st  notabl y the i r  act i on i n  c a u s i ng t i ghtne s s  
o f  t he  c h e s t  a n d  bl u rred v i s i on .  T h i s  i n format i on may have been 
i n st rumenta l  i n  l ead i ng Schrader to expl ore t h i s  c l a s s  for i n s ect i c i -
d a l  act i v i ty .  Dur i ng the  synt he s i s  and  i nve s t i g at i on of  appro x i mate­
ly  2000 compounds ,  Schrader8 descr i bed structural  req u i rements  for 
i n sect i c i da l  ( and s ubsequentl y ant i - C h E )  act i v i ty .  One compound of  
t h i s  s er i e s ,  parath i on ( J) ,  h a s  become the  mos t  w i d e l y  emp l oyed 
i n sect i c i de o f  th i s  c l a s s . 
EtO-� 0 ---JC)\N02 
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Pr i or  to  and dur i ng Worl d War I I ,  the e fforts of  Sch rade r ' s 
g roup were d i rected toward devel o p i ng chem i c a l  warfare agent s . 
Several  compounds  of  much greater tox i c i ty than  parath i on ,  such  as  
s a r i n ( 1) ,  s oman (�) , and  t abun ( 2) were manufactured for the  German 
government for th i s  purpo s e .  
o 
II 




I n  v i ew o f  t he  w i despread d i s t r i but i on of  cho l i nerg i c  neuron s ,  
i t  i s  not  u nu s ua l  t h at t he  a n t i chol i n e sterase  agen t s  a s  a group have 
rece i ved more appl  i cat i on s  a s  tox i c  agent s  i n  t he  form of  agr i cu l -
tura l  i n sect i c i de s  and potent i al chem i ca l  warfare " nerve g a s e s "  t h an 
a s  t herapeut i c  agen t s . 
B .  C haracter i s t i c s  of  Cho l i nesterases  
Cho l  i ne sterases  can  be def i ned a s  a g roup  o f  s er i ne e s terases  
wh i ch are capabl e o f  hydrol yz i ng esters  o f  cho l  i ne a t  a very h i g h 
rate . A l l cho l i nesterases  w i l l  hydrol yze nonchol i ne e sters . Other  
esterases  i n  t he  body e i ther do not hydro l yze cho l i ne e sters  or  the  
rate o f  hydrol ys i s  i s  very l ow .  The  maj o r i ty of  cho l i nesterases  are  
compl ete l y  i nh i b i ted by  phys o s t i gm i ne or  organophosphates  i n  
concentrat i on s  o f  1-10 �. 
There a re two types  o f  C h E  i n vertebrates .  They d i ffer i n  
s ub strate  preference and spec i f i c i ty ,  ki net i c s  o f  substrate  hydro l y ­
s i s and spec i fi c i ty to  i nh i b i tors . T h e  terms acetyl cho l i nesterase  
( ACh E) and  nonspec i f i c  chol i ne sterase  are accepted and  most  frequent -
1 y u s ed for t he  two types  of  t he  enzyme . There i s  no  genera l l y  
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accepted n ame for nonspec i fi  c cho  1 i nesterase . The  1 i terature often 
u s e s  the term butyry lchol  inesterase  or  p seudochol  ine s terase ll . 
Subst a n t ia l  d ifferences  in s ubstrate pre ference and spec if ic ity a s  
wel l a s  s en s it iv ity towards inh ib itors  may exis t  among C h E s  of  
d ifferent a n imal spec ie s 11,12. 
Acetyl cho l inesterase  hydrolyzes  ACh faster  t h an butyryl cho l ine ; 
t he  reverse is true  o f  butyryl cho l inestera s e . Al so , acetyl - �-methyl  
cho l ine  ( methacho l ) is not  hydrol yzed a s  fast  as  ACh but is con s i­
dered a spec ific s ubstrate  for ACh E  because  it is prac t ica l l y  not 
hydrol yzed by nonspec ific ACh E .  The  rel a t ion s h ip between s ub strate 
concentrat ion  vers u s  act iv ity a l s o  d iffere n t iates  the two types  of  
C h E .  ACh E  is inh ib ited by  h ig h  concentrat ions  o f  ACh where a s  
nonspe c if ic cho l inesterase  is not  inh ib ited by h igh  substrate 
concentrat ions . D iis opropyl fl uorophosphate ( DF P )  appears  to be a 
more potent  inh ib itor o f  nonspec ific chol inesterase13 . 
A s ig n ificant  a mount  o f  informat ion h a s  accumu l ated on the  
d is t r ibut ion o f  ChEs  in various  neuronal  and nonneurona l  t is s ue s  of  
d ifferent vertebrate spec ies 12, 14 . I t  is general l y  agreed t h a t  ACh E  
is t h e  o n l y  type o f  C hE  p l ay ing a fun c t iona l  rol e  in the  nervou s  
system . Neural  t is s u e  con t a in s  acetyl chol inesterase  wh il e  non -
neuronal  t is s ue u s u a l l y  con t a in s  non spec ific o r  butyryl chol ines ­
tera s e . As  poin ted out , d ifferences  in the  d is t r ibut ion and act iv ity 
of ACh E  e x is t  among various  spec ies 15 , but a va l id concl u s ion can be 
drawn t h a t  nervous s t ructures  whose  funct ion is ba sed on cho l inerg i c  
mecha n isms  exh ib it the  h ig h e s t  ACh E  act iv ity 16. AChE  is not on l y  
a s soc iated w it h  cho l inerg ic s tructure s , but is o ften  present  in other  
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transm i tter  systems a s  wel l a s  effector organ s  s uch  a s  s tr i  ated and 
smooth musc l e or  gl and s . ACh E  can a l s o  be found i n  nonexc i tab  1 e 
t i s s ue s  s uch  a s  red bl ood ce l l s  and al s o  i n  the  l i ve r ,  ki dneys and 
p l acenta13 , 14 . The  p redom i nant  type of  ChE i n  the  s ke l eta l  mu sc l es  
of  vertebrates  i s  ACh E ,  but l ow act i v i ty o f  non s pec i f i c  ChE  i s  often 
present 17 . 
Acetyl cho l i n e sterase  i s  an e s sent i al part  o f  the  ACh system 
together w i t h  t he  cho l i nerg i c  receptor , the ACh synthe s i z i ng enzyme , 
cho l i ne acetyl tran s fera s e ,  and  the  mechan i sms control l i ng the  chol i ne 
upta ke and  the  ACh s t orage and rel ease . B ased on the  neurohumoral 
theory of t ransmi  s s i on , the p hys  i 01 og i ca 1 funct i o n  o f  t he  enzyme i s  
t o  s peed u p  t he  termi n at i on of  t he  act i on o f  presynapt i cal l y  rel eased 
ACh at t he  p o s t synapt i c  receptor . The  pre sence o f  ACh E  at a part i cu -
l ar synapse  i nd i cates  but  does  not  nece s s ar i l y  mean that  the  synapse  
i s  cho l i nerg i c 14 . 
The  e s sen t i a l  rol e of  ACh E  i n  exc i tabl e t i s s ue i s  the  hydrol y s i s 
o f  acetyl cho l i ne to  acet i c  ac i d  and chol i ne ( Eq .  1 ) .  
Eq . 1 
o H 20 
II + 
CH3COCH 2CH 2N ( CH 3 ) 3 - - - -) CH3COOH 
ACh E  
+ 
+ HOCH2CH 2N ( CH3 ) 3 
The  enzymat i c  c l  eavage of  ACh proceeds i n  several  steps . An acetyl 
enzyme i ntermed i ate i s  formed from the M i chae l i s  enzyme - substrate 
comp 1 ex  after wh i ch the rel ease  of  cho  1 i ne  occurs . Oeacety 1 at i on  
occurs  dur i ng the  next step  and the  react i on can be v i ewed a s  
7 
i rrevers i bl e  a s  l ong a s  the  concentrat i on of  t he  hyd ro l yt i c  products  
i s  so l ow that  they cannot  affect the  react i on k i net i c s 18-20 ( Eq .  2 ) . 
Eq . 2 ACh + E --- + ACh - E  ---� A - E  --- � A + E 
C h  
T he  act i ve s i te o f  ACh E  con s i s t s  o f  two subs i te s : an  an i on i c  and 









F I GURE  1 
The Act i ve S i te of  ACh E .  The quaternary n i trogen head o f  ACh i s  
bound to t he  an i on i c s ubs  i te . The  ser i  ne hydroxyl  group , made a 
s trong nuc 1 eoph i l e  by a charge - re l ay system, d i s p l aces  cho l i ne from 
the subs trate dur i ng the  acetyl at i on step . An ac i d i c  group (AH )  i s  
a l so i nvol ved i n  cata lys i s .  The s h aded areas represent  the  hydropho ­
b i c  reg i on s  o f  the act i ve s i te .  T a ken from Reference 197.  
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The quaternary ammon i u rn  group o f  ACh i s  bound to the  an i on i c 
s ub s  i te .  I on i c  e l ectrostat i c  forces  enhance b i nd i ng of  c harged 
mol ecul e s  to  the enzyme 18 , 22. Hydrophob i c  i nterac t i ons  between the 
methyl  g roups  o f  the c at i on i c  head and the  i mmed i ate s urround i ng s  of  
t he  a n i on i c  s i te cont r i bute s i gn i f i c ant ly  to the  b i nd i ng ,  and proper 
or i entat i on o f  ACh may be even more i mportant than cou l omb i c  
forces 21 , 23 . 
I t  i s  a t  the e sterat i c  s i te that  the cata lyt i c  proc e s s  takes  
p l ace . The  reac t i on i s  b a s ica l l y  a nuc l eoph i l i c  s ub st i t u t i o n .  The  
nuc l eoph i l e  i n  the e s terat i c  s i te o f  the act i ve center of  ACh E  
d i s p l aces  cho l i ne from ACh . I t  i s  general l y  agreed that  the  hydroxyl 
g roup  of s er i ne i n  the e s terat i c  s i te i s  the n u c l eoph i l e  and i s  
f i n a l l y  acetyl ated , a l though other n e i g h bor i ng func t i on a l  groups  are 
a l so  nec e s sary for t h i s  step to occu r .  
A n  i mportant feature of  t h i  s enzyme - i s  a system o f  hydrogen 
bonds  i n  the act i ve cente r ,  cons i s t i ng of  a s er i ne hydroxy l g roup ,  an 
i m i dazol e r i ng of  h i s t i d i ne ,  and a carboxyl  group of  a d i ba s i c  ami no 
ac i d 24 ( Fi g .  2 ) . 
� 
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FI GURE 2 
C harge  Rel ay System i n  the Act i ve Center o f  ACh E . 
Taken from Reference 1 98. 
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The  funct i on of the  c harge rel ay system i s  to deprotonate  the  s er i ne 
hydroxy l g roup , t hereby i ncreas i ng i t s nuc l eoph i l i c i ty ,  and i n  th i s  
way accel erat i ng acyl at i on of the  enzyme . 
Dur i ng enzymat i c  attack  on the  e ster ,  a tetrahedral  i ntermed i ate 
i s  formed that  col l a p se s  to an acetyl enzyme conjugate w i th  the 
s i mu l taneous  rel ea s e  of  cho l  i ne .  The  acetyl enzyme i s  1 a b i  1 e to 
hydrol y s i s ,  wh i ch resu l t s  i n  the  format i on of acetate and act i ve 
enzyme 25. AChE  i s  one of  the  most  e ff i c i ent  enzymes known and h a s  
the  capac i ty to hydrol yze 3 x 1 05 ACh mo l ecu l e s  per mo l ecu l e of  
enzyme per m i nut e ;  t h i s  i s  equ i va l ent  to  a turnover t i me of  1 50 
m i c ro seconds 26. 
C .  I n h i  b i tors  of ACh E  
Cho l i ne e s ters  are among t h e  best  s ubstrates  for ACh E ,  but there 
are many other esters  t hat are a l so  hydrol yzed by t h i s  enzyme . In  a 
homol ogous  s er i e s  of cho l i ne ester s ,  ACh i s  hydrol yzed faster  than 
propi onyl cho l i ne ,  whereas butyryl chol i ne i s  hard l y  hydrol yzed at  a l l .  
Butyry l cho l i ne does  b i nd to the  act i ve s i te and therefore can  
fun ct i on a s  a n  i nh i b i tor of  AChE . O i  fferent compounds  that  b i  nd 
e i ther  to the an i on i c  or  e sterat i c  subs i te s  of  the act i ve center of 
ACh E  i n h i b i t  the hydrol ys i s  o f  ACh by the  enzyme . Al s o ,  per i pheral  
b i nd i ng s i tes  are thought  to ex i  s t  on ACh E  and several  1 i g ands  are 
known to  produce enzyme i nh i b i t i on by b i nd i ng to these  s i te s 27 . 
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1. An i on i c Si te I n h i b i tors 
Many mon o - and b i squaternary ammon i um compounds were shown to 
revers i bl y  i nh i b i t  ACh E  through b i nd i n g  to the an i on i c  s ub s i te of the 
enzyme I S act  i ve center20 . The best  known amon g these  are tetra -
methyl ammon i um ,  tetraethyl  ammon i  um , phenyl tr i methyl ammon i um  and  i t s 
der i va t i ve edrophon i um ,  and decamethon i um ( F i g. 3 ) . 
F I GURE  3 
I n teract i on of  Edrophon i um w i t h  the  An i on i c  Sub - S i te o f  ACh E .  
T a ken from Reference 199. 
Bes i de s  el ectrostat i c  forces , hydrophob i c  i n teract i on s  are 
i mportant for the b i nd i n g  of  these s ubstances  to the  an i on i c  subs i t es  
and the i r aff i n i ty for  AChE  u s ua l l y  i ncreases  w i t h  bu l ki er hydropho ­
b i c  s u b s t i tuents  on quaternary n i tro gen 28 . B i s quaternary a gents  w i t h 
the  proper i n terhead d i s t ance such  a s  decamethon i um (2) probab l y  
br i d ge the d i s t ance between the act i ve center and a per i pheral  
an i on i c  center 29 . 
+ + 
( C H3 ) 3 - N - ( CH 2) 10- N - ( CH 3 ) 3 z 
1 1  
The  ki net i c s o f  i n h i b i t i on o f  AChE  by an i on i c  s i te i n h i b i tors  
may be comp li cated , s i nce  bes i de b i nd i ng to  the  free enzyme and t h u s  
preven t i ng t h e  acce s s  o f  t h e  substrate to the  act i ve cente r ,  many of  
them often  b i  nd the  acetyl - enzyme i ntermed i ate and  s l ow or  prevent 
deacetyl at i on .  Th i s  type o f  i nh i b i t i on may therefore be compet i t i ve ,  
o r  often o f  a m i xed compet i t i ve - uncompet i t i ve type . 
2 .  E s terat i c  S i te I n h i b i tors  
I n h i b i tors  o f  t h i s  type  react  w i t h  ACh E  by  e s sent i al l y the  s ame 
mechan i sm as do s ub strates  30 . They are a l so  ca l l ed " a c i d  tran s ferr­
r i ng i nh i bi tors " 29 becau se  the  s er i ne re s i due i n  the  e s terat i c  
s ub s i te i s  acyl ated dur i ng the  f i r s t  s tep o f  t h e  reac t i on 21 . I n  
contrast  to t h e  s ub s trat e s , t h e  deacety l at i on s t e p  i s  u sua l l y  much 
s l ower so t h a t  many of t hem are actua l l y  known as " i rrevers i bl e "  
i n h i b i tors  o f  AChE .  Organophosphorus  compound s ,  c arbamates  and 
methanesu l fo ndt e s  are repre sentat i ve of  t h i s  type of  i nh i b i tor  and 
are w i d e l y  u s ed as i n sect i c i de s , and becau se  of  t he i r  extreme 
tox i c i ty some are synthe s i zed and stored as poten t i a l  chem i c a l  
warfare agent s .  
1 2  
a .  Organophosphoru s Compounds 
The organophosphoru s type AChE i nh i b i tors can  be represented by 
t he  fo l l ow i ng general  formul a .  
A great var i ety o f  s u b s t i tuents  are po s s i bl e .  Rl and R 2 may be 
a l kyl , a l koxy , aryl oxy , am i do ,  mercapto , or other  group s , and X may 
repre sent  a h a l i de ,  cyan i d e ,  t h i ocyan i d e ,  phenoxy , th i ophenoxy , 
phosphate  or  c arboxyl ate g roup . A chemi ca l  c l a s s i f i c a t i o n  of  the 
compounds  i n  t h i s  c l a s s  that  are of  p harmacol og i ca l  or  tox i col og i c al  
i nterest  has  been devel oped by Hol mstedt31 , 32  ( Tabl e 1 ) . Exten s i ve 
rev i ews o f  the  organophosphorus  compounds  and the i r  tox i c i ty h a s  been 
comp i l ed by Frear33 and G a i nes 34 . 
The org-:lnophosphorus i n h i b i tors serve a s  true  hem i s ub strates , 
s i  nce the  resu l  tant phosphoryl  ated or phosphonyl ated enzyme i s  very 
s tabl e ( F i gure 4 ) . 
�--
F I GURE 4 
The  I n teract i on o f  D FP  w i th the E s terat i c  S i te of ACh E .  
Taken from Reference 199. 
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TABLE  1 
C h em i ca l  C l a s s i f i cat i on o f  Representat i ve Org anophosphorus  Compound s 
of  Part i cu l ar  Pharmacol og i ca l  or Tox i co l og i ca l  I n terest 
T a ken from Reference 200 . 
Group A ,  X = ha l ogen , cyan i de ,  or  t h i ocyanate ; group 8, 
X = a l kyl , a l koxy , or  ary l oxy ; g roup C = th i ol - or t h i onophosphorus  
compoun d s ; group  D ,  pyrophosphates  and s i mi l ar compound s ; 
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CHEM ICAL , AND 
OTHER NAMES COMMENTS 
DFP  Potent , i rrevers i bl e 
D i i s opropyl i n act i vator 
phosphoro -
fl uori date 
Tabun Extreme l y  tox i c  
Ethyl N - d i methyl - " nerve g a s "  
phosphoram i do -
cya n i date  
Sar i n ( G 8) Extreme l y  tox i c  
I sopropyl methy l - " nerve g a s "  
phosphonofl uor-
i date 
Soman Extreme l y  tox i c  
P i nacol yl  methyl - " n erve g a s "  
phosphono-
fl uor i date 
Paraoxon , Act i ve metabo l i te of 
M i ntacol , E 600 parath i on 






TABLE  1 ( Cont i n ued ) 
COMMON , 
CHEM I CA L ,  AND 
OTHER NAMES 
Parath i on 
D i ethyl  0 - ( 4 -
n i trophenyl ) -
phosphoro ­




O - Ethyl 0 - ( 4 -
n i trophenyl ) 
phenyl pho s ­
phonot h i oate  
(!) 0 
(CH3)N - �-O-�-N(C.Hl\ 
l I , · h. 
(c.H3)l.N N(C.HJ)1. 
Mal ath i on 
O , O - D i methyl 
S - ( l , 2 - d i carb­
ethoxyethyl ) 
phosphorod i ­




OMPA , Schradan 
Octamethyl pyro­
phosphoram i de 
Echot h i ophate , 
Phosphol i ne ,  2 1 7M I  
D i ethoxyphos -
ph i nyl th i ochol i ne 
i od i de 
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COMMENTS 
W i de l y  empl oyed 
ag r i c u l t u r a l  i n ­
s e c t i c i de ,  resu l ­
t i ng i n  n umerous 
cases  of  acc i d enta l  
po i son i ng 
W i de l y  empl oyed 
agr i cu l tura l  i n ­
s ec t i c i de 
W i de l y  empl oyed 
i n sect i c i de o f  
greater s a fety 
than  parath i on or 
EPN because  of  
rap i d  detox i cat i on 
by h i gher  organ i sms 
Earl y i n sect i c i de 
I n sect i c i de ;  i n act i ve 
in vitro, but met a ­
bl i zed by an i ma l s 
and p l ant s to 
potent ant i - ChE  
agent 
Extreme l y  potent 
cho l i ne der i vat i ve ;  
empl oyed i n  tre a t ­
o f  g l aucoma ; rel a ­
t i ve l y  stabl e i n  
aqueous  so l u t i on 
1 5  
T h e  reac t i on w i th ACh E  i s  that  of  nuc leoph i li c  subst i t ut i on by the 
s er i ne hydroxy g roup  from the  e s terat i c  s ubs i te ,  the  lea v i ng  group  X 
be i ng rep laced and the  phosphory lated enzyme re s u lt s . The  react i on 
i s  enhanced by the  geometry of  the  tetrahedral  phosphate s ,  wh i ch 
resemble s  t he  tran s i t i on s tate for acety l ester  hydro ly s i s .  Cert a i n 
quaternary organophosphorus  compounds ( echot h i  ophate ; Tab  1 e 1 )  
i nteract w i t h  both the  e s terat i c  and an i on i c  s u b s i t e s  i n  the  act i ve 
center to  produce a s t a b le comp lex ;  th i s  contr i butes  to  t he  h i g h 
potency of  these  compounds 32. I f  t he  a lky l g roups  i n  the  phosphory l­
ated enzyme are ethyl or  methy l, a s i gn i f i cant  degree of  spontaneous  
regenerat i on o f  t he  act i ve enzyme requ i re s  s evera l hours . Secondary 
( D F P )  or  tert i ary a lky l groups  enhance t he  s tab i li ty of  t he  phosphor­
y lated enzyme and s i gn i f i cant  regenerat i on of  act i ve enzyme i s  not  
observed . Therefore , t he  return  of  ACh E  act i v i ty depends on synthe ­
s i s  o f  new enzyme30 . 
I f  t he  i n h i  b i ted enzyme i s  stored for a peri  od o f  t i me ,  i t  
cannot be reac t i vated . The  s t a b i li ty of  the  phosphory lated enzyme i s  
further enhanced by a proces s  c a  1 1  ed " ag i  n g "  and i s  cau sed by the 
los s  o f  a n  a lky l g roup  from t he  organophosphate mo i ety of  the 
i n h i b i ted enzyme35 ( see  F i g .  6) . The  rate of  ag i ng depends on the 
e lectron dona t i ng capac i ty of  t he  a lky l group3 6. Th i s  dea lky lated 
enzyme - i nh i b i tor  comp lex i s  not s u scept i b le to nuc leoph i li c  attack, 
and  therefore cannot  be rea c t i vated . 
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b. Carbamates  
Deta i l  ed i n format i o n  on these s ubstanc e s  h a s  bee n pub­
l i s hed20 , 37. Numerou s  c arbamate cho l i nesterase  inh i b i tors  are u sed 
c l i n i ca l l y  ( F i gure 5 ) . 
F I GURE 5 
Representat i ve " Revers i bl e " Ant i chol i ne sterase  Agent s  
Empl oyed Cl i ni cal l y .  
T a ke n  from Reference 201 . 
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A carbamy l - enzyme i ntermed i ate i s  formed a fter the  l eav i ng g roup X i s  
repl a ced ( F i g .  6 ) . 
l. I F •• 
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The I n teract i on of  Neo s t i gmi ne w ith  AChE . 
Taken from Reference 199. 
The decarbamyl a t i on of  the  enzyme is rel a t i ve l y  fa s t ,  there fore , 
these  type of  ACh E  i nh i b i tors  are o ften ca l l ed revers i bl e20 , 2 1 . 
There i s  no bas i c  d i fference between the  revers i bl e  and i rrevers ibl e 
" a c i d  tran s ferr i ng "  inh i b i tors ( o rganop h 6sphate s )  a s  far a s  the 
react i on pathway of  i nh i bit i on is concerned . The  s i g n s  and symptoms 
of po i son i ng by carbamate  type ChE i nh i b i tors c l o s e l y  resembl e s  those  
o f  the  organophosphate  type 38 . 
1 8  
c .  M i scel l aneous . 
Methanesu l fonates ( CH3S02X) are strong i rrevers i b 1 e i nh  i b i tors 
for ACh E ,  wh i ch means that desul fonat i on i s  extreme l y  s l ow .  Methane­
sul fonyl fl uoride  i s  a useful  probe for the esterat i c  s i te because  of 
i ts smal l s i ze 39 ,40. 
The methanesul  fonyl g roup al so  serves as  a hemi substrate (1 i ke 
the  organophosphates) by form i ng a conj ugate w i th the ser i ne hydroxy 
g roup on ACh E . L i ke the phosphoryl ated enzyme , methanesul fonyl AChE 
i s  res i stant  to hydro l y t i c  react i vat i on4 1. 
The ex i stence of peri pheral an i on i c  s i te l i g ands on AChE was 
f i rst  hypothes i zed from k i net i c  stud i e s  of  the i n h i b i t i on of  AChE by 
d - tubocurari ne (�) and ga l l ami ne ( 2)42 . 
These two compounds are bound to AChE out s i de i t s act i ve center43-45. 
Severa 1 per i phera 1 an i on i c s i tes appea r to be 1 oca ted on each ACh E 
subun i t46 , o r  a broader an i on i c  l ocus may pos sess  several negat i ve 
charges , each serv i ng to b i nd several cat i on i c  l i gands41. 
1 9  
I t  i s  general l y  ag reed that a second mol ecu l e  of ACh i s  bound to 
the enzyme at h i g h  substrate concentrat i ons  and t h at the catal yt i c  
effi c i ency of such a compl ex i s  reduced , l ead i ng t o  substrate 
i nh i b i t i on .  Op i n i on s  d i ffer as  to where and when the second mol ec u l e  
i s  bound . The exi stence of two an i on i c  subs i tes  i n  the act i ve center 
has  been suggested , and the  ster i c  h i ndrance of two mol ecul es  of ACh 
at  the esterat i c  s i te has  been proposed to expl a i n  the catal yt i c  
i nact i v i ty of the ternary compl ex47 . The second molecul e of ACh may 
b i nd to the  acetyl - enzyme i ntermed i ate and bl ock deacetyl at i on48 . 
I nvol vement of  a peri pheral an i on i c  s i te and of conformat i onal  
changes has  been sugges ted49 , as  we 1 1  as  the b i  nd i ng of the second 
substrate mol ecul e to the hydrophob i c  reg i on s  near the act i ve s i te 50 . 
D .  Chol i nesterase React i v ators 
Wh i l e  the  phosphoryl ated esterat i c  s i te of AChE undergoes 
hydro l y s i s to regenerate act i ve enzyme at a s l ow or negl i g i bl e  rate , 
W i l son 51 d i scovered that nucl eoph i l i c agen ts  such as  hydroxyl am i ne 
(H2NOH) , hydroxami c ac i d s  ( RCONHOH) , and ox i mes  ( RCH=NOH) react i vate 





React i vat i on of Al kyl phosphoryl ated Acetyl chol i nesterase 
Ta ken from Reference 52 . 
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A sel ect i ve regenerat i on i s  ach i eved by a s i te d i rected nucl eo-
ph i l e  where i n  i nteract i on of a quaternary n i trogen wi th  the  negat i ve 
subs i te of the  act i ve center pl aces the  nucl eoph i l e  i n  cl ose apposi-
t i on to the  phosphorus . W i l son and Gi nsberg53 demonst rated this 
se l ect i ve regenerat i on on phosphoryl ated AChE w i t h  pyr i d i n e-2-
al dox i me methyl ch l o r ide  (pral i doxi me; 2-PAM; lQ). 
2 1  
I t  was s hown that  reac t i vat i on w i th 2 - PAM was one mi l l i on t i mes  the 
rate of that  w i th hydroxyl ami ne . Cert a i n b i s - quaternary ox i mes  such 
as  o b i d ox i me (11) were s ubsequentl y shown' to be even more potent 
react i vators 54 . 
11 
W i th these  type of agents the ox i me i s  or i ented prox i mal l y  to 
render a nucl eoph i l i c attack on the phosphoru s .  The ox i me - phos pho­
nate i s  then hydrol yzed , l eav i ng the regenerated enzyme 55 (see F i g .  
7 ) . The ox i me s  are not a s  effect i ve i n  antagon i z i ng the tox i c i ty of 
carbamyl ester i n h i b i tors as  wi th organophosphorus type agent s .  
22 
E .  Pharmacol ogi cal  and Tox i col ogi cal  Propert i es of  Acetyl chol i ne s ­
terase I nh i bi tors 
Compounds wh i ch i nh i b i t  AChE prevent the hydrol ys i s  of  ACh ; 
therefore , ACh accumul ates at cho 1 i nerg i c syn apses throughout the 
cent ra 1 and peri  phera 1 nervous system . The propert i es  of ant i - Ch E 
agents can  be d i scus sed by know i ng the l ocat i on where ACh i s  rel eased 
phys i ol og i c al l y  by nerve i mpulses  and the res pon ses of the corre s ­
pond i ng  effector organ s . I n  general , the sympathet i c and para sym­
pathet i c  systems are v i ewed as  phy s i ol og i cal  antagon i sts . I f  one 
system i nh i b i t s  a certa i n  funct i on ,  the other usual l y  augments  that 
funct i on 56 . S i nce most v i scera are i nnervated by both components of 
the autonom i c nervous sys tem , the l evel of act i v i ty represents the 
i ntegrat i on of  the i n fluence of the two d i v i s i ons . 
The i ntegrat i ng act i on of  the autonomi  c nervous system i s  o f  
i mportance for the  wel l be i ng of  t h e  organ i sm .  I n  general , the 
autonomi c nervous system regul ates the act i v i t i es of structures not 
under vol unt ary control . Thus , resp i rat i on ,  c i rcul at i on , d i gest i on ,  
metabol i sm ,  body temperature , sweat i ng ,  and the secre t i ons  of 
endocri  ne g l  ands are regul  ated by the autonomi c nervous system and 
i t s  central  mechan i sms . 
The parasympat het i c  sys tem , i n  contrast to the sympat het i c  
sys tem , i s  organ i zed ma i n l y  for d i screte and l ocal i zed d i scharge and 
not for a ma s s i ve res pon se . I t  i s  concerned pr i mar i l y  wi th the 
23 
funct i on s  of con servat i on and res torat i on of energy , rather than 
expend i ture of  energy. Th i s  system s l ows the heart rate, l owers 
bl ood pres sure , s t i mul ates gastro i ntes t i nal  movements  and secret i ons , 
a i d s  absorpt i on of  nutrients , protects  the eyes from exces s i ve l i ght 
and empt i es  the  bl adder and rectum. There i s  no purpose for the 
parasympathet i c  system to d i s charge s i mul t aneous l y. 
In contrast to other chol  i nerg i cal l y  i nnervated cel l s ,  smooth 
muscl e  and the card i ac sys tem exh i b i t  i ntr i n s i c  el ectr i cal  and 
mechan i cal  act i v i ty wh i ch i s  mod i fi ed ,  not i n i t i ated , by ACh. The 
add i t i on of  ACh to i sol ated i ntes t i na l  smooth musc l e  causes a fal l i n  
the  rest i ng poten t i a l  ( membrane potent i al becomes more pos i t i ve) and 
an i ncrease i n  membrane conduct i on fol lowed by a ri se i n  tens i on .  
ACh i n i t i ates these effects  probabl y by depol ar i zat i on of the cel l 
membrane by an i ncrease i n  Na+ conductance . ACh can produce contrac ­
t i on of  smooth muscl e when the membrane has  been compl etely  depol ar­
i zed . St i mul at i on of  chol i nerg i c  i nnervat i on or d i rect appl i cat i on 
of ACh c auses i nh i b i t i on of  the card i ac conduct i on system assoc i ated 
w i th hyperpo 1 ar i  zat i on of the  fi ber membrane and a decrease i n  the 
rate of  depol ar i zat i on .  These effects are due to a sel ect i ve 
i ncrease i n  permeabi l i ty of  K+ 57 . 
ACh has  three ma i n  effects on the  card i ovascul ar sys tem: 
vasod i l at i on ,  a decrease i n  card i ac rate ( negat i ve chronotro p i c  
effect) , a n d  a decrease i n  t h e  force of card i ac cont ract i on ( negat i ve 
i onotrop i c  effect) . The negat i ve i onotrop i c  effect i s  more pronoun ­
ced i n  the atr i al muscl e than i n  the ventr i cal  muscl e .  The i n tra­
venous i nj ect i on of a smal l dose of ACh i n  an anesthet i zed an i ma 1 
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produces a fal l i n  bl ood press ure due  to vasodi l at i o n ,  accompan i ed by 
t ac hycard i a .  A l arger dose wi l l  el i c i t  bradycard i a  by bl ock of the 
A-V node conduct i on from the d i rect act i on of  ACh i n  the heart . 
I nj ect i on of  ACh produces d i l at i on of es sent i al l y  al l vascul ar bed s 
i nc l ud i ng pul mon ary and coronary58 . 
ACh produces an i ncrease i n  ton e ,  ampl i tude of contract i ons  and 
per i sta l t i c  act i v i ty of the stomach and i ntes t i nes  as wel l as 
enhanced secretory act i v i ty of  the gastro i ntest i nal  tract. ACh 
s t i mu l a t i on i ncreases urethral per i sta l s i s ,  contracts the  detrusor 
mu sc l e of  the  ur i n ary bl adder ,  i ncrea ses the max i mum vol unt ary 
vo i d i ng pressure ,  and decreases the capac i ty of the bl adder . At the 
neuromuscu l a r  j unct i on ACh comb i nes wi th the n i cot i n i c  chol i nerg i c  
receptor t o  i n i t i ate a n  endpl ate poten t i al  and s t i mul ate musc l e  
contract i on .  
The pharmacol ogy of gangl i on i c  transmi s s i on i s  ba sed on the 
mod i f i cat i on s  of  the avai l ab i l i ty or the act i on of  the pri mary 
neurotran smi tter ACh. Neurotransmi s s i on i n  autonom i c g angl i a  i s  more 
compl ex than can be descri  bed by a s i ngl e neurotran smi tter receptor 
sys tem . The pri mary pathway i nvol ves the depolari zat i on of postsyna­
pt i c  s i tes  by ACh . The receptors are c l a s s i fi ed as  n i cot i n i c  and the  
pathway can be  bl ocked by the c l ass i cal  non- depol ar i z i ng blocki ng 
agent hexamethon i um (Il). 
+ + 
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ACh st i mu l ates the secre t i on o f  al l g l ands that rece i ve i n put 
from the  para sympathet i c  nervous system , i nc l ud i ng l ac r i mal , tracheo ­
bronch i al ,  sa l i vary ,  d i ges t i ve and exocri ne sweat g l ands . The 
effects  on the  res p i ratory system in add i t i on to i ncreased bronc h i a l  
secret i on i nc l ude bronchoconstri ct i on and s t i mul at i on o f  t h e  chemore ­
ceptors i n  the  carot i d  and aort i c  bod i e s .  
The pharmacol og i cal  effect s  of ant i  -AC h E  agents  are due to the  
prevent i on of  hyd ro 1 ys i s  of  ACh  by AChE  at s i tes  of cho 1 i nerg i c 
t ransmi s s i on .  The transmi tter accumul ates and the act i on of ACh 
wh i ch i s  1 i berated by cho l i  nerg i c i mpul  ses i s  enhanced . W i th the 
org anophosphorus agents al l of the acute effects at moderate doses 
can be attri buted to th i s  act i on .  The d i verse number of chol i nerg i c  
synapses  i ncreases the  compl ex i ty o f  the pharmacol og i cal  respon se . 
Al l ant i - C h E  agents are respon s i bl e  for ( 1 )  s t i mul at i on of muscar i n i c  
receptor responses at autonomi c effector organ s ;  ( 2) s t i mul at i on , 
fol l owed by depres s i on or paral y s i s of al l autonomi c g angl i a  and 
s kel etal  muscl e ( n i cot i n i c  acti on) ; ( 3) s t i mul at i on fol l owed by 
depre s s i on of  chol i nerg i c  receptor s i tes  (ma i n l y  muscar i n i c) i n  the 
CNS . The compounds conta i n i ng a quatern ary ammon i um g roup do not 
read i l y  penetrate the bl ood - bra i n  barr i e r .  The l i p i d  sol ubl e agents 
such as the  tert i ary ami nes and the organophosphorus compounds are 
wel l absorbed and have effects at  both peri pheral and central  
cho 1 i nerg i c receptor s i tes . The l i  p i  d sol  ub 1 e organophosphates can 
read i l y  be absorbed through the s k i n .  The act i on s  of excess  ACh i n  
the peri  p h  era 1 and central nervous system where the receptors are 
mu scar i n i c  can be bl ocked by atrop i ne (11) .  
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The ma i n  act i on s  of  ant i - ChE  agents that are of therapeut i c  
i mportance are concerned w i th the eye , the i ntest i ne and the s kel etal 
neuromuscu l ar j unct i on .  Al though  ant i -ChE  " agents have been recom­
mended for the  t reatment of  a w ide  vari ety of  cond i t i on s ,  the i r  
acceptab i l i ty over other drugs o r  therapeut i c  approaches i s  e s ­
tabl i s hed on l y  i n  four  ma i n  areas : atony of t h e  smooth musc l e  of the 
i ntes t i na l  t ract and the ur i nary bl adder , g l aucoma , myas then i a  
gravi  s ,  and term i  nat i o n  o f  the effects o f  compet i t  i v e  neuromu scu1  ar 
bl ocki ng drug s . Other c 1  asses  of  drug s are often recommended as 
adj unct therapy or i n  preference to ant i -AChE  drug s bec ause of the 
l ac k  of  sel ect i v i ty and the tox i c i ty assoc i ated w i t h th i s  c l ass  of 
compound s .  The most exten s i ve appl i cat i on s  of AChE i n h i b i tors are as 
tox i c  agents  i n  the form of agr i cul tural pest i c i des  and i n sect i c i des 
and as  c hemi cal  warfare " nerve gas  agent s " . 
Po i son i ng wi th a vari ety of i n h i b i tors has  been repo rted to 
produce es sent i a l l y  the  same c l i n i c al p i cture 59 . The accumul at i on o f  
A C h  at s i tes  where i t  funct i on s  as  t h e  chemi cal  transmi tte r ,  t h a t  i s ,  
at postg angl i on i c  para sympat het i c  nerve end i ng s  (muscar i n i c  s i tes ) , 
at autonomi c gangl i a  and the s ke l etal neuromusc u l ar junct i on ( n i co -
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t i n i c  s i te s )  and  in  the central nervous system ( predomi nant ly  central 
mu scar i n i c  s i te s )  can be rel ated to the  s i g ns  and symptoms of 
poi son i ng by ant i -ChE  agent s . The tox i col og i cal  man i festat i on s  of 
the ant i -ChE  agents are of  pract i cal  i mportance to the phys i c i an .  I n  
add i t i on to the n umerous cases  o f  acc i dental  i ntox i cat i on from the 
use and manufacture of  org anophosphorus compounds as  agri  cu l tura 1 
i n sect i c i des 60-62 , these  type s of compounds have been empl oyed 
frequent l y  for homi c i dal  and su i c i d al  purposes , l arge l y  because of 
the i r  ease  of acce s s i b i l i ty .  
After l ocal  exposure to vapors or aerosol s ,  ocul ar and re s p i ra­
tory effects  general l y  are the earl i e st s i gns  of  po i son i ng by 
ant i chol i nesterase agent s .  The ocu l ar effects i nc l ude mi o s i s ,  ocu l ar 
p a i n ,  conj unct i val  congest i on ,  c i l i ary spasm,  and brow ache al ong 
w i th nasa l  d i scharge63 . Res p i ratory effects con s i st  of t i ghtness  i n  
the chest  and wheez i ng due to a comb i n at i on o f  bronchoconstr i ct i on 
and i ncre ased bronch i a 1 secret i ons . A general i zed st i mu 1 at i on o f  
smooth musc l e resul t s  i n  contract i on s  a n d  i ncreased peri stal s i s  i n  
the  stomach and i ntest i ne ,  and contract i on of the musc l e s  i n  the 
wal l s  of  the  ur i nary tract . There i s  s t i mu l at i on o f  secret i on by 
l ac h r i mal , sweat , sa l i vary ,  bronch i al ,  gastr i c and pancreat i c  
g l ands 65. Exces s i ve secre t i ons of the sal i vary and bronch i a l g l and s 
l ead to part i al bl ockage of the a i rway and re s p i ratory d i ffi cu l ty .  
Effects  on the  card i ovascu l ar system i nc l ude a s l ow i ng o f  the heart 
and a fal l i n  bl ood pre s s ure . Two factors seem to be operat i ng to 
produce hypoten s i on ,  decrea sed peri pheral res i s tance due to vasod i l a ­
t i on and a reduced card i ac output 64 . Severe i ntox i cat i on i s  man i fe s -
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ted by extreme s a l i vat i o n ,  l ac r i mat i on ,  bradycard i a  and hypoten ­
s i on 63 . 
Ske l etal  muscl e s  and autonom i c  g angl i a  are s t i mu l ated by l ow 
doses  of  ant i chol i nesterase agents and depre s sed by h i gher doses 65 . 
There are fas i cu l a t i ons  of the musc l es  of  the eye l i d .  D i ffi cu l t i e s 
i n  accommodat i on occur s i nce t here i s  contract i on of the  c i l i ary 
muscl e ,  mak i ng the  l en s  spheri cal . These effects , p l us  m i os i s ,  make 
v i s i on d i ffi cu l t .  The comp l ex act i ons  of  ant i - ChE  agents at the  
autonomi c gangl i a  h ave been rev i ewed by Z a i mi s66 . At the  neuromu s ­
cu l ar j u nct i on ,  muscu l ar fasc i cu l at i on s  fol l owed by muscul ar weakness 
and eventual l y  neuromuscu l ar bl oc kade occur . The most ser i ous effect 
on the neuromuscul ar j unct i on i s  paral y s i s of the  re sp i ratory 
muscl es 63 . 
The central  act i on s  of ant i chol  i nesterase agents can be ex­
p l a i ned by s t i mu l at i on fo l l owed by i n h i b i t i on .  The  s t i mu l ant 
effect s ,  such as  apprehen s i on ,  d i zz i nes s ,  tremo r ,  atax i a  and convu l ­
s i on s , are succeeded by i n h i b i tory effects wh i ch l ead to coma . 
Effects  on the  re s p i ratory center i n  the  bra i n are character i s t i c  of 
re s p i ratory s t i mu l at i on fol l owed by res p i ratory depres s i on and 
eventual l y  res p i ratory fa i l ure . The central effects of an t i - C h E  
agents a r e  of  s i gn i f i cance because death from pOi son i ng by these  
compounds i s  p r i mar i l y  due to central res p i ratory fa i l ure . Therapeu ­
t i c  or protec t i ve procedures are a i med p r i mar i l y  at revers i ng or 
prevent i ng t h i s  act i on .  Karczmar67 has rev i ewed the acute and l ong­
l as t i ng central  effects of the  act i on of  org anophosphorus agent s .  
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F .  Treatment of  Ant i chol i nesterase Po i son i ng 
Occa s i ona l l y  overdose w i th ant i chol i nesterase agents may occur 
dur i ng the i r  med i cal  u se for the cond i t i ons  ment i oned prev i ou s l y .  
Much more common 1 y ,  acc i denta 1 over- expo sure to ant i cho 1 i nesterase 
i n sect i c i des  and the potent i al u se of  org anophosphorus agents i n  
chem i c a l  warfare a s  the  " nerve gas  agen t s "  cou l d  con s t i tute a 
con s i derabl e therapeut i c  or prophyl act i c  probl em .  A s  i de from 
protect i ve c l oth i ng or re s p i rators , tre atment of th i s  s i tuat i on must 
be d i rected at e i ther protect i ng AChE from the i nh i b i to r ,  rel eas i ng 
an act i ve enzyme from the enzyme - i n h i b i tor compl ex or mi n i mi z i ng the 
act i on s  of accumul ated acetyl chol i ne wh i ch i s  respon s i bl e  for al l the 
ma i n  effect s  of  ant i chol i ne sterase s .  I n  pract i ce , metabo 1 i sm or 
destruct i on of the i nh i b i tor before i t  can i n h i b i t  s i gn i fi cant 
proport i on s of the enzyme or i nh i b i t  i on of the rel ease of acetyl ­
chol i ne or accel erat i on of i t s destruct i on have proven to be of 
l i tt l e or no val ue . The ma i n  probl ems ari se  wi th  the organopho s ­
phorus i nh  i b i tors where the  effects are l ong ( days o r  weeks ) i n  
compar i son wi th  the carbamates where the effects pers i st for n o  more 
than a few hours because  of the rel a t i vel y rap i d  rate at wh i ch 
spontaneous react i vat i on of  the  enzyme occurs 12 . 
The onl y way of  protect i ng AChE from an i rrevers i bl e  i n h i b i tor 
i s  to use another compound wh i c h wi l l  react wi th the enzyme . Th i s  
w i l l  i n h i b i t  the enzyme to ensure that the i nh i b i t i on i s  of  a read i l y  
revers i bl e  type . Revers i bl e  i n h i b i tors such a s  edrophon i um ( l! )  are 
not of  pract i c al i mportance s i nce the l ength of t i me that they wi l l  
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protect the  enzyme from i rrevers i bl e  i nh i b i t i on wi l l  be short . 
Koster68 fi rst  proposed and demonstrated that carbamate type chol i n ­
esterase i nh i b i tors were effect i ve i n  protect i on ag a i nst  po i s on i ng 
from org anophosphorus compound s .  To be effect i ve i n  th i s  approach , 
they mu st  be g i ven before poi son i ng by the org anophosphorus compound 
bec ause  the i nh i b i ted enzyme woul d  then not be ava i l abl e and cou l d  be 
react i vated . 
Any drug s wh i c h effec t i ve ly  destroy the i nh i b i tor before i t  can 
attack the  enzyme or wh i ch protect the enzyme from i nh i b i t i on need to 
be present when poi son i  ng occurs . They demons trate no therapeut i c  
potent i a 1 but rather presupposes some expectat i on that expos ure to 
ant i chol i nesterase agents i s  l i ke l y  to occur ( p rophyl act i c  treat -
men t )  . A much more l i ke l y  occurrence ( acc i dental  po i son i ng i n  
ag r i cu l tural  or chemi cal  warfare ) i s  that po i son i ng wi l l  occur i n  an 
un protected i nd i v i dual  who wi l l  then requ i re treatment . I n  th i s  
s i tuat i on an  enzyme i nh i b i tor compl ex wi l l  al ready have been formed 
and thus  w i l l  need to be broken down to rel ease  ac t i ve enzyme . 
Convent i ona 1 therapy for i ntox i cat i on by organophosph ate AChE 
i n h i b i tors con s i sts  of coadm i n i strat i on of atrop i ne ( to antagon i ze 
3 1  
the effects  o f  accumul ated acetyl chol i ne )  and a pyr i d i n i um ox i me to 
reac t i vate the i n h i b i ted enzyme59 , 61 , 69 . 
W i l son 51 fi rst  demonstrated that chem i cal  react i vat i on of 
org anophosphate i n h i  b i ted AChE  w i th hydroxyl ami ne coul d be ach i  eved 
at a faster rate than wi th  water al one . I n  th i s  and i n  s ubsequent 
stud i e s W i l son 53 , 70 found that the ease wi th  wh i c h react i vat i on coul d 
be effected depended on the nature of the i nh i b i tor . For exampl e ,  
d i i sopropyl phosphoryl acetyl chol i nesterase was much more d i ffi cul t to 
react i v ate than the d i ethyl phosphoryl ated enzyme . Hydroxam i c ac i d s  
a r e  not effec t i ve ant i dotes73 . Stud i e s found that  oxi mes were even 
more effec t i ve reac t i vators 53 , 71 . The mo st exten s i ve ly  stud i ed 
compounds of  th i s  c l ass  of agents i n  treat i ng poi son i ng by ACh E  
i nh i bi tors have been pyr i d i ne - 2 - al dox i me meth i od i de ( 2 - PAM ) ( lQ )  and 




The b i s - quaternary pyr i d i ne al dox i mes  con s t i tute the mo st potent 
g roup of  ox i me react i vators known . Hobbi nger et a 1 . 71 showed the 
p o tent compound 1 , 3 - b i s - ( pyri d i n i um - 4 - al dox i me ) propane d i brom i de 
( TMB - 4 )  (�) was a more rap i d  react i vator of  sari n - i n h i b i ted chol i n ­
esterase in vitro than e i ther 2 - PAM o r  P2 S .  Eng l ehard and Erdman 72 
reported 1 , 3 - b i s - ( pyr i d i n i um- 4 - al dox i me )  methyl ether b i c h l or ide ( H -
32  
6 ,  toxogon i n ,  12 )  to b e  an even more effect i ve reac t i vator t h a n  TMB-
4 .  
A vast  amount o f  work has  been carri ed out o n  the effect i veness  
of  react i vators in  protec t i ng a n i mal s from the l ethal  effects  of  
org anophosphorus C h E  i n h i b i tors . There are d i fferences between 
var i ou s  react i vators and i nh i b i tors and the expe r i mental  cond i t i on s  
u sed . T h e  d i fference i n  spec i es response makes t h e  s i tuat i on more 
compl ex . The ox i mes  are the onl y  cl ass  wh i ch are t ru l y  effect i ve for 
th i s  u se .  
I t  i s  known that the bl ood - bra i n  barr i er i mpedes the tran sport 
of  the  cat i on i c  pyr i d i n i um compounds i nto the CNS , but read i l y  passes  
typ i cal  l i poph i l i c org anophosphorus ant i -AChE agent s . Treatment of 
ant i -ACh E poi son i ng w i th  pyr i d i n i um ox i mes  i s  h i gh l y  effect i ve for 
per i pheral reg i ons , but i t  fai l s  to restore act i v i ty to a l arge 
fract i on of i nh i b i ted bra i n  AChE74 , 75 . The i s sue of CNS ac t i v i ty of 
ACh E  reac t i vators i s  compl i c ated because there are reports that 
pyr i d i n i um ox i mes  devo i d  of CNS act i v i ty are effect i ve ant i dotes 76 . 
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Low concentrat i ons  of 2 - PAM h ave been shown to penetrate i n to the 
bra i n77 . 
Bodor et al . 78-81 appl i ed the " prodrug " concept to the probl em 
of  ant i -AC h E  agent therapy i n  an attempt to understand the CNS 
effects  of  ACh E  react i vators . I -Methyl - l , 6 - d i hydropyr i d i ne - 2 -
carbal dox i me ( proPAM , 11) rap i d l y  ox i d i zes  i n  v i t ro and in  v i vo to 
PAM UQ) 80 . 
., O CH=NOH 
1 +  
CH 3 
11 
The tert i ary ami ne can penetrate i nto the CNS and ox i d i ze to PAM . 
Admi n i strat i on of  pro PAM i n  mi ce poi soned by OFP enh anced react i v a ­
t i on of  bra i n  AChE rel at i ve t o  a n  equ i val ent dose of  PAM79 . Stud i e s 
have shown , thoug h ,  t h at proPAM prov i des on ly  a s l  i gh t  i mprovement 
over PAM i n  OFP poi son i ng and no i mprovement when g i ven as an 
ant i dote ag a i nst  other org anophosphorus ant i -ACh E  agents 75 , 82 , 83 . 
The l ac k  of  correl at i on between react i vat i on of bra i n  ACh E  and 
ant i dotal effi cacy ( survi val  rat e )  has rai sed the ques t i on of whether 
react i v at i on of  CNS ACh E  i s  cr i t i cal  for surv i v al 12 , 83 . Pro - PAM 
reac hes  the  bra i n ,  reac t i vates AC h E ,  but i t  i s  no more e ffect i ve an 
ant i dote than 2 - PAM w i th or wi thout atrop i n e .  I t  has  been suggested 
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that  the  onl y  contr i but i on toward protect i on from ant i -AChE  po i son i ng 
i s  per i phera1 84 even t hough the  ma i n  cause  of  death  i s  central  
res p i ratory i nh i b i t i on .  No react i vator a l one w i thout the  add i t i on of  
atrop i ne  or  other ant i muscar i n i c  d rug i s  therapeut i ca l l y  succ e s s fu l  
a fter  a l etha l  dose  o f  the  organophosphate . 
Dur i ng po i son i ng w i th  ant i -AChE  agents  ACh accumu l ates  at 
per i pheral  n i cot i n i c  and muscar i n i c  s i te s  and a 1  so  at  var i ou s  s i te s  
i n  the  central  nervous  system . No one  drug can  antagon i ze t he  
act i on s  o f  ACh  at a l l s i te s .  The  n i cot i n i c  act i on s  can  be  antago­
n i zed at  the  autonomi c gangl i a  by gangl i on i c  bl ocki ng d rug s and at 
the  neuromus c u 1  ar  j unct i on by curare - 1  i ke agent s . The  predomi nant  
centra l  act i on s  can  be  antago n i zed by ant i mu scar i n i c  drug s .  I n  most  
reported s tud i es gangl i on i c  a nd  neuromu scu l ar bl ock i ng drug s have 
been u s ed i n  conj unct i on w i t h  atrop i ne .  The i r use a l one wou l d  not be 
very s i gn i f i cant  s i nce they act at on l y  one s i te where ACh accumu ­
l ates . 
The  f i r s t  reported u se  of  an a n t i mu scar i n i c  drug a s  an ant i dote 
o f  an ant i chol i nesterase  agent was  i n  1 864  when K1 e i nwachter descr i ­
bed the  u s e  o f  atrop i ne for the  treatment  of  po i son i ng w i t h  physo­
s t i gm i ne  i n  man85 . Con s i derabl e emph a s i s  h a s  been  p l aced on tr i al s 
of  ox i me s  or  comb i n at i on s  of  o x i me s  for i mproved ant i dota l  effect i ve ­
nes s ,  b u t  onl y  a few stud i e s have been undertaken to determ i ne 
whether atrop i ne s u l fate i s  the most effect i ve chol i no l yt i c  agent for 
comb i ned t reatment . Pre sent l y  atrop i ne s u l fate i s  the s tandard 
ant i mu scar i n i c  agent u sed c l i n i c al l y  a s  an ant i dote . Atrop i ne 
s u l fate  i s  a potent ant i muscar i n i c  agent w i th both per i pheral  and 
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central  e ffects .  However,  atrop i ne h a s  two d i s t i nct  d i s advantages  a s  
a n  ant  i dote for nerve g a s  p o  i s o n  i ng . I t  i s  much l e s s  effec t i ve 
central l y  than  peri pheral l y  a s  an ant i mu scar i n i c  ( when admi n i s tered 
per i phera l l y )  and i t  further promotes  the  rel ease  of ACh from 
chol i nerg i c  neuron s by bl ock i ng i nh i b i tory muscar i n i c  receptors 
presynapt i c a  1 1  y .  There i s  reason to bel i eve t hat other ant  i mu s c a -
r i n i c  agent s  m i g ht  b e  better t h a n  atrop i ne ,  part i cu l arl y for combat -
t i ng the  central  effect s  o f  the  exce s s  ACh .  Apparent l y  the  Ru s s i an 
Army ha s  swi tched to a synthet i c  compound cal l ed aprophen (�)  as i t s 
preferred a n t i dote86. Because  of i t s h i gh ant i mu s c ar i n i c  potency 
and ab i l i ty to  penetrate the bl ood - bra i n  barr i er i t  i s  adm i n i stered 
prophyl act i ca l l y  and therapeut i ca l l y  as an ant i dote to nerve 
agent s 87 . 
Col eman et  a l . reported a number of  s tud i e s on the  effec t i vene s s  
of  ant i mu s c ar i n i c s  a s  ant i dotes 88-92 . I n i t i a l l y  34 compounds were 
tested for t he i r  ab i l i ty to protect m i ce and rats  from l etha l  doses  
of  sar i n  compared to a trop i ne88 . The  effec t i venes s  of  the  compounds 
was  determ i ned  in  a t reatment u t i l i z i ng the ox i me P2S (30 mg/kg ) p l us  
50 Jlmol e s/kg of  the  ant i muscar i n i c  compound . The  comb i nat i on was 
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admi n i stered 15 m i n  pr i or  to i nj ect i on of s a r i n .  I n  m i ce and rats  
f i ve o f  t he  compounds  exh i b i ted marked l y  enhanced protect i ve potency 
compared to atrop i ne .  A compar i son to atrop i ne of  the most  effect i ve 
compounds  i n  t he  s t udy for m i ce and rats  are s ummar i zed i n  Tabl e 2 .  
A potency rat i o ,  ( PR- l )  =< LOso of  s ar i n  i n  treated an i ma l s/LOso of 
s a r i n i n  untre ated control s .  I n  th i s  Tabl e a PR-2  i s  the  potency 
rat i o  o f  t he  LOso of  s a r i n i n  a n i mal s treated w i th  a spec i f i c  
ant i mu scar i n i c  d i v i ded by the  LOso o f  s ar i n i n  a n i ma l s treated w i th  
atrop i ne .  
Se l ect i on o f  cand i d ate compounds i n  t h i s  reported study was 
based on prev i ou s l y  reported act i v i ty i n  ant i mu scar i n i c  a s s ays wh i ch 
i nd i cated potency approx i mat i ng that  o f  atrop i ne .  The  pharmacol og i ­
c a l  t e s t s  i nc l uded mydr i a t i c  act i on i n  m i ce and rabbi t s ,  i nh i b i t i on 
o f  ACh - i nduced s p a sm i n  g u i nea  p i g  i l eum and rabb i t i l eum in v i t ro ,  
and i nh i b i t i on o f  gut  mot i l i ty i n  v i vo i n  dog s . Compar i  son of  
resu l t s  from these  a s s ays  of  the  34 compounds  w i th  the i r  act i v i ty i n  
conj unct i on w i t h  P2S  i n  protec t i ng m i ce or rats  from s ar i n po i son i ng 
fa i l ed to  reveal  any correl at i on .  Al l of  the  c r i ter i a ment i oned are 
t e s t s  o f  i nh i b i tory potency at per i pheral  chol i nerg i ca l l y  i nnervated 
smoot h  musc l e s  or  g l and s . These  funct i on s  are not as s i g n i f i cant i n  
po i son i ng by ant i chol i nesterase  i n h i b i tors a s  i n  central  re sp i ratory 
i n h i b i t i on .  Therefore , the  compar i son i s  not l og i cal . 
N u m b e r  
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TABLE  2 
Rel at i ve E ffec t i venes s  of  Some Ant i mu scar i n i c s i n  the  
Protec t i on o f  M i ce and  Rats  From Sar i n  Po i son i ng 
Taken from Reference 88 . 
C o mp o u n d  
Orl 
HC-("-C-o-Ch,-- ClI,-�([\), 
CS 2Lo-,",-,",-, ",', 
0 ::--- I � 6-0-0-'"' 
C"r-�-F-t�r 
CH.oII CH, - CH - Ch, 
P R - 2  
M o u s e  
1 . 8  
1 . 6  
2 . 3  
1 . 4  
! . 0 9 
1 . 5  
3 7  
R e �  
4 . 8  
1 . 4  
4 . 1  
1 . 2  
1 . 7 
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Many of the compounds  wh i ch g ave more protec t i on than atrop i ne 
were tested i n  comb i n at i on wi th  atrop i ne or  w i t h  each other90 , 92 . 
Ten of  the  compounds were s hown to ra i s e  the  LD50 of  s ar i  n by a 
factor o f  4 to 20 when g i ven i n  combi nat i on w i th atrop i ne or each 
other p l u s  an  ox i me reac t i vator . Of  the  26 comb i n a t i ons  where j o i n t 
act i on exceeded i n  protec t i on the  s um of  the  act i v i t i e s of  the  
i nd i v i dual  component s , c arami phen (12) and three of  i t s ana l og s ( 20 ,  
£1 ,  2 2 )  were i nvol ved i n  1 7 .  Two o f  the  ten best  compounds were the 
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phenoth i a z i ne der i va t i ves  t r i fl upromaz i ne ( 24 )  and d i ethaz i ne ( 2 5 ) , 
wh i ch are u s ed c l i n i ca l l y  for other purposes . 
The order o f  the  act i v i ty of  the compound or comb i nat  i on of 
compounds  var i ed con s i derably  w i th d i fferent test systems , and no one 
compound was  best i n  m i ce and rats  under every cond i t i on .  Carami phen 
was se l ected for i nten s i ve study w i th d i fferent ACh E  i n h i b i tors , 
o x i me reac t i v ators and an i ma l  spec i e s  i n  compar i son w i t h  atrop i ne .  
The  mean act i v i ty o f  caram i phen rel at i ve to atrop i ne taken from 1 02 
separate t r i a l s i nd i c ated i t  to be 4 . 2  t i me s  a s  effect i ve an an -
t i dote . 
Co l eman et al . further exami ned the effect  on dose  l evel , w i t h 
p rotec t i on by caram i phen and atrop i ne po i soned w i th s ar i n92 . As the 
dose of  caram i phen was i n creased , the protec t i on afforded al so 
i ncreased , and up to 1 50 mg/ kg there was no i nd i cat i on of  a l i m i ted 
protect i on l evel . Atro p i ne i n creased i n  protect i on to a va l ue of 2 . 1  
at  2 0  mg/kg , but after t h i s l evel was  ach i eved l i t tl e i mprovement was 
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demonstrated even at doses  of  200 mg/kg . At 1 50 mg/kg caram i phen was 
over s i x  t i me s  as  act i ve as atrop i ne ( F i gure 8 ) . 
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F I GURE 8 
Protect i on Afforded M i ce Exposed to  Sar i n W i t h I ncreas i ng Dose of 
Carami phen ( 1 9 )  o r  Atrop i ne (11) i n  Comb i nat i on W i th P 2S  ( 30 . 0  
mg/kg ) . Taken from Reference 9 2 . 
PR = 
LDso dose  sar i n i n  an i ma l s treated w i th  ox i me + chol i no lyt i c  
LDso dose  s ar i n i n  untreated an i ma l s 
4 1  
Jov i c  a n d  M i l osev i c93 conducted a n  exten s i ve study empl oy i ng 
twe l ve cho 1 i no 1 yt i cs and n i ne d i fferent ant i chol i nesterase  i n h i b i tors 
on  po i son i ng i n  m i ce .  I n i t i a l l y the  doses  of 1 2  cho1 i no 1 yt i c s wh i ch 
p rotected 5 0% of  the  an i mal s po i soned by 1 . 3 x LOso of  arm i n (dose  
wh i ch caused 1 0 0% l etha l i ty i n  control untreated an i ma l s )  were 
determi ned . The  quaternary compounds ,  methyl atrop i ne and methy1 sco -
p o l  ami n e ,  o n l y  protected 50% of a n i mal s po i soned by 1 . 3 x LOso of  
arm i n  i n  doses  equa l  to the i r  LOso. Th i s  therapeut i c  va l ue i s  very 
poor due to poor penetrat i on i nto the eNS . The most  act i ve compound s 
were scopo 1 ami ne ( hyosc i ne ; 2 6 ) , at rop i ne (lJ) , c arami ph en (�)  and 
benacty z i ne ( 2 7 ) . 
o 
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On t h i s bas i s these  four compounds a nd  methyl atrop i ne ( a s  a represen ­
t at i ve quaternary compound )  were se l ected for further s tudy . The 
prev i ou s  s t udy l oo ked at d i fferent chol i nol yt i c s  aga i n s t  the  s ame 
ant  i cho 1 i nesterase  i nh i b i tor ( a rmi  n )  . S i nce protect i on afforded by 
d i fferent  chol  i no l yt i cs was  dependent on the org anophosphate ( OPC ) 
u sed , i t  was  i mportant to s ee i f  s i m i l ar resu l t s  w i t h  the  most  act i ve 
antagon i st s  were obt a i ned u s i ng other OPC . N i ne d i fferent ant i -
chol  i ne sterase  i nh i b i tors  were u sed , and a s ummary of  these  res u l t s  
i nc l ud i ng t h e  more i mportant " nerve g a s "  agent s  s ar i n ,  soman and 
t abun i s  presented i n  Tabl e 3 .  The res u l t s  demonstrate that the  
order of  protect i on i s  dependent on the  antagon i st and the  OPC u sed . 
Carami phen was  the  most  act i ve aga i n s t  s ar i n ,  soman and tabun , wh i l e  
atrop i ne and s copol ami ne  were better aga i n s t  ami ton . Methyl atrop i ne 
was  i n act i ve aga i n s t  a l l three nerve g a s  agent s .  Benactyz i ne was  
approx i mate l y  equal  to  atrop i ne aga i n s t  the  nerve agen t s . The most  
act i ve chol i no l yt i cs col l ect i ve l y  aga i n s t  s a r i n ,  soman a nd  tabun were 
caram i phen and atrop i ne ,  of  wh i ch carami phen was the most  act i v e .  
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TABLE  3 
The  Protect i ve Do ses  ( PDso) and Protec t i ve I ndex ( P I ) of  
Some Ant i mu scar i n i c  Agents  i n  M i ce Po i soned by OPC93 
PDso ( mg/kg ) , ( P I )  
Benact - Methyl -
OPC Atrop i ne Hyosc i ne Carami phen yz i ne atrop i ne 
Armi n 3 . 1 2 3 . 39 1 . 7 1  2 . 7 5 1 . 3 9  
( 2 7 . 2 )  ( 45 . 1 )  ( 2 1 . 3 )  ( 1 1 . 0 ) ( 5 . 0 )  
Sar i n 4 . 1 2 1 0 . 00 3 . 45 5 . 20 I n act i ve  
( 2 0 . 6 )  ( 1 5 . 3 )  ( 1 0 . 6 ) ( 5 . 8 )  
Soman 9 . 87  1 3 . 90 4 . 40 9 . 03 I n act i ve 
( 8 . 6 )  ( 1 1 . 0 )  ( 8 . 3 )  ( 3 . 3 )  
Tabun 3 . 2 5 8 . 63 2 . 05 1 .  78  I n act i ve 
( 2 6 . 4 )  ( 1 7 . 7 ) ( 1 7 . 8 )  ( 1 7 . 1 )  
Ami ton 0 . 44 0 . 33 1 .  78 2 . 1 2 0 . 5 2 
P I  = LDso o f  chol i no l yt i c/ PDso of  s ame chol i no l yt i c .  
I t  i s  wel l known that  atrop i ne potent i ates  the  protec t i ve 
effects  o f  ox i me s  and that  a comb i n at i on of  ox i me and atrop i ne g i ves  
t he  be s t  protect i on and t herapeu t i c  effect aga i n s t  organophosphate 
po i son i ng .  Therefore a further s tudy compared the  protect i on 
afforded by atrop i ne and carami phen w i th the ox i me 2 - PAM . The 
resu l t s  ( Tabl e 4 )  show that  caram i phen i n  combi nat i on w i th  2 - PAM 
potent i ated t he  protect i ve effect . A comb i n at i on of caram i phen ( 1  x 
PDso) , and 2 - PAM ( 50 mg/kg i . p . )  protected al l a n i ma l s poi soned by 
1 0 . 4  x LDso o f  arm i n  and 50% of an i mal s po i soned by 1 5  x LOso of 
arm i n .  The PDso o f  atrop i ne i n  comb i nat i on w i th  the  s ame dose  of 2 -
PAM ( 50 mg/kg ) o n l y  gave 1 00% protect i on a t  6 x LDso o f  armi n .  
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TABLE  4 
Therapeu t i c  E ffect s  o f  Carami phen and Atrop i ne  W i t h  2 - PAM93 
Drug 2 - PAM Armi n Re s u l t 
(mg/ kg )  ( mg/kg ) L050  Death/Tested % Surv i va l  
Caram i phen 
1 . 7 1  0 1 . 0 0/6 1 0 0  
1 . 7 1  0 1 . 3  3/6 50 
0 50 . 0  1 . 3  2/6 66 
1 . 7 1  5 0 . 0  1 . 3  0/6 1 0 0  
1 . 7 1  5 0 . 0  2 . 6  0/6 1 0 0  
1 . 7 1  5 0 . 0  5 . 2  0/6 1 00 
1 . 7 1  5 0 . 0  1 0 . 4  0/6 1 00 
1 . 7 1 5 0 . 0  1 5 . 0  3/6 50 
1 . 7 1 5 0 . 0  20 . 8  6/6 0 
Atrop i ne 
3 . 1 2 0 1 . 0  0/6 1 00 
3 . 1 2 0 1 . 3  2/6 66 
3 . 1 2 5 0 . 0  1 . 3 0/6 1 0 0  
3 . 1 2 5 0 . 0  6 . 0  0/6 1 0 0  
3 . 1 2 5 0 . 0  1 1 . 5  4/6 3 3  
3 . 1 2 5 0 . 0  1 4 . 3  6/6 0 
Co l eman et al . h a s  s tated that  the  E050 of  an ant i mu scari n i c  drug 
may not  a l ways be a good i nd i cat i on of  i t s effi cacy i n  treat i ng 
an i ma l s po i s oned by organophosphates88 . I t  has  been proposed that at 
h i gh doses  d i fferent mechan i sms may be opera t i ng i n  the protect i ve 
act i on aga i n s t  po i son i ng ( a l though compet i t i on at central mu scar i n i c  
s i t e s  i s  the  most  i mportant mecha n i sm for protect i on ) 88 , 89 , 95 . Green 
et a l . 94 proposed t h i s add i t i ona l  mechan i sm to be due to an ant i con­
vu l s an t  e ffect a t  h i g h  doses , wh i ch add i t i ona l l y  contr i butes to  
protect i on .  Convul  sant  s e i  zures  cau sed by  ant i cho  l i  nesterases  are 
reversed by ant i convul s an t s96. I n  a further ser i e s  of  experi ments , 
Jov i c  and M i l o sev i c93 exam i ned carami phen and atrop i ne for the 
4 5  
protect i o n  a fforded to  m i  ce  when the  d o s e  of  the  c h o  1 i no  1 yt  i c w a  s 
a l tered from 2 . 0  t o  1 0 . 0  x POso i n  a n i mal s po i s oned by a constant  
dose  of  3 . 0  x LOso o f  ami  ton . The re su l tant  protect i on p l otted 
aga i n s t  dosage  i s  s h own i n  F i gure 9 .  I t  can be s een t hat atrop i ne 
gave i ncreased protec t i on w i th i nc rea s i ng do sage unt i l  max i mum 
protect i on was  obt a i ned w i t h  4 . 0  X POso. In cont  ras t ,  protect i on 
g i ven by carami phen was s t i l l  i ncrea s i ng w i th  10 x POso. 
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The  Protect i ve E ffect s  of  Carami phen and Atrop i ne 
a s  a Func t i on of  the  Doses  to M i ce Po i s oned 
by 3 x LOso of Ami ton93 
The mos t  effect i ve compounds  have many d i verse s tructura l  
features . Carami phen and s ome of  i t s deri vat i ve s  do  seem to  con st i ­
t u te one s tructural  type of  agent wi t h  good protec t i ve act i v i ty .  I t  
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i s  not  apparent why some agent s  wh i ch are more potent  ant i mu scar i n i c s  
a re not a s  effect i ve ,  but a report by Mad i l l  e t  a l . 97 s ugges t s  that 
i t  depends on t he i r CNS act i v i ty .  I t  was found t hat for a s er i e s of 
n i ne compounds ,  abi l i ty to protect g u i nea p i g s  from sar i n po i s on i ng 
para l l el ed t he i r CNS a n t i muscar i n i c  act i v i ty ,  not  the i r  per i pheral 
act i v i ty .  For exampl e ,  caram i phen was the  mos t  e ffect i ve protect i ng 
agen t , a l though  i t  h ad on l y  1 / 1 00 the  peri pheral  ant i mu scar i n i c  
act i on o f  atrop i n e .  H i g h  1 e v e  1 s of  therape u t i  c protect i on were 
d i rect l y  rel ated to  h i gh l evel s of  central  an t i c ho l i nerg i c  potency . 
Green e t  a l . 94 l oo ked at the  centra l - and peri pheral  ant i mu s -
car i n i c  act i v i t i e s o f  atrop i ne and f i ve rel ated d rugs . Al l f i ve 
compounds  were super i or to atrop i ne i n  protect i ng rats  po i s oned by 
s ar i n .  The  mos t  effect  i ve compounds  were G3063 ( 2 0 )  ( ana l og of 
caram i phen ) and PMCG ( 28 ) . 
At l ow do se s  of  s ar i n a l l s i x  drugs  showed a d i rect rel a t i onsh i p  
between centra l  ant i mu scar i n i c  act i v i ty ( antagon i sm o f  oxotremor i ne 
i nduced tremors ) and protect i on .  
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B r i mbl ecombe e t  al . 95 compared the  central  and peri pheral  
ant i acetyl cho l i ne potenc i e s  of  a number of  drugs w i t h  t he i r  effect ­
i veness  when u sed al one  and i n  conj unct i on w i t h  P2S i n  protec t i ng 
m i c e ,  rats  and g u i nea  p i gs . The compounds tested and the  resu l t s  of 
protect i ve act i on are s ummar i zed in  Tabl e 5 .  The re su l t s  demonstrate 
that  t he add i t i on of  the  o x i me markedl y  poten t i ated the  protect i ve 
act i on o f  al l t he  ant  i cho  1 i nerg i c drugs tested . The h i gher protec ­
t i on was  obta i ned w i t h  carami phen (l�)  and i t s anal og G3063 ( 2 0 ) . 
There was no  s t at i s t i cal l y  s i gn i f i cant  correl at i on between the  
per i  phera  1 ant  i c ho  1 i nerg i c potenc i e s  (measured e i ther  by product i on 
of  myd r i a s i s or by bl ockade of  oxotremor i ne- i nduced sa l i vat i on )  or 
the cent ra l  poten c i es ( bl ockade of oxotremor i ne - i nduced tremors ) and 
t he i r  ab i l i ty to protect from the l et hal effects  of sar i n .  
TABLE  5 
The  Protect i ve Act i on s  Aga i n st  Sar i n of  Some 
Ant i acetyl chol i ne Drugs When Used Al one or i n  Comb i nat i on 
W i t h  the Ox i me P2S  i n  Rat s ,  M i ce and Gu i nea  P i g s95 
Protect i on Rat i o s 
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Ant i acetyl - Rats M i ce Gu i nea  P i g s  
chol i ne Drug Drug Drug Drug Drug Drug Drug 
( 50 tunol /kg ) Al one + P2S Al one + P2S Al one + P2S 
Atrop i ne 1 . 2 2 7 . 5  1 . 1  2 . 6  1 . 3 35 . 8  
Hyosc i ne 1 . 2 9 . 3  1 . 3 2 . 0  1 . 4 2 1 . 4  
C arami phen 4 . 1  1 1 . 8 1 . 1  2 . 5  1 . 1  1 8 . 6  
G3063 9 . 3  79 . 5  1 . 4  6 . 3  1 . 5  58 . 3  
PMCG 2 . 0  6 2 . 3  1 . 5  3 . 0  1 . 5  84 . 2  
D i tran 2 . 0  33 . 6  1 . 4  2 . 4  1 . 4 70 . 2  
P2S  1 . 1  1 . 2  1 . 1  
Ant i acetyl cho l i ne drugs and/or P2S  were g i ven i ntramuscu l arl y 1 5  m i n  
before s ar i n  subcutaneou s l y .  
T h e  dose o f  P2S  g i ven i n  conj unct i on w i th  drug was 1 4 0  �mo l / kg .  
L u l l man et al . 98 compared t he  t herapeut i c  effect i venes s  of 
dexet i m i de ( 29 )  and atro p i ne i n  po i son i ng .  Dexet i m i d e ,  the  b i o -
l og i ca l l y  act i ve enant i omer o f  benzet i m i de ,  i s  a potent ant i muscar ­
i n i c  drug99 . S i nce i t  i s  more hydrophob i c  and  po s se s s  a l ower pKa 
( 8 . 7 )  than a tropi ne ( 9 . 8 - 1 0 . 2 ) , i t  read i l y  penetrates  l i p i d  barr i ers 
and becomes h i g h l y  accumul ated i n  d i fferent t i s s ues , i nc l ud i ng the 
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CNS a s  e v i dent  from the  h i gh central  potency of  the  drug . Bertram et 
a l . 100 i n i t i al l y s howed t hat dexet i mi de appl i ed prophyl act i cal l y  was  
s u pe r i o r  to atro p i ne  i n  m i ce po i soned w i th DFP . Lu l l man et al . 98 
s h owed 29 was  better t han atrop i ne when appl  i ed after the  onset of  
i ntox i cat i on .  Atrop i ne ( 1 00 J1ITlol ) gave a protect i ve factor of  12, 
wh i l e  dexet i m i de ( 1 0 0  J1ITlol ) gave a factor of  90 aga i n st DFP po i son i ng 
i n  m i c e .  
OMPA , an ant  i cho  1 i nesterase  agent w i  th  1 i tt 1 e eNS effects ,  was  
admi n i s tered to i nduce a pure l y  per i pheral  i ntox i cat i on .  No d i f ­
ference i n  p rotec t i on of  the  tox i c i ty o f  th i s  ant i -AChE  agent cou l d  
b e  not i ced between atrop i ne o r  dexet i mi de .  I n  g u i nea  p i g s , the 
tox i c i ty of  t he  central l y  act i ng organophosphates  was  e s t i mated to  be 
20 J1ITlol / kg for DFP ,  and 4 J,lmol  for paraoxon ( Tabl e 6 ) . The doses  as 
shown coul d be i ncreased drast i ca l l y  i f  the g u i nea  p i g s were treated 
w i t h  the ant i dote m i  xture at the onset of  i ntoxi  cat i on .  They noted 
that  w i th i ncre a s i ng dos e ,  part i cu l arl y w i t h  DFP ,  the  i ntox i cat i on 
devel oped very rap i dl y .  The  LD50 of  DFP  i ncreased to 1 300  J,lmo l / kg 
when treated w i th dexet i mi de ( a  6 5 - fo l d i ncreas e )  wh i l e  the LD50 of  
paraoxon cou l d  be i ncrea sed to approx i matel y 300  J,lmol / kg (a  7 5 - fol d 
i ncrease ) . 
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TABL E  6 
Treatment of  Organophosphate I ntox i cat i on i n  Gu i nea P i g s98 
Atro p i ne  1 0 0  J'M/kg Dexet i m i de 1 0 0  J'M/kg 
Drug Ob i dox i m  1 0 0  J'M/kg Ob i dox i m  1 00 J'M/kg 
24 Hr . 24 H r .  1 0  M i n .  24  Hr . 
DFP  J'M/kg 
1 7  0/3 
2 1  2/3 
28 3/3 
1 2 50  2/3 1/4 1/4 
1 3 2 0  2/3 1/4 1/4 
1 360  3/3 3/6 3/6 
Paraoxon J,LM/kg 
3 . 7  0/3 
4 . 5  2/3 
5 . 2  3/3 
272  1/2  
309  0/3 1/4 1/4 
363  2/3 2/4 2/4 
Lu l l man et a l . 98 add i t i ona l l y  compared the  d i str i but i on and ac ­
cumu l at i on of atrop i ne and dexet i m i de i n  var i ous  central  and per i phe -
ral  t i s sues  and organ s .  The compounds d i  ffered remarkab l y  w i t h  
respect to  t he i r  pharmacoki net i c s . They i nd i cated t hat dexet i m i de 
accumu l ated much more rap i d l y  i n  t i s sues . Of part i cu l ar s i gn i fi cance 
i n  organophosphate po i son i ng i s  t he  accumu l a t i on rate i n  the  eNS . 
Dexet i mi de atta i n s  i t s h i ghest  accumu l a t i on rate ( t i s sue/pl a sma rat i o  
o f  4 )  w i t h i n  5 m i nutes  after appl i cat i on , whereas atrop i ne req u i res 
60  m i nutes  to reach a t i s sue/pl asma rat i o  of  0 . 4 .  The over propor -
t i on a l  accumu l at i on of  dexet i m i de i n  compar i son to atro p i ne can be 
shown as t he  t i s sue/pl a sma rat i os of dexet i mi de are expres sed as the  
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mul t i pl es of  atrop i ne t i s s ue/pl a sma rat i o  i n  var i ous  central  and 
per i pheral  t i s s ues  ( Tabl e 7 ) . T h i s shows dexet i mi de rap i d l y  pene ­
trates  the  b l ood - bra i n  barr i er ,  therefore y i el d i ng a h i gher  protec -
t i on o f  the  central  muscar i n i c  receptors . 
Organ 
L i ver  
K i dney 
D i aphragm 
TABL E  7 
T i s s ue/Pl a sma Rat i os of  Dexet i m i de Expres sed a s  
Mul t i pl es o f  the  T i s sue/Pl a sma Rat i os of  Atrop i ne 
i n  D i fferent Organs  and At D i fferent T i mes  
After Appl i cat i on 98 
Mul t i pl es of Atrop i ne T i s sue/Pl asma Rat i o  
( T i me After I nj ect i on )  
5 M i n .  1 5  M i n .  3 0  M i n .  
3 . 0  3 . 6  1 0 . 9  
3 . 0  2 . 1  4 . 7  
2 . 9  3 . 8  4 . 9  
Cerebrum 
Cerebe l l um 
Bra i n s tem 
1 2 . 5  
1 3 . 3  
1 5 . 3  
1 5 . 0  1 9 . 4  
1 6 . 5  1 1 . 3  
1 3 . 4  1 2 . 4  
60 M i n .  
6 . 6  
4 . 1  
1 . 2  
5 . 5  
2 . 7  
4 . 7  
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I t  i s  known that the  revers i bl e  type ACh E  i nh i b i tors cou l d  
demons trate  some protect i ve act  i on i n  organophosphate i ntox i cat  i on 
when admi n i s tered prophyl act i cal l y .  Lu l l man et a l . 101 i nterest i ng l y  
reported a new ser i e s  of  al kane- l , 6 - b i s ( a l kyl d i methyl ammon i um) 
deri  vat  i ves  wh i c h  showed good protect i on w i thout  any i n terference 
w i t h  the enzyme act i v i ty ( 30 ) . 
R methyl -decyl 
n 4 - 9  
The  opt i mum d i s t ance between the  cat i on i c  n i trogens for protec t i on 
was  s i x  c arbon s . The act i ve compounds d i d  not exert gang 1 i on i c 
bl ock i ng act i v i ty .  The subst  i tut i on o f  one methyl group at each 
n i trogen atom by l arger groups y i e l ded compounds  w i t h  reduced gangl i ­
on i c  or  neuromuscu l ar bl ock i ng act i v i ty102 . Some add i t i ona l  hexane -
b i s - ammon i um compounds were a s  effect i ve a s  atrop i ne i n  combatt i ng 
the  tox i c i ty o f  DFP  i n  m i ce 103 . The effect was found rel ated to the  
antagon i st i c  act i on of  the  compounds aga i n s t  ACh and carbachol . The 
mode of  act i on of  the  most  effect i ve hexane - b i s - ammon i um compound s as  
a n t i dotes  d i ffers  from that of  atrop i ne i n  that  they were found to be 
non -compet i t  i ve antagon i s  t s 104 . Lu l l man et al . therefore proposed 
these  compounds  react w i t h  s i de receptors ,  produc i ng an a l l oster i c  
antagon i sm ,  and d i m i n i s h i ng the acces s i b i l i ty o f  ACh for the  recep ­
tor . The  mos t  powerful protec t i ve agent i n  th i s  ser i e s  wa s hexane-
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b i s - ( d i methy l - phtha l i m i dopropyl - ammon i um brom i d e )  (Jl) . I t  h ad a 
protect i ve rat i o  of  2 . 84 compared to 1 . 85  for atrop i ne ( Tabl e 8 ) . 
TABLE  8 
Act i on of  Some Hexane - 1 , 6 - B i s -Ammon i um Der i vat i ve s  
on the  Tox i c i ty of  DFP  i n  M i ce 103 
R 





Phtha l  i m i dopropyl (Jl) 
Atrop i ne (U) 
Me  Me 
1 +  + I 
R- N - ( CH2 ) 6- N - R  I I 
Me Me 
Dose 
( mo l e x 1 O-5/kg )  
ll) 1 7 . 5  
1 0 . 0  
8 . 4  
4 . 8  
7 . 6  
2 . 7  
1 . 0 
5 . 0  
1 0 . 0  
LD50 of  DFP  
(mo l e x 1 0-5/kg )  
2 . 6 5 
6 . 90 
6 . 80 
4 . 90 
2 . 80 
4 . 30 
7 . 50 
4 . 90 
5 . 60 
5 . 60 
F 
2 . 60 
2 . 5 5 
1 . 83 
1 .  05  
1 .  62  
2 . 84 
1 . 85  
2 . 1 1 
2 . I I  
F Protec t i ve Rat i o  LD50 of DFP  after  pretreatment/LD50 of  DFP . 
o 0 
� CH! CH3 � ©t ' 0 '  '0 / 1QJ N -(CH ) - N - (CH ) - N - (CH ) - N  0 C/ 2 ! , 2 6 ,  2 !  'c 
• CH! CH! " o 0 
The comb i ned pretreatment w i th  atrop i ne and a hexane - b i s -
ammon i um der i vat i ve gave  a more than add i t i ve protect i on ag a i n s t  DFP  
i n to x i c a t i o n .  H e x a n e  b i s - ( d i methyl - phtha l i m i dopropyl - ammon i um 
brom i d e )  was  the most powerfu l  protect i ve agent u sed a l one . I n  
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comb i n at i on w i t h  atrop i ne i t s protec t i ve factor wa s about 16 ( Tabl e 
9 ) . 
TABLE  9 
I n fl uence o f  Pretreatment by a Comb i nat i on of Atrop i ne and 
Hexane - B i s - Ammon i um Der i vat i ve s  Upon the  Lethal  Dose of  
DFP  i n  M i c e 103 
Do se  
Me Me 
1 +  + I 
R - N - ( CH 2 ) 6- N - R  I I 
Me Me 
Atrop i ne Dose 
R ( mo l e x l O-S/ kg )  ( mo l  e x l O -S/ kg )  LDso DFP 
Methyl (1) 1 7 . 5  0 . 5  
( Hexamethon i um )  1 7 . 5  5 . 0  
Propyl 8 . 4  0 . 5  
8 . 4  5 . 0  
Phenacyl 7 . 6  0 . 5  
7 . 6  5 . 0  
Phtha l i m i do - 2 . 7  0 . 5  
propyl ell) 2 . 7  5 . 0  
F Protect i ve Factor = LDso of  DFP  After Pretreatment 
LDso of  DFP  
7 . 9  
37 . 0  
1 0 . 0  
1 2 . 0  
8 . 6  
1 3 . 0  
38 . 5  
4 1 . 5  
F 
3 . 0  
1 4 . 0  
3 . 8  
4 . 5  
3 . 2  
4 . 9  
1 4 . 5  
1 5 . 7  
The  mos t  effect i ve compounds a s  ant i dotes  have many d i verse 
s t ructura  1 feature s . Caram i phen does seem to con s t i tute  one 
s t ructura l  type of  agent w i t h  good protect i ve act i v i ty .  Of  i mportant 
concern i n  the key tox i c  effect for l etha l i ty i s  the act i on of ACh on 
po s t synapt i c  muscar i n i c  receptors i n  the bra i n  to produce resp i ratory 
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para l ys i s .  Therefore , there are  t h ree reasons  wh i c h cou l d  i n fl uence 
the  ant i dota l  propert i es of  an ant i muscar i n i c  for organophosphate 
po i son i ng .  
One approach to an i mproved protec t i ve agent wou l d  t h u s  i n vo l ve 
a search for compounds w i t h  greater eNS act i v i ty compared to per i phe ­
ral  act i on .  I n  whol e an i ma l  t e s t s  d i fferent ED50 va l ues  are often 
found for per i p heral  ( mydr i at i c )  and central  ( bl ock of  oxotremor i ne ­
i nduced t remors ) act i on s  o f  a g i ven muscar i n i c  agent l05-107 . I n  man 
the dose of a trop i ne requ i red to produce per i pheral  effects  i s  0 . 2 5 - 2  
mg/kg , whereas t h e  dose t o  produce central  effects  wh i ch rel i eve 
symptoms of Park i n son ' s  d i sease  i s  54 mg/day . A s i ng l e dose of  3 0 - 50 
mg of  atrop i ne i s  requ i red to produce centra l  p sychotomi met i c  effects  
i n man . I t ' s  not  surpr i s i ng that  drugs  s i gn i f i cant l y  more potent 
t h an a trop i ne and s copol am i ne in  v i vo i n  t he  per i phera l  nervous sys ­
tem have not  been found . Usua l l y  for a g i ven dose  o f  agent t he  per i ­
phera 1 effect i s  more pronounced , and t h  i s  h a s  been attr i  buted to a 
greater d i ff i cu l ty i n  obta i n i ng the  s ame bra i n  a s  per i pheral  concen ­
t rat i on rather t h an to d i fferences  i n  the  receptors at  d i fferent 
s i te s . The  rat i o  of  the  potenc i e s of  the  enant i omers of  d i methyl ­
ami noethyl  2 - cycl ohexyl - 2 - hydroxy - 2 - phenyl acetate  was e s s e nt i a l l y  
con stant  when ca l cu l ated from aff i n i ty con s t a n t s  determ i ned o n  g u i nea  
p i g  i l eum,  from mydr i at i c  potenc i e s i n  m i c e ,  and from poten c i e s  for 
bl ockade of  oxotremor i ne - i nduced s a l i v at i on and tremor i n  m i ce 106 . 
Other stud i e s us i ng rad i ol abel ed compound s h ave fa i l ed to f i nd d i f­
ferences i n  spec i f i c  b i nd i ng of  some antagon i s t s  to mu scar i n i c  recep ­
tors  o f  bra i n  compared to i n te s t i n a l  smooth  musc l e 157 , 158 . On l y  
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recen t l y  h a s  i t  been recog n i zed that  t here are two or more subc l as ses  
o f  mu scar i n i c  receptors p resent  i n  vary i ng proport i on s  in  d i fferent 
organ s  and t i s s ues . Neverthel e s s ,  the more l i poph i l i c an tagon i s t may 
be ab l e to penetrate the  bra i n  to a greater extent and exert a better 
p rotec t i ve effect . 
A second approach for ga  i n  i ng i ncreased ant  i dota  1 act  i on wou 1 d 
be to  search  for antagon i s t s  w i th a greater rel a t i ve affi n i ty for the 
rel evant central  muscar i n i c  receptors . There i s  now s ubstant i a l 
e v i d ence s ugges t i ng the  ex i s tence of  ph armaco l og i ca l l y  and funct i on ­
a l l y  d i st i nc t  mu scar i n i c  receptor systems l08-111 ( see F i gure 1 0 ) . 
Receptor c l a s s i f i cat i on i s  based on the  d i fferent i a l sens i t i v i ty to 
p i renzep i ne ( 3 2 ) , a muscar i n i c  antagon i s t .  Those  receptors wh i ch  
d i s p l ay a h i g h aff i n i ty for p i renzep i ne are c l a s s i f i ed as  M I , whereas 






Wh i l e  atrop i ne fa i l s  to d i s t i ng u i sh  between these  receptor systems , 
p i renzep i ne d i spl ays a much greater than the  neces s ary ten - fol d 
aff i n i ty for the  M I  than the  M2 s i te 109 . 
A d i s t i ng u i s h i ng feature of these  receptors i s  that  they are 
uneven l y  d i s tr i buted throughout var i ous  organs and t i s s u e s . Yamamu ra 
et  a l . 1l3 found that  p i renzep i ne preferent i a l l y  b i nd s  w i t h h i g h 
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aff i n i ty i n  the  rat  cerebral cortex , h i ppocampus  a nd  corpus s t r i atum 
and w i th l ow aff i n i ty i n  the heart , cerebel l um and i l eum . Appl i c a ­
t i on of autorad i ograph i c  v i s ua l i za t i on of t h e  mu scar i n i c  receptors 
has revea l ed the  Ml s i te s  predom i nate i n  the  basa l  gangl i a ,  h i ppo ­
campus ,  cortex and s t r i atum ,  wh i l e  the M2 s i te s  predom i nate i n  the 
bra i n stem ,  medu l l a , cerebel l um ,  the heart and smooth mu sc l e l13-116 . 
I n  contrast  to  the  M l  receptor , there are currentl y no se l ect i ve 
M2 receptor rad i ol i gand s for d i fferent i at i ng between these  receptors 
i n  the  bra i n .  Therefore , another way to exami  ne s e l ect i v i ty i s  to 
s tudy the e ffect on funct i ona l  respon ses  that have been character i zed 
on the  ba s i s  of the  M I -M2 c l a s s i f i cat i on .  The muscar i n i c  receptor­
s t i mu l ated phosphat i dyl i no s i to l  turnover i n  rat  bra i n  appears  to be 
predom i n a n t l y  an Ml respon s e ,  whereas chol i nerg i c  receptor-med i ated 
i nh i b i t i on of  adenyl ate cycl a se  act i v i ty has been c l a s s i f i ed as an M2  
receptor phenomenon l17 . 
Several  known mu scar i n i c  antagon i st s  have been found to be 
se l ect i ve compounds . G i bson et al . p urported 3 - q u i nucl i d i nyl  
xanthene - 9 - carboxy l ate ( QNX )  to be  M l  se l ect i v e  118 . N i l vebrand and 
Sparf  reported p i renzep i ne ( 3 2 ) , oxybutyn i ne ,  t r i hexyphen i dy l  and 
d i cycl om i ne h ad g reater affi n i ty for parot i d  g l and receptors than 
i l eum or  b l adder receptors  i n  gu i nea  p i g s l19 . They found secover i ne 
had the  oppos i te se l ect i v i ty .  Secover i ne ,  wh i c h i s  0 . 6  t i me s  a s  
act i ve a s  atrop i ne on i n test i n a l  smooth mu sc l e ,  i s  more effect i ve a t  
i n h i b i t i ng oxotremor i ne - i nduced tremors than l acr i mat i on or sa l i v a ­
t i on 120 . Add i t i ona l  reports  have conf i rmed tr i hexyphen i dyl , d i cycl o ­
m i ne ,  and oxybutyn i n  are  Ml  se l ect i ve muscar i n i c  antagon i s t s 12 1-123 . 
FIGURE 1 0  
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A recent report has i nd i cated secover i ne may be a non - se l ect i ve M2 
muscar i n i c  antagon i s t on rat heart and bra i n  receptors 124 . A group 
of  compounds  wh i ch do  exh i b i t  an  M2  se l ect i v i ty are the b i s - and 
t r i s - qu aternary neuromus cu l ar bl ock i ng agents 125 . They are more 
potent at antagon i z i ng n i cot i n i c  effect s ,  but they al s o  i n h i b i t  
mus c ar i n i c  receptors . Ga l l am i ne h a s  been exten s i ve l y  s tud i ed for i t s 
M2  se l ect i ve act i v i ty 126 , 127 . I f  a d i fference ex i s t s  i n  the type of 
receptors at t he  c r i t i ca l  s i te in  the  resp i ratory center and at s i te s  
g i v i ng tox i c  effects  ( on heart or  bra i n  areas t hat produce convu l ­
s i on s ) , then  an antagon i st w i th  proper receptor se l ect i v i ty wou l d  be 
more bene f i c i al . 
An add i t i on a l  pos s i bl e  approach for f i nd i ng a better protect i ve 
agent wou l d  be to s e arch for ant i mu scar i n i c s that  are se l ect i ve for 
po st synapt i c  receptors . I t  i s  wel l e stabl i s hed that  there are 
mu scar i n i c  presynapt i c  receptors  that  i n h i b i t  ACh re l ease  from both 
central and per i pheral  chol i nerg i c  neuron s . I t  i s  pos s i bl e  that  
there may be d i fferences  between pre- and po s t synapt i c  muscar i n i c  
receptors t hat cou l d  affect the affi n i ty o f  d i fferent antagon i s t s ,  
j u s t  a s  h a s  been e stabl  i s hed w i th  other neurotransm i tter receptor 
systems . 
I n  t he  presence of  a cho l i nesterase i nh i b i to r ,  the pot as s i um 
( K+) - or e l ectr i ca l l y - s t i mu l ated rel ease  of  ACh from rat cort i ca l  
bra i n  s l i ce s  i s  poten t i ated by  atrop i ne 128-130 . Th i s  potent i at i on i s  
reversed by the  appl i cat i on of oxotremor i ne or methacho l i ne .  I t  has  
a l s o  been s hown that  K+- st i mu l ated rel ease of  ACh  from rat bra i n  
h i ppocampa l  synaptosomes i s  i n h i b i ted by ACh ,  and atrop i ne reverses  
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th i s  act i on 131 . K i l b i nger132-134 reported s i m i l ar exper i ments  w i th  
s tr i p s of  gu i nea  p i g  i l eum . It  has  al so been shown that  atrop i ne 
i ncreases  and oxotremor i ne  decreases  rel ease  of  ACh i n  the  rat 
phren i c  nerv e - d i aphragm preparat i on 135 . 
K i l b i nger136 has  s t ated the  funct i on of  presynapt i c  muscar i n i c  
receptors  i s  t o  modul  ate  the  output o f  neurotransm i tters  such as 
dopam i ne  and norep i nephr i n e ,  i n  add i t i on to  ACh i t se l f .  Therefore i t  
i s  fel t t hat  receptors  l ocated presynap t i cal l y  may d i ffer from those  
receptors  l ocated post synapt i c a  1 1  y .  K i 1 b i  nger e t  a 1 . 137 found the 
pA2 va l ues  of  a range of  muscar i n i c  antagon i s t s  were s i m i l ar at both 
pre- and po s t synapt i c  muscar i n i c  receptors us i ng the rabb i t  i so l ated 
heart  preparat i on .  Several  other stud i es of  antagon i st s  at  pre - and 
postsynapt  i c receptors have shown the receptors to  be s i m i l ar  at  a 
g i ven s i te 138 , 139 . I t  has  yet to  be es tabl i s hed whether  presynapt i c  
receptors  i n  the  bra i n  are M I , M2  or a d i fferent type receptor . 
Marc h i  and coworkers 140 , 141 have reported that  presynapt i c  receptors 
wh i ch i n h i b i t the  rel ease  of  ACh d i ffer from those autoreceptors 
wh i ch i nh i b i t the outfl ow of  dopam i ne from dopam i nerg i c  termi na l s .  
T h i s  was ba sed upon the  ab i l i ty o f  the  M I  antagon i s t s  d i cycl omi ne and 
p i renzep i ne to i n h i b i t  those  receptors modu l at i ng dopam i ne rel ease  
and not those med i at i ng ACh  rel ease  from superfu sed rat s t r i ata l  
synapto some s . I n  contrast , t he  M2 antagon i s t gal l am i ne has  been 
s hown more potent at autoreceptors i nh  i b i t i ng overfl ow of  ACh than 
dopam i ne from rat neo s t r i ata l  s l  i ce s ,  whereas p i renzep i ne was not 
sel ect i ve 142 . Therefore , presynapt i c  receptors may not be homogene­
ou s ;  some may be M I  wh i l e  some may be M2 . 
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An ana l ogue o f  oxotremori ne , BM - 5  ( 33 ) , h a s  been reported to 
enhance ACh outfl ow and a l so contract smooth  musc l e 143 . Th i s  
compound h a s  therefore been proposed to act a s  a pre synapt i c  antag o ­
n i s t and a po s t synapt i c  agon i s t 143 , 144 . 
I n  c a s e s  of  po i son i ng by chol i nesterase  i nh i b i tors , the  i n -
creased l evel s o f  ACh wou l d  hel p retard further re l e ase  o f  ACh from 
nerve end i ngs . However ,  i f  an ant i muscar i n i c  agent i s  admi n i stered 
wh i ch bl ocks  pre synapt i c  as wel l as postsynapt i c  receptors , then  the 
auto i n h i b i t i on i s  removed . Add i t i ona l  ACh w i l l  be rel ea sed , and the 
i ncreased l evel s in the synapses  w i l l  tend to reverse the compet i t i v e 
i n h i b i t i on of  the antagon i s t .  
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G .  Concl u s i on 
The  mos t  effect i ve muscar i n i c  antagon i st s  as  ant i dotes  have many 
d i verse structural  feature s . Carami phen and aprophen appear to 
con s t i tute  types of  agents  w i th  good protect i ve act i on .  I t  i s  
i mportant  to recogn i ze the  key tox i c effect for 1 etha  1 i ty i s  the 
act i on o f  ACh on postsynapt i c  receptors in  the  bra i n  to produce 
resp i ratory paral y s i s .  An i mproved ant i muscar i n i c  agent wou l d  not 
neces s ar i l y  need to be more potent than atrop i ne ,  but rather i t  wou l d  
need t o  have  a proper bal ance o f  central  versu s  per i pheral  act i on 
w i th  a s  l i tt l e  bl ock  of  presynapt i c  receptors a s  po s s i bl e .  I ncreased 
a n t i dota l  act i on may be obt a i ned w i th g reater rel a t i ve  affi n i ty for 
the rel evant  central  muscar i n i c  receptors . An i deal  agent shou l d  
e ffect i ve l y  i nh i b i t  t h e  centra l l y - med i ated resp i ratory depre s s i on at 
a dose  t h at i s  not too tox i c .  I n  cases  o f  h uman po i son i ng w i th  
organophosphate  i n sect i c i de s , doses  o f  atrop i ne are g i ven wh i ch wou l d  
b e  l etha l  i n  t h e  absence of  excess  ACh . The pat i ent mus t ,  i n  effect ,  
be t i t rated w i th  a n  ant i chol i nerg i c  t o  combat the  bu i l d  u p  o f  ACh ,  
but a n  excess  o f  t he  ant i cho l i nerg i c  drug must a l so  be avo i ded . The 
m i l i t ary s i gn i f i cance of h av i ng an e ffect i ve ant i dote i s  obv i ou s . 
I I .  RESEARCH A IMS 
Po i son i ng by organophosphate cho l i nesterase  i n h i b i tors resu l t s  
i n  a r i se i n  A C h  concentrat i on s  i n  synapses  at n umerou s  l ocat i on s  i n  
the  body , resul t i ng i n  many pronounced pharmacol og i c  effects . 
Al though a fal l i n  bl ood pre s s u re , exce s s i ve s ecret i on s , bronc h i a l  
constr i c t i on ,  a nd  thorac i c  mu scl e weakness  contr i bute to  resp i ratory 
d i s tre s s , the  key tox i c  e ffect for l et h a l i ty i s  the  act i on o f  ACh on 
postsynapt i c  muscar i n i c  receptors i n  the bra i n ,  produc i ng re s p i ratory 
paral ys i s 159 . The  treatment for organophosphate po i son i ng i n vol ves  
admi n i ster i ng a n  ox i me reac t i vator to restore t he  act i v i ty of  
acetyl cho l i ne sterase  a nd  an ant i muscar i n i c  agent to bl ock  t he  
response of  many t i s sues  a nd  organs  i n  the  h uman body to the  exces s  
ACh .  Ox i me react i vators o f  chol i nesterase  c a n  b e  u sefu l  i n  restor i ng 
enzyme act i v i ty ,  but  even i n  the  most  favorabl e c i rcumstances ,  an 
ox i me react i vator wh i ch i s  a quaternary s a l t wi l l  not read i l y  
penetrate the  CNS ; there fore , reac t i v at i on w i l l  not occur  at central  
synapses  a s  e ffect i ve l y  a s  i t  does at per i pheral  s i te s . Presen t l y  
atrop i ne s u l fate i s  the  s tandard ant i muscar i n i c  agent u sed c l i n i c al l y  
a s  a n  ant i dote . Atrop i ne i s  a potent ant i muscar i n i c  agent . However ,  
i t  h a s  two d i s t i nct d i sadvantages as  an  ant i dote for  nerve gas  
po i son i ng .  I t  i s  l es s  e ffect i ve centra l l y  t han peri pheral l y  as  an 
ant i muscar i n i c  (when adm i n i stered peri pheral l y ) and i t  promotes  the 
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rel ease  of  ACh from chol i nerg i c  neurons  by bl oc k i ng i n h i b i tory mu s ­
car i n i c  receptors presynapt i ca l l y .  The un l i m i ted u se  o f  atrop i ne i n  
treatment o f  men po i soned by organophosphate chol i nesterase  i n h i b i ­
tors  cou l d  be i neffect i ve i n  therapy and very d angerous .  The 
resu l t s  of  Col eman et a l . 92 and Jov i c  a nd M i l osev i c93 demon strate i t  
i s  probabl y s a fer  t o  g i ve repeated therapeut i c  doses  o f  carami phen 
than atrop i ne i n  the  treatment  of  po i son i ng by organophosphates .  
The a i m  of  t h i s  research i s  to f i nd a more effec t i ve ant i muscar ­
i n i c  agent  than  atrop i ne a s  an  ant i dote for  organophosphate  chol i ne s ­
terase  i n h  i b i tors . An i mproved agent wou l d not neces s a  r i  1 y need to 
be a more potent antagon i st  t han atrop i ne ,  but  rather i t  wou l d  need 
to have  a proper bal ance o f  central  versus  per i pheral  act i on w i th  as  
l i tt l e bl ock  o f  presynapt i c  receptors a s  pos s i bl e .  I ncreased 
ant i dotal  act i on may be obt a i ned w i t h  greater rel at i ve a ff i n i ty for 
the rel evant  central  muscar i n i c  receptors . 
Correl a t i ons  are to be sought  between the  rel a t i ve  ab i l i ty of  
the  compounds  to protect aga i n s t  soman po i son i ng and act i v i ty i n  
n umerou s  p harmacol og i cal  tests  de s i gned to g i ve i nformat i on on the 
s tructure - act i v i ty rel at i on sh i ps for p harmacol og i c  propert i e s wh i ch 
m i g h t  be i mport ant  i n  a better ant i dote . 
The  chem i s try i nvol ved i n  th i s  project  i s  a port i on of a 
cont i nu i ng program d e s i gned to d i scover a better  ant i mu scar i n i c  a s  an 
a nt i dote . The rat i on a l e l ead i ng to the de s i gn of the compounds  
descr i bed and des i red to  be synthes i zed in  th i s  project w i l l  be  
d i scus sed here i n  deta i l . W i th i n  the  scope of  the  program was chosen  
a l i m i ted set  of  compounds conta i n i ng many d i verse structural  
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features for con s i derat i on among the  h undreds of  reasona b l y  act i ve 
ant i muscar i n i c  agents . Some of  these  compound s are curren t l y  
marketed by var i ous  manufacturers and an authen t i c  s amp l e was  
requested . Numerous other compounds were e i ther  synthes i zed i n  other 
port i on s  o f  the  project or prev i ou s l y  ava i l ab l e from t h i s  l aboratory . 
Structures  o f  these  compounds w i l l  a l so be shown , and the  rat i ona l e 
for the  compounds to be i nc l uded i n  the  program w i l l  be d i scussed . 
A .  Caram i phen and aprophen compound s .  
Because  caram i phen 1.2 ,  and some of  i t s ana l og s  had prev i ou s l y  
been reported by Col eman e t  al . 88-92 to  be effec t i ve ant i dotes  
aga i n s t  s a r i n p o i son i ng ,  i t  wou l d  be i mportant  to  make a n umber of  
add i t i on a l  structural  v ar i at i on s  of  t h i s  mo l ecul e .  Compound s 34 - 38 
are s tandard var i at i on s  i n  the  am i no - a l cohol port i on of  caram i phen 
wh i ch may s how changes i n  the  act i v i ty of  the parent compound . 
Compound 38  i s  t he  I - phenyl cyc l ohexanecarboxyl ate ana l og . Th i s  can 
not on l y  be con s i dered a caram i phen  ana l og but a l so a var i at i on of 
d i cyc l om i ne  ( the  Ml sel ect i ve antagon i st )  cont a i n i ng an aromat i c  
phenyl  r i ng i n stead of  the  reduced cyc l ohexy l  mo i ety . Compounds  3 9 -
II a r e  s i mi l ar var i a t i ons  of  ami de ana l ogs o f  caram i phen . 
Aprophen  h a s  been reported to be a potent ant i muscar i n i c  agent 
and an e ffect i ve ant i dote86 , 87 . Therefore i t  woul d be i mportant to 
exam i ne  s t ructural  ana l og s of  t h i s  mol ecu l e .  Compounds  4 5 - 48 
represent s i mi l ar var i at i on s  i n  the  am i no a l cohol port i on of  aprophen 
as  were descr i bed for caram i phen . Compounds  42 - 44 are var i at i on s  i n  
the  prop i on i c  ac i d  port i on of aprophen . Compound 44 has  a reduced 
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phenyl  r i ng ;  4 2  conta i n s an add i t i ona l  methy l ene i n  the  a l ky l 
s i dech a i n  ( et hyl  i n stead o f  a methyl group ) . Compound 43 cou l d  be 
con s i dered a r i g i d  ana l og of  42  such that the ethyl i s  fu sed to one 
pheny l  r i ng to form an i ndane r i ng system . Th i s  wou l d  a l so be a 
novel  type o f  structure to exam i ne because i t  may be con s i dered to 
conta i n  features of  both c arami phen and aprophen . I t  may be cons i ­
dered to be an i ndane- aprophen ana l og ( or a r i g i d  ana l og of  � and 
4 2 ) .  Add i t i on a l l y  i t  may be con s i dered a caram i phen ana l og cont a i n ­
i ng a n  add i t i ona l  p henyl r i ng fused t o  the cyc l opentyl mo i ety o f  the 
1 ead compound c arami phen . Neverthe l e s s  th i s  mol ecu l e wh i ch i s  a 
c ro s s  between aprophen and carami phen cou l d  prove va l uabl e i n  
devel o p i ng the  s tructure - act i v i ty rel at i on s h i p s for pharmacol og i c  
propert i es i mportant i n  a n  ant i dote . 
B .  N - subst i tuted - 1 , 6 - hexaned i ammon i um compounds ;  N - subs t i tuted - 1 , 6 -
hexaned i am i nes ; and N - ( 4 - d i al kyl ami no - 2 - butynyl ) phtha l i m i des . 
Lu l l man et al . 10l-103 reported a ser i es  of  symmetr i ca l  N - s ub -
s t i t uted 1 , 6 - hexaned i ammon i um compounds wh i ch showed good ant i dotal  
protect i on .  The  effect was found to be  an a l l oster i c  ( no n - compet i ­
t i ve )  antagon i sm aga i n s t  ACh and c arbachol 104 . The best  ant i dote i n  
t h i s  s er i e s was N , N , N '  , N ' - tetramethyl - N , N ' - b i s [ 3 - ( 2 - phtha l i m i do ) pro-
pyl ) ] - 1 , 6 - hexaned i ammon i um brom ide  (11) . These compounds cont a i n  
more t h an one pos i t i ve center l i ke ga l l ami ne ( see F i gure 1 0 )  and 
other b i s - quaternary neuromuscu l ar bl oc k i ng drugs wh i ch are known to 
demons trate a non -compet i t i ve M2 se l ect i ve antagon i sm125-127 . The 
b i s N - s ubst i tuted 1 , 6 - hexaned i ammon i um compound s may al so be act i ng 
i n  t h i s  fa s h i on a l though th i s  has never been determ i ned . 
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In  the  ser i e s  of  compounds s t ud i ed by Lu l l man et  al  , 101 , 103 o n l y  
the  Quatern ary agents  were ever reported or tested for ant i dota l  o r  
a nt i mu scar i n i c  propert i es .  A n  i mportant  property of a n  ant i muscar i n ­
i c  drug a s  a n  ant i dote i s  i t s ab i l i ty t o  penetrate t h e  bra i n  and act 
on central  muscar i n i c  receptors to  prevent central l y  med i ated 
res p i ratory para l y s i s .  S i nce  t he quaternary ammon i um compound s do  
not  read i l y  enter  the  bra i n  i t  wou l d be i mportant  to  exam i ne the  
tert i ary ami ne compound of  t h i s ser i es . I f  compound 49 ret a i n s  the  
ant i mu s c ar i n i c  propert i e s observed w i th the  N - s u b s t i t u ted 1 , 6 -
hexaned i ammon i um compound ( 11 )  i t  s hou l d  b e  a more favorabl e ant i dote 
becau se  i t  cou l d  act  on the eNS . 
Al s o ,  i n  t he  research descr i bed by Lu l l man et  a1 . 101 , 103 o n l y  
the  symmetr i ca l l y  N - s u b s t i tuted 1 , 6 - hexaned i ammon i um compounds were 
syn t h e s i zed and tested . I t  h a s  not been determ i ned i f  both 3 - ( 2 -
phtha l i mi do ) propyl  port i on s  o f  compound 11 are nece s sary for act i v i ty 
or  con t r i bute i n  b i nd i ng t o  the  recepto r .  There fore , t h e  un symmetr i ­
c a l  compound 50  wh i ch i s  a part i a l s t ructure of  the  parent compound 
11 and cont a i n s  o n l y  one 3 - ( 2 - phtha l i m i d o ) propyl mo i ety woul d contr i ­
bute i nformat i on on t h e  SAR of  t h i s  ser i e s .  For the  s ame reasons  as  
prev i ou s l y  d i s c u s sed for compound 49 , t he  un symmetr i ca l  tert i ary 
am i ne s hou l d a l s o  be syn t h e s i zed and exam i ned for ant i mu scar i n i c  and 
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Oxotremor i ne ,  the  metabol i c  ox i d at i on product  of  tremor i ne 149 , 
h a s  been s hown to  be a potent muscar i n i c  agon i s t i n  the  central  
nervous  system150. Wh i l e  the  pr i nc i pal  pharmaco l og i ca l  propert i e s of 
( 0 1  
.. 
Tremorlne Oxot remorine 
oxotremor i ne appear to  be a s soc i ated w i t h  i t s i n tense  muscar i n i c  
act  i v i ty ,  i t s act i on s  upon the  CNS  are more marked than  those  of 
muscar i n i c  tert i ary ami nes  such a s  arecol i ne ,  p i l ocarp i ne ,  and 
acecl i d i ne .  The h i gh degree o f  potency l ed t o  the  i nvest i gat i on of 
oxotremor i ne and s tructural  anal ogs  a s  a new c l a s s  of  CNS act i v e 
muscar i n i c  agon i s ts 151-153 . I t  was observed wh i l e  mak i ng s t ructural  
v ar i at i on s  that repl acement of  the  2 - oxo - pyrrol i d i no mo i ety of the 
oxotremor i ne  mol ecul e by a succ i n i m i de group l ed to compounds  w i t h 
a n t  a g o  n i s t i c  pro  p e r  t i e  s 154 , 155 . N - ( 4 - d i ethyl ami no - 2 - butynyl ) -
succ i n i m i d e  ( 52 )  was found to be qu i te potent i n  bl oc k i ng the mo tor 
e ffec t s  of  oxotremor i ne ,  wh i l e  the effect on per i pheral  cho l i n erg i c  
symptoms , s uch  a s  ACh - i nduced spasms i n  g u i nea p i g  i l e al  s t r i ps , i s  
of  l ower magn i tude 154-156 . The rel at i ve spec i f i c i ty of oxotremor i ne 
on the CNS s uggest s  that  these  type anal ogs m i ght  a l so  be se l ect i ve ly  
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central  i n  t he i r  b l oc k i ng act i on s . I nt roduct i on of  l arge subst i t u ­
e n t s  i nto  agon i s t mol ecu l e s  frequent l y  y i e l d s  compounds po s ses s i ng 
antagon i s t i c  propert i e s . Add i t i ona l l y ,  i ncorporat i on of  a l i poph i l i c 
mo i ety such  a s  a phenyl r i ng i n to  the  structure of  a prototype 
compound s hou l d  t heoret i cal l y  i ncrease  eNS act i v i ty pro v i ded the 
i nherent act i v i ty of t h e  parent compound i s  not destroyed . Therefore 
compounds  53 and 54 wou l d  be i mportant to  synthes i ze and exam i ne w i th 
t h e  a i m  of  devel op i ng potent central l y  act i ve antagon i s t s , wh i c h may 
s how good a n t i dotal  propert i e s .  
53 R Methyl 
54 R Ethyl 
It was  prev i ou s l y  reported that  N , N , N '  , N ' - tetramethyl - N , N ' ­
b i s [ 3 - ( 2 - p h t ha l i mi do ) propyl ] - l , 6 - hexaned i ammon i um brom i de (11) was an 
effec t i ve a n t i dote and a l so d i sp l ayed ant i muscar i n i c  act i v i ty lOl , lOJ . 
The  corres pond i ng b i s - tert i ary am i ne ( 4 9 )  wa s de s i gned w i t h  the a i m  
7 3  
of  reta i n i ng the  ant i mu s c ar i n i c  propert i e s ,  but w i t h  good central  
act i v i ty ,  wh i ch i s  an  i mportant ant i dota l  property . Based on these  
rea so n s  and the  fact  that  the  oxotremor i ne - l i ke antagon i s t s  ( 53 and 
54 ) may show se l ect i ve central  ant i muscar i n i c  act i v i ty ,  i t  wou l d  be 
de s i rabl e to  synthe s i ze compound 5 5 ,  wh i ch wou l d i ncorporate features 
of  the  ami n o - al kyne compounds ( oxotremor i ne - l i ke antagon i s t s  53 - 54 )  
and the  tert i ary ami ne N , N ' - d i methyl - N , N ' - b i s [ 3 - ( 2 - phtha l i mi do ) pro­
pyl ] - 1 , 6 - hexaned i am i n e ,  compound 49 . 
Th i s  woul d represent  a novel  type of  compound des i gned to  be a b i s -
type mu scar i n i c  antagon i st ( pos s i bl y  M2 ) wh i ch may demo n s trate good 
central  act i v i ty .  S i nce the  s ucc i n i m i de ana l og 52 was  the  mo st 
potent i n  the  ser i e s  of oxotremor i ne - l i ke antagon i s t s 154 , 155 , 
compound 56 , a b i  s s ucc i n i m i de - al kyn e ,  wou l d  a l  s o  be i mportant to 
synthes i ze and exam i ne as an ant i muscar i n i c  for the s ame reason 
prev i ou s l y  descr i bed . 
74 
C .  Para s u bs t i t uted caram i phen ana l og s ( four corners approach ) .  
Structure 57  represents  a set  o f  compounds that  are der i vat i ves 
o f  caram i phe n ,  1.2, wh i ch h ave d i fferent subst i tuents  i n  the para 
pos i t i on o f  the  p henyl ri  ng . The purpose  of  t he  set  i s  to test  the 
e ffect of  d i fferent s u b s t i tuents on  the  ant i mu s c a r i n i c  act i v i ty and 
to  l ook  for any pos s i bl e  rel at i on s h i p  of act i v i ty w i th s u b s t i tuent 
p arameters  such a s  Hammett ' s  s i gma (0)  constant or  Hansch ' s  p i  ( 11 ) 
va l ue s . I n  the  numero u s  cases  o f  both the  e l ectron i c  (0 )  and 
l i poph i l i c (\( ) characters of  aromat i c  r i ng s ubs t i tuents  p l ay i ng 
rol e s  i n  the  equ at i on t h at rel ates  s tructural  propert i e s to  b i o l og i ­
c a l  act i v i ty ,  both the s i g n  and mag n i tude o f  the coeff i c i en t s  must  be 
con s i dered . A two - d i men s i ona l  p l ot of  Hammett s i gma constants  
aga i n s t  Hansch  p i  val ues  for aroma t i c  s u b s t i tuents  was proposed by 
C ra i g 148 to perm i t  ready sel ect i on o f  novel compounds  wh i c h may be 
expected to s how i mproved b i o l og i ca l  act i v i ty i n  compar i son to the 
l ead compound i n  s i t uat i on s  where these  parameters  can be d i rect l y  
corre l ated t o  act i v i ty .  The u se  of  two parameters i n  a mul t i p l e  
regre s s i on by the u s ua l  methods for determ i n i ng quant i t at i ve struc ­
ture- act i v i ty rel at i on s h i p s ( QSAR ) wou l d  requ i re 1 2  or more compounds 
i n  order to obt a i n  a va l i d  equat i on .  I n  the cu rrent researc h ,  
because  the i mportant factor was t o  determ i ne i f  t h e  parameters s i gma 
7 5  
and/or p i  had a s i g n i f i cant  i n fl uence o n  t h e  ant i muscar i n i c  act i v i ty 
rather than  to  e stabl i sh the  quan t i t at i ve rel at i on sh i p ,  i t  s eemed 
th i s  c ou l d  be determ i ned w i t h  on l y  four properl y chosen s u b s t i tuent s . 
I n  th  i s  approac h , a s ubst  i tuent i s  se l ected wh i c h  h a s  an extreme 
va l ue for s i gma and for p i  i n  a pos i t i ve or negat i ve d i rect i on ,  i n  
a l l comb i n at i on s  ( F i g ure 1 1 ) .  Compar i son o f  the  act i v i ty o f  the  four 
subst  i tuted der i  vat i ves  and wi th  the p arent compound shou l  d reveal  
the i mportance of  one or  both of  these parameters . The  compounds  
chosen  for use  i n  th i s  approach  are the  ami no ( - 0 . 66 a ,  - 1 . 2 3 'i'r ) 
( 57 a ) ; I - tetrazo l yl ( +0 . 50 a "  - 1 . 04 1T' )  ( 57b ) ; I - pyrrol i d i ny l  ( - 0 . 83 
a ,  + 1 . 30 /T )  ( 57c ) ; and t r i fl uoromethyl ( +0 . 54 a ,  +0 . 88 11') ( 57d ) . 
I t  i s  not  known i f  the  receptor can  accomodate bul ky subst i tu ­
ent s i n  t h i s po s i t i on .  The  l i poph i l i c reg i on where the  phenyl r i ng 
b i nd s  may be a pocket  o n l y  l arge enough for the  phenyl r i ng i t se l f .  
T h i s  h a s  never been determ i ned w i t h  s t ructural  ana l og s .  Th i s  effect 
may be revea l ed w i th  var i a t i ons  i n  the act i v i ty of  the der i va t i ves  
wh i ch can  not  be expl a i ned by the  s i gma or p i  parameters . 
D .  Add i t i on a l  compounds  chosen for test i ng .  
A n umber of  compounds were o r i g i na l l y  chosen for te s t i ng i n  t h i s 
program so  a s  to pro v i de a very d i verse group of  structural  features . 
Compounds  2 4 ,  58 , 6 0  and §.l were cho sen because  of  the prev i o u s l y  
reported e ffec t i ven e s s  aga i n s t  t h e  l etha l  effect s  of  s ar i n  and other  
cho  1 i nesterase  i nh  i b i tors . Compound 2 9  i s  benzet i m i  de ; !l i s  a 
d i oxol ane  and 4 2  i s  a furan type ant i mu s c ar i n i c .  The rema i n i ng 
members  of  the  set  were a l s o  chosen  j u st  to  prov i de add i t i ona l  agent s  
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Two - D i me n s i onal  C ra i g  P l ot of  S i gma Con s tant s  Versus  Pi  Va l ues  
for Aromat i c  S u b s t i tuen t s  
I n fo rmat i on i n  t h i s  Tab l e was  comp i l ed from Reference 1 4 7 . 
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w i t h  d i verse s tructural  features . Compounds 24 , 6 9 - 74 , 7 6 - 78 and 82 
are curre n t l y  marketed ant i mu scar i n i c s and an authent i c  s amp l e  was 
requested from the manufacturer . Compound 24  i s  t r i  f1  upromaz i ne  
( E . R . Squ i bb and Sons ) ;  69  i s  cycl opentol ate (Al con Laborator i e s ) ; 70  
i s  the M 1  se l ect i ve compound oxybutyn i n  (Mar i on Laborator i e s ) ; Zl i s  
c h l orophenoxam i ne (Astra -Werke AG , Germany ) ; 7 2  i s  benztro p i ne 
( Merck ,  S h arp and Dohme ) ; 73 i s  b i per i den ( Knol l Pharmaceu t i ca l ) ;  74  
i s  met h i xene ( Dorset  Laboratori e s ) ;  76  i s  oxyphencyc l i m i ne ( Beecham 
Laborator i e s ) ; 7 7  i s  ethopropaz i ne (Warner- Lambert Co . ) ;  78  i s  
orphenad r i ne ( R i ker Laborator i e s )  and 8 2  i s  t he  M 1  se l ect i ve antago­
n i s t t r i hexyphen i dyl ( Lederl e Laborator i es ) . Compound 68 i s  t he  M2  
s e l ec t i ve antagon i s t secover i ne and  7 5  i s  an  e ster  ana l og of secover­
i ne .  
I t  was  de s i red that  p i renzep i ne a l s o  be i nc l uded because  of  i t s 
se l ect i ve M 1  antagon i s t propert i e s .  However ,  i t  i s  known that  
p i renzep i ne ,  des p i te i t s aff i n i ty for  bra i n  mu scar i n i c  receptors , 
does  not  exh i b i t  central  act i v i ty when admi n i stered peri pheral l y  
becau se  i t  does  n o t  cro s s  t h e  bl ood - bra i n barr i er 145 . T herefore an 
ana l og , 6 7 ,  wh i ch l acks  the pol ar ami do  group  b r i d g i ng the two 
aroma t i c  r i ng s ,  was chosen  for i nc l u s i on rather than p i renzep i ne .  
Compounds  80 and 81 were prev i ou s l y  ava i l abl e i n  t h i s l aboratory from 
another  s tudy and were d e s i gned as l i poph i l i c ana l ogs  of the  Ml 
se l ect i ve antagon i s t p i renzep i ne .  Compound 79 i s  the  Ml se l ect i ve 
antagon i s t QNX , and 83 i s  the M l  se l ect i ve compound d i cycl om i ne .  
62 
64 
CZHS "- N - CHZ-/"Y C H C H / \yt 6 S Z 5 C H 
6 5  6 5 
6 3  
C6HS 
C H -CH - NJt10 6 5 2 NH 
2 9  0 
7 8  
o 
� II ,. C 6 H S CH3- �J N - C HZ - C - N , � C 6 H S 
6 7  
@ 
7 5  
C H 3  0 
79  
CH3-0-@-C HZ�H - �  - C HZ - C H Z - C H z - �D 
C z H s 68 
C6H5 
O - CH Z - CH Z - �V 
OH 
7 3  





8 1  
From a purel y theore t i ca l  con s i derat i on o f  t h e  preferred 
conformat i on of a l arge set  of ant i muscar i n i c  agents ,  Paul i ng 146 
proposed that  e i ther  one of two part i c u l  ar pharmacophori  c patterns  
was  nece s sary for b i nd i ng to the receptor ( F i gure 1 2 ) . Some s i m i -
l ar i t i e s and d i fferences  can  be determ i ned from the chem i ca l  s t ruc -
ture a l on e .  Both  conta i n a tert i a ry or  quaternary ami  ne  ( on l y  the 
tert i ary am i ne s  enter the  CNS ) , a p henyl r i n g ,  and u s u a l l y  a hydroxyl 
and a l arge l i poph i l i c g roup , s uch  as a cyc l ohexyl or  an add i t i ona l  
p henyl r i n g ,  bonded to  t he  carbon atom i n  wh i ch the  phenyl r i ng i s  
bonded . The  two patterns  d i ffer i n  the  d i s t ance  between the  n i trogen 
and an aromat i c  r i ng .  Wh i l e  i n  t he  e ster  type ant i chol  i nerg i c  
s ubstances  the  n umber o f  bonded atoms between the  ba s i c  n i trogen atom 
and t he  p henyl r i ng i s  u s u a l l y  f i ve ,  i n  ant i - Park i n son ' s  syndrome 
ant i cho l i nerg i c  drugs  i t  i s  u sua l l y  t hree . I t  was  s uggested that 
agents  wh i ch f i t the  pattern w i t h  the  shorter d i s t ance  between the  
R 
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Comp a r i son of  Pharmacophor i c Patterns of  E s ter and Non - E ster  Type 
Ant i muscar i n i c  Agent s  
n i trogen and phenyl r i ng m i ght  be s l  i gh t l y  se l ect i ve for central  
e ffec t s . Some non - ester  type ant i muscar i n i c  agent s  wh i ch f i t t h i s 
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pattern are benzet i m i  de  ( 2 9 ) , t r i  hexyphen i dy 1 ( 82 ) , ethapropaz i ne 
( 7 7 ) , orphenad r i ne ( 78 ) , i n  add i t i on t o  compounds  such  a s  62 , 7 2 , 73 , 
74 and 2 4 .  It i s  not  c l ear  whether  non - e s ter  ant i - Park i n son agents  
are u seful  becau se  o f  a se l ect i v i ty due to d i fferences i n  d i s t r i bu ­
t i on ,  receptor b i nd i ng o r  other  pharmaco l og i c  propert i e s .  Al though 
no  non - ester  type ant i mu scar i n i c s  are to  be synthe s i zed i n  t h i s  
port i on of  the  proj ect ,  these  types of  compounds  are i nc l uded because  
a compa r i son of  the  var i ou s  s t ructural  types  of  ant i mu scar i n i c s i n  
t e s t i ng for ant i dotal  propert i es may prove fru i tful . 
The  compound s i n  t h i s  project w i l l  be pharmaco l og i ca l l y  eval u a ­
ted i n  compar i son  to  atrop i ne a s  ant i dotes  for s oman po i s on i ng ( i n  
comb i n at i on w i th 2 - PAM ) and a l so w i l l  be te s ted i n  n umerous in  v i t ro 
and i n  v i vo t e s t s  de s i gned to  g i ve i n forma t i on on the  s tructure­
act i v i ty rel a t i o n s h i ps for pharmacol og i c  propert i es wh i ch m i g h t  be  
i mportant  i n  a better ant i dote . T hu s , ant i mu s c ar i n i c  act i v i ty w i l l  
be mea s u red for ab i l  i ty to  bl ock  ACh - i nduced contrac t i on s  o f  the  
smooth musc l e of  g u i nea p i g  i l eum and  potency to  d i s p l ace rad i o l a ­
bel ed q u i nuc l i d i nyl  benz i l ate  ( QN B )  from spec i f i c  b i nd i ng s i t e s  i n  
mou s e  bra i n  homogenates  i n  order t o  compare central  versus  peri pheral  
ant  i mu scar i  n i  c act  i v i ty .  The  compounds  w i l l  a l s o  be exami ned i n  two 
in v i vo t e st s ,  t he  b l ock  of oxotremo r i ne - i nduced t remors  and bl ock  of  
t h e  CNS s t i mu l u s  o f  oxotremo r i n e  or arecol i ne i n  a d rug d i scr i m i n a ­
t i on a s s ay .  These  t e s t s  i nd i cate  a comb i nat i on o f  ab i l i ty to 
penetrate t h e  bl ood - bra i n barr i e r ,  and a l s o  to act on central  
muscar i n i c  receptors . S i nce the  M l  and M2  subtypes  are not eve n l y  
d i s t r i buted i n  the  bra i n ,  a preference or se l ect i v i ty of  these  
83 
receptors for one s ubtype may be a favorabl e property i n a better 
ant i dote . Therefore t he  compounds w i l l  be eva l uated for the i r  
potency to d i sp l ace [ 3H ] QNB from b i nd i ng s i tes  i n  homogenates 
prepared separatel y  from rat forebra i n  (Ml  s i te s )  and medu l l a  
( predom i nant l y  M2  s i te s ) . 
I I I .  D I SCUSS I ON 
A .  Chem i s t ry 
1 .  Caram i phen  and aprophen compound s . 
T h ree general  procedures  are mos t  frequen t l y  u sed to  synthes i ze 
ami no e s ter  a nd ami de  type ant i mu scar i n i c s .  I n i t i a l l y a l l t h ree 
approaches  were u sed to synthes  i ze  the  1 e ad compound carami  phen i n  
order to  determ i ne wh i ch approach wou l d  be mos t  favorab l e to  u se  
t h roughout  t h i s proj ec t . The  t h ree approaches  are  out l i ned i n  Scheme 
1 .  Method A160-163 , 168 i nvol ve s  react i ng 1 - pheny1 cyc1 opentanecarbox ­
y 1 i c  ac i d  ( 8 4 )  w i t h  t h i ony1 c h l or i de to form the  correspond i ng ac i d  
c h l or i de .  Th i s  i ntermed i ate  i s  t hen react ed w i t h  2 - d i ethy1 am i noet h a ­
no 1  i n  an  aromat i c  so l vent to g i ve 2 - ( d i ethy1 am i n o ) ethy1 1 - pheny 1 cy ­
c 1  opentanecarboxy1  a t e  (12) . I n  Method B160 , 165 , 166 , 168 t h e  carbo x ­
yl i c  ac i d  8 4  i s  s t i rred i n  2 - propano1  w i t h  fresh l y  prepared 2 -
d i e t hyl ami noethy1  c h l or i de 8 6  to y i e l d  the  HC 1  s a l t o f  the  am i no 
e s ter  12 .  Method C 160 , 167 i nvol ves  mak i ng pota s s i um l - pheny1 cyc l o ­
pentanecarboxy l ate ( 8 7 )  and s i mp l y  s t i rr i ng t h i s at  refl ux w i t h 
fre s h l y  prepared 2 - d i ethyl ami noethyl  c h l or i de ( 8 6 )  or  i t s hydroc h l or ­
i de s a l t i n  e t hano l  to g i ve 12 .  The  transester i f i cat i on method u s i ng 
t h e  e t hyl  e ster  o f  84 w i t h  an ami noa l coho1  and sod i um i n  an aroma t i c  
so l vent s uch  a s  xyl ene o r  tol uene i s  ut i l i zed much l es s  frequent l y  
because  o f  poor y i el d s 160 , 168 . I n  t h i s  re search  y i e l d s  for the 
synthe s i s  of  12 were 68% for Method A,  5 2% for Method B and 56% for 
84 
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Method C .  Obv i ou s l y  there i s  not a s i g n i f i cant  d i fference i n  y i e l d s 
but  i t  was  dec  i ded t hat Method A was  the  most  favorabl e and d i rect 
approach to  make th i s  type o f  compounds and was  u sed p r i mar i l y  
t hroughout the  proj ect . I n  no c a s e  was  t he  i ntermed i ate ac i d  
c h  1 o r i  d e  i so  1 ated a n d  c haracteri  zed . The ac i d c h  1 or i  de  was  formed 
u s i ng t h i onyl c h l o r i de as a so l vent . After removal  of the so l vent 
and d ry i ng ,  the  i ntermed i ate  ac i d  ch l o r i de was  i mmed i ate l y  reacted 
w i t h  t he  appropr i ate ami noa l cohol  u s i ng benzene a s  a so l vent . 
C rysta l l i n e  hydroch l or i de s a l t s  cou l d  read i l y  be prepared and 
p u r i f i ed by recry s t a l l i z at i on .  Therefore t he  synth es i s  of  t he  other 
der i vat i ve s  o f  t h i s s er i e s  u s i ng th i s  method was  read i l y  accom-
p l i s hed . React i ng fresh l y  d i s t i l l ed 4 - hydroxy- N - methyl p i peri d i ne 
w i t h  t he  ac i d  c h l o r i de formed from I - phenyl cycl opentanecarboxyl i c  
ac i d  ( 8 4 )  y i el ded compound 2 0 ;  u s i ng fre s h l y d i s t i l l ed 3 - hydroxy - N ­
methyl p i per i d i ne gave compound 34 ; 3 - q u i nuc l i d i no l  y i el ded compound 
3 5 ;  t rop i ne y i e l ded compound 3 6  and u s i ng fre s h l y d i s t i l l ed 3 -
( d i ethyl ami n o ) - I - propanol  g ave compound 3 7 . Benzene was  u sed a s  
s o  1 vent i n a 1 1  c a s e s  except for compound 3 5 . Because  o f  the poor 
so l ub i l i ty of  3 - q u i nuc l i d i no l  i n  benzene e i ther  CHC 1 3 or  THF was u s ed 
a s  a so l ven t ,  and a y i el d  of  3 5% was  obta i ned . Parkkari  et a l . 161 
synthe s i zed t h i s compound i n  28% y i e l d  by transester i f i cat i on of 
m e t h y l  I - p henyl cyc l opentanecarboxyl ate  w i th  3 - q u i nuc l i d i no l  i n  
tol uene w i t h  a cata l yt i c  amount o f  sod i um .  Tran sester i f i c at i on w i th  
ethyl  1 - pheny 1 cyc 1 opentaneca rboxyl ate was  reported to be un s ucce s s ­
ful . 
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C ompound 38  was  synthes  i zed by the  s ame procedure ( Method A )  
u s i ng 1 - ph enyl cycl ohexanecarboxyl i c  ac i d  8 5 . The ami de  compounds  3 9 -
4 1  can  a l s o  be read i l y  syn t he s i zed by the  s ame procedure . N , N ­
d i ethyl e thyl ened i am i ne  gave compound 3 9  and N - methy l p i peraz i ne g ave 
40 . Compound 11 was  made by reac t i ng N , N - d i ethyl ethyl ened i am i ne w i t h  
the  ac i d  c h l or i de  from 1 - phenyl cyc l ohexanecarboxyl i c  ac i d  ( 8 5 ) . 
The  aprophen ana l og s  4 5 - 48 wh i ch have  s i m i l ar var i at i on s  i n  the  
ami noal cohol  mo i ety o f  the  mol ecu l e were not  syn t h e s i zed i n  t h i s  
project . T hese  compounds  were syn t he s i zed i n  another project  i n  t h i s  
1 a boratory and were read i l y  prepared by t h e  s ame procedure 164 a s  
descr i bed i n  Scheme 1 Method A .  
The  method o f  Larsen  e t  a l  . 173 was  u s ed a s  a general  method for 
mak i ng var i at i on s  i n  the prop i on i c  ac i d  port i on ( compounds  4 2  and 44 )  
o f  aprophen ( Scheme 2 ) . Commerc i a l l y ava i l abl e d i phenyl aceton i t r i l e  
( 88 )  react s  w i t h  exac t l y  one equ i v al ent  o f  s od i um am i d e  fo l l owed by 
t h e  add i t i on of ethyl i od i de i n  d i ethyl  ether  a t  l ow t emperatures to 
y i e l d  2 , 2 - d i phenyl butyron i tr i l e  ( 89 ) 173 . Al ternat i ve l y ,  s tart i ng 
w i t h  cyc l ohexyl phenyl aceton i tr i l e  ( 9 0 )  and reac t i ng i t  w i t h  methyl 
i od i de under s i m i l ar cond i t i on s  gave 2 - cycl ohexyl - 2 - ph enyl prop i on i ­
t r i l e  ( 21.) 174 i n  h i gh y i el d .  The next s tep  i nvo l ve s  hydrol ys i s  of 
the h i ndered n i tr i l e  to t he carboxyl i c  ac i d .  When the  de s i red 
product  i s  a c arboxyl i c  ac i d  i n  the  hydro l ys i s  of a n i t r i l e ,  the  
reagent  of  c ho i ce  i s  mos t  frequent l y  aqueous  a l kal i 17o . Al though 
ac i d - c a t a l yzed hydrol ys i s  i s  a l so  u sed , these cond i t i on s  are most  
o ften u sed for  stopp i ng at  the  am i de s tage l7l . A rev i ew of  the  
l i terature i nd i cates  the  hydro l ys i s  of  h i ndered n i tr i l e s to the  
�HCN 
8 8  - R = C 6H S 
90  - R = C 6H ll 
1 1 S0C I2 
2 1 HOCH2CH�Et2 
3 1 HC Ig 
= Ethyl  
Scheme 2 
88 
89 - R = C6H S ;  R' = E t  
21 - R = C6H 11 ;  R '  = Me 
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correspond i ng carboxyl i c  ac i d  often g i ve s  l ow y i e l d s by a n umber of 
methods  and has  been proven very d i ff i c u l t to  accompl i s h .  C a se l 7 2 
reported t h a t  h i ndered n i tr i l e s conta i n i ng the  cyc l opentane and 
cycl ohexane r i ngs  on the a c arbon atom were re s i s t ant  to  hydro l ys i s 
by al cohol i c  KOH . Larsen  et  a l . 1 7 3 found t r i s ub st i tuted aceton i tr i l e s 
were re s i s t ant to  hydro l ys i s  w i t h  a l ka l i and water or a l cohol . The 
pr i nc i pa l  product i s o l ated was  the  ami de . 
A n umber of  method s were attempted i n  t h i s  proj ect u s i ng ac i d i c  
cond i t i on s . St i rr i ng the  n i tr i l e  at  refl ux w·i t h  concentrated HC 1 , or 
6 N HC l  was  u n succe s s fu l . C a se l 7 2 u sed concentrated HC l  and s od i  um 
n i t r i te  for the  hydrol ys i s  of I - phenyl cyc l oa l kyl carbon i tr i l e s , wh i ch 
cou l d  not  be hydrol yzed beyond the  ami de .  Larsen  e t  a l . 1 7 3 reported 
l ow y i e l d s  of  ac i d  by hydro l y s i s of  the  n i tr i l e s i n  a sea l ed tube 
w i t h  hydroc h l or i c and s u l fur i c ac i d s a l though  the  method req u i red 
l o ng reac t i on t i me s  and was general l y  d i ff i cu l t to  run . They d i d  
report good y i el d s  of  2 , 2 - d i phenyl butyr i c  ac i d  u s i ng 70% s u l fur i c  
ac i d  ( d .  1 . 6 1 )  a t  h i g h  temperatures  ( ref l ux ) . When t h i s  method was 
attempted i n  t h i s  proj ect  o n l y  am i de ,  water so l ubl e product s ,  t ar ­
l i ke mater i a l a nd  a neg l i g i bl e  amount  of  ac i d  cou l d  be  obt a i ned . 
Vary i ng t h e  reac t i on temperature and react i on t i me ( up to  7 d ays ) d i d  
not  i mprove t h e  y i el d s . Larsen  et  a l . l 7 3 reported cond i t i on s  from 
1 50 C to refl ux and reac t i on t i me s  of 60 hours . Though good y i el d s  
were reported they were a l ways based o n  un recovered s t a rt i ng mater i a l  
( n i t r i l e ) and not  the  f i na l  product  ( a c i d ) . 
I t  was  determ i ned i n  th i s  research that  the  req u i red ac i d  
i n termed i ates  coul d b e  read i l y  obt a i ned i n  good y i e l d  by s i mp l y  
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s t i rr i ng the n i tr i l e  i n  48% HBr at v i gorous  refl ux for per i od s  of up 
to  10 d ay s 167 . Hydrol y s i s  of  89 under these cond i t i on s  g i ves  2 , 2 - d i ­
pheny l butyr i c  ac i d  ( 9 2 )  i n  40% y i el d ,  and hydro l ys i s  of  9 0  g i ve s  2 -
methy l - 2 - p henyl cyc l ohexaneacet i c  ac i d  ( 93 )  i n  86% y i el d .  The 
reac t i on s  of ac i d s  9 2  and 93 w i t h  t h i onyl ch l o r i de fol l owed by 
e ster i f i ca t i on w i t h  2 - d i ethyl ami noethanol  y i e l d s  the  am i no e sters  42 
and 44 respect i ve l y .  Al l attemp t s  to prepare a c rysta l l i ne hydro­
c h l o r i de s a l t o f  44 fa i l ed .  Therefore a water so l ub l e oxal ate  s a l t 
was  made of  t h i s  compound . 
The  synt hes i s  of  2 - ( d i ethy l am i no ) ethy l  I - phenyl - l - i ndanecarboxy ­
l at e  ( 43 )  i s  s hown i n  Scheme 3 .  The  nec e s s ary i ntermed i ate  i n  the  
synthes i s  i s  I - phenyl - l - i ndanecarboxyl i c  ac i d  ( 98 ) . Th i s  compound 
has never been descr i bed i n  the l i terature but the synthes i s  of  the 
correspond i ng n i tr i l e  ( 9 7 )  h a s  been descr i bed by Ph i l pott and 
Barl trop176 . Phenyl aceton i tr i l e  ( 94 )  was  read i l y  al kyl ated wi th  
p henyl ethyl  brom i de and exac t l y one equ i va l ent  of  sod i um ami de i n  
d i ethyl  ether  t o  g i ve 2 , 4 - d i phenyl butyron i tr i l e  ( 9 5 ) . I n i t i a l l y  
brom i n at i on was  carr i ed out  a s  descr i bed by Ph i l pott  and Barl trop 176 
i n  1 , 2 - d i c h l oroethane , fol l owed by i mmed i ate  cyc l i zat i on to the 
n i t r i l e  9 7  i n  a one pot reac t i on . Th i s  approach gave poor y i e l d s  of 
the de s i red product  ( approx i mate ly  20%)  and a l arge amount  of ether 
i n so l ubl e materi a l . Therefore , brom i nat i on was carr i ed out i n  
methyl ene  ch l o r i de and the  c rude bromo product 9 6  was i s o l ated i n  87% 
y i el d .  Cycl i z at i on of 96 w i t h  A1 C 1 3 in  1 , 2 - d i ch l oroethane gave 
n i t r i l e  97 i n  58% y i e l d ,  wh i ch cou l d  be read i l y  pur i f i ed by d i s t i l l a ­
t i on .  Hydrol ys i s  of  the  n i tr i l e  97  i n  48% HBr gave c arboxyl i c  ac i d  
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98 i n  7 5% y i el d .  Prec i p i tat i on o f  t h i s  ac i d  from a col d d i l u te 
so l ut i on of NaOH g ave a v i scous  brown semi - so l i d .  Al l attemp t s  to 
recrysta l l i ze the compound fa i l ed .  Therefore t h i s  crude ac i d  was 
reacted w i t h  t h i onyl c h l o r i de ,  then e ster i f i ed w i t h  2 - d i ethyl ami n o ­
ethano  1 and pur i f i  e d  a s  t h e  hydroch 1 or i  de  s a l t to  g i ve t h e  d e s  i red 
ami no e ster  ( 4 3 ) i n  46% y i e l d .  
2 .  N - Subs t i t u ted - 1 , 6 - hexaned i ammon i um compound s ; N - s u b s t i t u ted -
1 , 6 - hexaned i am i n e s ; and N - ( 4 - d i a l ky l am i no - 2 - butynyl ) ph tha l i m i de s . 
The  mos t  d i rect approach to  synthes i ze the  quaternary ammo n i um 
compound N , N , N '  , N ' - tetramethyl - N , N ' - b i s [ 3 - ( 2 - ph t h a l i m i do ) propyl ] - 1 , 6 -
hexaned i ammon i um brom i de ( 3 1 a )  was  t o  react two equ i va l ent s o f  N - ( 3 -
bromopropyl ) phtha l i m i de ( 1 02 ) and one  equ i va l ent  of  N , N , N ' , N ' ­
tetramethyl - 1 , 6 - hexaned i am i ne ( 1 03 ) i n  an a l cohol  so l vent 103 ( Scheme 
4 ) . Mu l t i pl e  recrysta l l i za t i ons  from methanol  gave the  de s i red b i s ­
quaternary compound 3 1 a  i n  45% y i e l d .  S i nce i t  was nec e s sary to  
syn t h e s  i ze the  correspond i ng tert i ary ami ne ,  an  a l ternate approach 
was  a l s o  emp l oyed . I n  t h i s  method two equ i v a l ent s of  N - ( 3 - bromopro­
pyl ) ph tha l i mi de ( 1 02 ) were  reacted w i t h  one equ i va l ent  of  N , N ' ­
d i methyl - 1 , 6 - hexaned i am i ne (104 ) ( Scheme 4 ) . Th i s  react i on g i ve s  a 
n umber o f  products  i nc l ud i ng the  des i red N , N ' - d i methyl - N , N ' - b i s [ 3 -
( 2 - phtha l i mi do ) propyl ] - 1 , 6 - hexaned i am i ne  d i hydrobromi de ( 4 9c ) . Th i s  
compound i s  more read i l y  sol ub l e i n  co l d methanol  wherea s  the  
quatern a ry compounds  ( by - product s )  are  not . Mu l t i p l e  recrysta l l i z a ­
t i on s  from met h ano l - ethyl acetate gave pure 49c . I n  add i t i on to 
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descr i bed , by a s i mi l ar method 49a , ( a s the  free base ) cou l d be 
i so l ated by neutral i z at i on of  the  react i on fol l owed by an extract i on 
of  t h e  product i nto  an organ  i c so l vent . Th i s  product  wa s ea s i 1 y 
pur i f i ed by recry s t a l l i z at i on from met h anol  - water . After dry i ng ,  
49a was  read i l y  converted to  the  d i hydroch l or i de s a l t 49b by prec i p i ­
tat i on from a met h ano l i c  - g aseous  HCl  so l ut i on w i t h  ethyl acetate . 
A 1 s o ,  49a was  converted to  the  quatern ary meth i od i de s a l t 3 1  b by 
a l l ow i ng 49a  t o  react w i t h  an exce s s  of  methyl i od i de i n  
benzene178 , 179 . Recry s t a l l i zat i on of  t h e  d i hydroch l or i de s a l t 49b  
and  t h e  d i hydrobrom i de s a l t 49c o f  the  tert i ary N - subs t i tuted 1 , 6 -
hexaned i am i nes  proved t o  b e  very d i ffi cu l t and ted i ou s . I n  n umero u s  
c a s e s  o i l s  were obta i ned upon the  add i t i on of  the  co - so l vent . 
N umero u s  recry s t a l l i zat i on s  were often necessary to  obta i n  pure 
produc t s . These  types of compounds  cou l d  not be pur i f i ed or ana l yzed 
for puri  ty by chromatography because  extens i ve  s t re a k i ng occurs on 
s i l  i c a .  Reverse phase  ( C - 1 8 )  c hromatography a l  s o  was  u n succe s s fu l . 
Kords e t  a l . 103 reported chromatograph i c  data  u s i ng cel l u l o se pl ates  
( phenol  : benzene : water ; 9 : 5 : 1 ) ,  but  Rf va l ues  o f  above 0 . 92 were 
reported . Accurate NMR data  and CHN anal ys i s  conf i rmed the proposed 
s t ructures  i n  t h i s  research . 
The  synthes i s  of  the  un symmetr i ca l  compounds  N - [ 3 - ( 2 - phtha l i m ­
i d o ) propyl ] - N , N '  , N ' - t r i methyl - 1 , 6 - hexaned i am i ne d i hydroch l or i de and 
N , N , N ' , N '  , N ' - pe n t amethyl - N - [ 3 - ( 2 - phtha l i m i do ) propyl ] - 1 , 6 - hexaned i a ­
mmon i um i od i de i s  s hown i n  Scheme 5 .  The  reac t i on o f  N - ( 3 - bromo ­
propyl ) ph tha l i mi de (lQZ) and an exc e s s  of  N , N ' - d i methyl - 1 , 6 - hexaned i ­
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1 , 6 - h exaned i am i ne ( 1 0 5 )  i n  6 7% y i e l d .  After workup and pur i f i cat i on 
t h i s compound was  i mmed i at e l y  u sed i n  the  next step . The  form i c  ac i d  
- formal dehyde methyl at i on o f  compound ( 1 0 5 )  ( E schwe i l e r - C l arke 
react i on ) 1 8 0  g ave compound 106 i n  h i gh y i e l d .  The d i hydroch l or i de 
s a l t � was  prepared i n  43% y i e l d  by react i ng an ether  so l u t i on of  
the  base  w i t h  g a seous  HC l  a nd  p ur i f i ed by recry s t a l l i zat i on from 
methano l - e t h e r .  
T h e  q u a t e rn a ry compo u n d  N , N , N '  , N '  , N ' - pentamethyl - N - [ 3 - ( 2 -
p h t ha l i m i do ) propyl ] - 1 , 6 - hexaned i ammon i um i od i de ( 50 )  was  prepared by 
a s i m i l ar method a s  descr i bed for compound 3 1 b I 7 8 . 1 7 9 . The  free base  
1 06 of  compound � was  synthe s i zed a s  prev i ou s l y  de scr i bed , t hen 
i mmed i ate l y a l l owed to  react w i t h  an exce s s  of  methyl  i od i de i n  
benzene t o  g i ve 50 i n  74% y i e l d .  The i n i t i a l attempt t o  synthes i ze 
t h i s compound  was  by exhau s t i ve methyl at i on o f  1 0 5  by the  method of 
Sommer et a l  . 1 7 8 , u s i ng t - butyl ami ne a s  a h i ndered base  to  react w i th  
the  HI  wh i c h i s  generated . Th i s  method proved u n s at i s factory for the  
synthes i s  o f  the  b i s - q uaternary am i ne s  i n  t h i s proj ect . I n termed i a te 
1 0 5  wh i c h conta i n s a secondary and a tert i ary am i ne al ways y i e l ded 
i mpure product s by t h i s method . An i mmed i ate  prec i p i tate  wou l d  form 
wh i ch appeared by spectral  data  to  be the mono -quaternary ami ne 
formed o n l y  from the  tert i ary ami ne . 
The  synthes i s  of  the  N - ( 4 - d i a l kyl ami no - 2 - butynyl ) phtha l i m i de s  i s  
s hown i n  Scheme 6 .  Compounds  53 and 54 were prepared by a general  
Man n i ch  react i on of  a term i na l  a l kyne w i th  formal dehyde , a secondary 
am i ne and a smal l amount  of cuprous  c h l or i de i n  e i ther  ethanol  or 
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propargyl brom i de i n  a methanol  so l u t i on y i el ded N - ( 2 - propynyl ) ph ­
t ha l i m i de (11 0 )  i n  h i g h y i el d 1 5 5 . The Mann i ch react i on of  1 1 0  w i th  
3 7% forma l dehyde and d i methyl am i ne ,  fol l owed by reac t i on w i t h  g a seous  
HC l  g ave  53 a s  the  hydroch l or i de s a l t i n  6 5% y i e l d .  Compound 54 was  
prepared u s i ng d i ethyl ami ne by the  s ame procedure i n  4 5% y i e l d .  
Bebbi  ngton  et  a 1 . 1 5 1 or i  g i n a 1 1  y reported t h  i s  compound a s  the  free 
ba s e ,  wh i ch was synth e s i zed i n  o n l y  1 1% y i e l d .  L ater , Dah l born et 
a l . 1 5 5 a l s o  o n l y  reported t he free base  of  54 ( 68% y i el d ) . The water 
so l ubl e hydroch l or i de sa l t of  54 , w h i ch  wou l d be more favorab l e for 
ph armaco l og i ca l  te s t i ng ,  was prepared i n  t h i s  s t udy . 
The  synthes i s  of  the  b i s - am i no - a l kyne , N , N ' - d i methyl - N , N ' - b i s [ 4 -
( 2 - ph t h a l i m i do ) - 2 - butynyl ] - 1 , 6 - hexaned i ami ne d i hydroc h l or i de ( 5 5b )  i s  
s hown i n  Scheme 6 .  T h i s compound was prepared by a doubl e Mann i c h 
reac t i on at  both secondary n i t rogen s of  N , N ' - d i methyl - 1 , 6 - hexaned i a ­
m i ne d i hydroch l o r i d e  ( I l l ) . Compound I I I  was  prepared by treat i ng a 
methano l  so l ut i on of  N , N ' - d i methyl - 1 , 6 - hexaned i am i ne ( 1 04 )  w i t h  
g a seous  HC 1 , fol l owed by prec i p i t at i on of  the  s a l t w i t h  ether 1 8 1 . 
The  react i on of  compound III w i t h  two equ i va l ents  of  1 1 0 ,  forma l d e ­
hyde a n d  a smal l amount  of cuprous  ch l or i de y i el ded 55a  i n  53% y i el d .  
Th i s  compound was  pur i f i ed by recrysta l l i z at i on from methanol  - water 
then ana l yzed . A water so l ubl e d i hydroch l or i de s a l t ,  5 5 b ,  was  
prepared by treat i ng a s o l ut i on of  55a  i n  methano l  w i t h  gaseous HC 1 . 
Recrysta l l i z at i on of  t h i s  compound was ach i eved from methanol  - ethyl  
acetate and was  c arr i ed out  w i t h  caut i on or on l y o i l s  were obt a i ned 
upon add i t i on of  the  co - so l vent . 
9 9  
The synthe s i s o f  N , N ' - d i methyl - N , N ' - b i s [ 4 - ( I - s ucc i n i m i do ) - 2 -
butynyl ] - 1 , 6 - h exaned i am i ne ( 56 )  i s  s hown i n  Scheme 7 .  Succ i n i m i de 
was reacted w i t h  an equ i va l ent of  sod i um met a l  i n  ethano l  fol l owed by 
the  add i t i on of  propargy l brom i d e  to g i ve N - ( 2 - propyny l ) s ucc i n i m i de 
( 1 1 3 )  i n  80% y i el d .  Mann i c h reac t i on w i t h  III and two equ i va l ents  of 
1 1 3 g ave the  free base  of  compound 56 a s  a v i  scous  o i  1 .  At tempted 
preparat i on of  a d i hydroch l or i de s a l t of  t h i s compound resu l ted o n l y  
i n  o i l s .  Therefore the  d i hydrobrom i d e  s a l t of  5 6  was  prepared . 
3 .  Para s u b s t i tuted carami phen ana l ogs  ( four  corners approach ) .  
The purpose of  t h i  s set  of  compounds  i s  to  t e s t  t he effect on 
ant i mu s c ar i n i c  act i v i ty of  d i fferent s u b s t i tuent s i n  the  para  
po s i t i on of  the  p henyl r i ng o f  carami phen , and to  l oo k  for any 
po s s i bl e  rel at i on sh i p  of act i v i ty w i t h  subs t i tuent  p arameters  s uch as 
Hammett ' s  s i gma (G") or Hansch ' s  p i  (11' ) va l ues . Subst i tuents  were 
chosen  wh i c h have  an extreme va l ue for s i gma and for pi i n  a pos i t i ve 
and  negat i ve d i rect i on ,  i n  a l l comb i nat i on s  ( s ee F i gure 1 0 ) . The 
subs t i tuents  wh i ch were chosen  for exami nat i o n are t he am i no ( 5 7 a ) ; 
I - tetrazo ly l  ( 57 b ) ; I - pyrrol i d i ny l  ( 5 7c ) ; and tr i f l uoromethyl  ( 57d ) . 
Th i s  method i s  not  l i m i ted o n l y  to  these  sub s t i tuents . The o n l y  para 
s u b s t i tuted caram i phen ana l og wh i c h has been synthe s i zed and exam i n ed 
a s  e i t her an ant i muscar i n i c  or an a n t i dote was  the  n i tro der i v at i ve .  
Bannard et  a l . 1 6 0  reported the  p - n i tro der i vat i ve o f  caram i phen had a 
protect i ve rat i o  i n  s ar i n - po i soned rat s of  1 . 3 .  Th i s  i s  a much l ower 
va l ue t h an t he u n subst i t uted parent compound carami phen ( 3 . 2 ) . The 
va l ue for atrop i n� was  2 . 03 i n  t h i s a s s ay .  The n i tro sub s t i tuent  i s  
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i n  t he  p l u s  s i gma ( +0 . 78 )  and m i n u s  p i  ( - 0 . 28 )  quadrant  o f  the  Cra i g  
p l ot  ( see F i g ure 1 0 ) . The tetrazo l y l  ( 5 7 b )  was  chosen  from t h i s  
quadrant  i n  t h i s  research proj ect . 
The synthes i s  of  the  am i no ( 57 a )  and 1 - pyrrol i d i nyl  ( 57 c )  com­
pounds  i s  s hown i n  Scheme 8 .  The n i trat i on of 1 - phenyl cyc l opentane­
carboxyl i c  ac i d  ( 87 )  w i th  fumi ng n i tr i c  ac i d  gave l - ( p - n i t rophen ­
yl ) cycl opentanecarboxyl i c  ac i d  (111) i n  87% y i e l d .  The corre spond i ng 
ac i d  c h l o r i de  was  formed u s i ng t h i onyl ch l or i d e ,  then  reacted w i t h  2 -
d i ethyl ami noethano l . The hydroch l or i de sa l t was  formed by reac t i on 
w i t h  g a s eou s HC l  t o  g i ve 2 - ( d i ethyl am i no ) ethyl l - (p - n i trophenyl ) cy ­
c l opent anecarboxy l ate hydroch l or i de ( 1 1 5 )  i n  78% y i el d .  A n  al ternate 
method t o  synthes i ze t h i s  compound  was  to  react potas s i um l - ( p ­
n i t rophenyl ) cycl opentanecarboxyl ate ( 1 1 6 )  w i t h  2 - d i ethy l ami noethyl  
ch l or i de ( 8 6 )  i n  2 - propanol . T h e  y i e l d  from t h i s  method w a s  58% . 
The n i tro compound 1 1 5  was  then  c a t a l yt i ca l l y  reduced on a Parr 
apparatu s  w i t h  1 0% p l a t i num on carbon under a hydrogen atmosphere to  
g i ve the  correspond i ng ami no compound 57a  i n  h i g h y i e l d l 8 2 . 
The route u sed to  prepare the  pyrrol i d i  nyl der i  vat  i ve 57c  i s  
shown i n  Scheme 8 .  Th i s  compound was  prepared by the  transester i fi -
c at i on method . The  requ i red i ntermed i ate  i n  t h i s  approach i s  an 
a l  kyl  e s t e r  o f  1 - [ p - ( l - pyrrol i d i nyl ) phenyl ] cycl opent anecarboxyl i c  
ac i d .  The  i ntermed i ate  p - n i tro -carboxyl i c  ac i d  1 1 4  was  converted to 
the  methyl e ster  1 1 7  v i a  the ac i d  ch l or i de route ( prepared from 
t h i onyl c h l o r i d e ) 1 6 1 . The n i tro - methyl  ester  was then cata l yt i ca l l y  
reduced t o  t he p - am i no -methyl ester  1 1 8 i n  77% y i e l d .  The p - pyrrol i ­
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react i on o f  1 1 8 w i t h  1 , 4 - d i bromobutane i n  DMF gave methyl l - [p - ( l ­
pyrro l i d i ny l ) p henyl ] cycl opentanecarboxyl ate (ill ) i n  63% y i e l d .  
I n i t i a l l y i n  t h i s  proj ect the ethyl e s ters  of these  i n termed i ates  
were  synthe s i zed . The tran sester i f i c at i on step  u s i ng ethyl  l - [p - ( l ­
pyrrol i d i ny l ) phenyl ] cycl opentanecarboxy l ate ( 1 1 9b )  was  un succes sfu l . 
Therefore the  methyl esters  were then  made of  these  i ntermed i ates . 
The  transester i f i cat i on u s i ng the  methyl ester  of  the  pyrrol i d i nyl  
compound  1 1 9 a w i t h  2 - d i ethyl am i noethano l  and a catal yt i c  amount  of 
sod i um i n  to l uene gave the  t arget compound 2 - ( d i et hyl am i no ) ethyl  1 -
[ p - ( l - pyrrol i d i ny l ) phenyl ] cycl opentanecarboxyl ate ( 5 7 c )  i n  approx i ­
mat e l y  50% y i e l d .  Th i s  compound cou l d be read i l y  i s o l ated and 
pur i f i ed a s  the hydroc h l or i de s a l t by recrysta l l i zat i on .  Apparent l y  
t h e  carbonyl i s  s i gn i f i cant l y  h i ndered such  t h a t  t h e  add i t i on of  one 
extra methy l ene i n  the  a l cohol  port i on of  the e s ter i n termed i ate 
( methyl  to  ethyl ) add s enough ster i c h i ndrance to  preven t transester ­
i f i c at i on . 
Al t hough many 5 - s ub s t i tuted tetrazo l e s  are known , fewer 1 -
s u b s t i tuted tetrazol e s  have been descr i bed . 1 - Aryl tetrazo l e s  h ave 
been prepared by add i t i on of  az i de i on to  i s on i tr i l e s ,  by the 
react i on of  d i azon i um s a l t s  w i th  d i formyl hydraz i ne and by cycl i z at i on 
o f  N - aryl formam i des  w i t h  az i de i on 1 8 5 - 1 8 7 . A more favorabl e general  
method t o  synthe s i ze 1 - aryl tetrazo l e s  from s ubst i tuted an i l i ne s  was  
reported by Kam i t a n i  and Sa i to 1 8 8 . I n  t h i s  approach the  tetrazol e i s  
prepared by react i ng an an i l  i ne or i t s s a l t w i t h ethyl orthoformate 
and sod i um az i de i n  acet i c  ac i d .  The approach to  the  1 - tetrazol yl  
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1 0 5  
phenyl ] cycl opentanecarboxyl ate ( 1 20 )  was  formed i n  6 5% y i e l d  by 
react i ng the  a n i l i ne 1 1 8a w i t h  ethyl orthoformate and s od i um az i de i n  
acet i c  ac i d  a t  7 0 - 7 5  C .  Al l attempt s t o  form the  target compound 
57b  by t ransester i f i cat i on of 1 2 0 w i t h  2 - d i ethy l ami noethanol  i n  
to l uene fa i l ed .  The  add i t i on o f  a c a t a l yt i c  amount ,  o r  an equ i va l ent 
of  s od i um meta l  to  the  react i on m i xture res u l ted in  ma s s i ve decompo ­
s i t i on .  I t  was  fel t a more favorabl e route  to form 57b  cou l d  be from 
the  tetrazol y l - ac i d  1 2 2 .  l - ( p -Am i nophenyl ) cycl opentanecarboxyl i c  
ac i d  ( 1 2 1 )  was  formed by cata l yt i c  reduc t i on o f  the  n i t ro - ac i d  111 i n  
h i g h y i e l d 1 8 4 • Al l attempts  to  form a tetrazo l e 1 2 2 by the  method 
prev i ou s l y  descr i bed proved u n s ucce s s fu l . A f i na l  approach was to 
form tetrazol e 57b d i rect l y  from the a n i l i ne 57a . Th i s  react i on g ave 
l ow y i el d s of  a crude product  wh i ch cou l d not be pur i f i ed by cryst a l ­
l i z at i on .  Co l umn chromatography of  t h i s crude product y i e l ded a 
smal l q uant i ty of  pure 57b . Large quant i t i e s nec e s s ary for comp l ete 
p harmaco l og i ca l  te s t i ng cou l d  not be obta i ned by t h i s  method . 
The  synthe s i s of  the  t r i fl uoromethyl  compound 57d  i s  out l i ned i n  
Scheme 1 0 .  4 - ( Tr i fl uoromethyl ) benzyl brom i de (ill) was  synthes i zed 
i n  h i g h y i e l d from 4 - ( t r i fl uoromethyl ) benzyl a l cohol 1 8 9 . The n i t r i l e  
1£1 was  read i l y  formed from ill and sod i um cyan i de i n  7 5% ethano l l 9 0 . 
Th i s  n i t r i l e  was  reacted w i t h 1 , 4 - d i bromobut ane and sod i um am i de ( 2  
equ i v a l ent s )  at  l ow temperature , i n  ether , to  g i ve a crude cyc l open­
tyl  compound l - [ p - ( t r i fl uoromethyl ) phenyl ] cycl opent anecarbon i t r i l e  
(12 5 ) 1 6 2 . 1 7 2 . The crude react i on m i xture con t a i ned a number of  m i nor 
produc t s . Al l at tempts to  obta i n  pure 1£1 ( c h romatography , d i s t i l l a ­
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( s o l vent s ,  temperature , react i on t i me s , and u s i ng var i ous  base s )  d i d  
not  afford a homogeneous  product . The crude n i t r i l e  1 2 5  was  there ­
fore hyd ro l yzed w i t h  48% HBr to g i ve ac i d  ill . Th i s  product was 
reacted w i t h  t h i onyl c h l or i de fol l owed by react i on w i t h  2 - d i ethyl ­
am i noethano l  to  g i ve 57d . A pure crysta l l i ne  hydroc h l or i de sa l t 
cou l d not  be prepared from t h i s  compound . Therefore a s o l i d  oxal ate 
s a l t was  made . A correct m i croanal ys i s  of  the  e l ement s  cou l d not  be 
obt a i ned on 57d . Because  of  the  d i ffi cu l ty i n  the  cycl i z at i on step 
to  g i ve pure 1 2 5 ,  an a l ternate approach was  attempted to  synthe s i ze 
57d . Mat s u i  et  al . 1 9 1 reported aromat i c  ha l i de s  cou l d be t r i fl uoro­
methyl ated w i t h  s od i um t r i fl uoroacetate and cuprous  i od i de i n  N­
methyl - 2 - pyrro l i d i none . Th i s  method was  attempted , but proved 
u n s ucce s s fu l  i n  form i ng ill d i rect l y  from l - ( p - bromophenyl ) cycl open ­
tanecarboxy l i c  ac i d .  
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B .  Pharmacol ogy 
The pharmaco l og i c a l  test i ng was conducted under the superv i s i on 
of  Dr . I L L .  Dewey , Department of  Pharmacol ogy , Med i ca l  Co l l ege  of 
V i rg i n i a ,  V i rg i n i a  Commonweal t h  Un i vers i ty .  The pharmaco l og i ca l  data  
for a l l compound s i n vo l ved i n  the  program are  i n c l uded i n  the  Tabl e s .  
The compounds  wh i ch were synth e s i zed i n  t h i s project  are i nd i cated 
w i t h an  a ster i s k  ( * ) and the d i scus s i on i s  p r i mar i l y  i n vol ved w i t h 
on l y  t hese  compound s .  The aprophen ana l og s w i t h var i at i on s  i n  the  
ami n o - a l cohol  port i on of  the  mol ecu l e are  a l so i nc l uded ( * )  for  t h i s 
purpo s e . Atrop i ne and scopo l am i ne  ( 2 6 )  h ave been i nc l uded a s  
s t andard s .  
The compounds  have been eva l uated for ab i l i ty to  b l oc k  ACh ­
i nduced contrac t i o n s  of  the  smooth musc l e of  the  g u i nea p i g  i l eum by 
Dr . J .  Kach u r ,  Department  of Pharmacol ogy , Med i ca l  Co l l ege of 
V i rg i n i a  accord i ng to  the  c l a s s i ca l  in  v i t ro a s s ay method of 
Magnu s l 9 Z • Th i s  demonstrates  the drug ' s  ab i l i ty to  act a s  a per i ph e ­
ra l  ant i mu scar i n i c  agent . I n  t h i s  a s s ay i ncreas i ng concentrat i on s  of 
ACh are u s ed i n  the  presence of  an antagon i s t to restore musc l e 
contract i on to  a l evel  produced i n  the  absence of antagon i s t .  Th ree 
concentrat i o n s  of antagon i s t were tes ted i n  dup l  i c ate . From the 
rel at i ve quant i ty requ i red ( dose  rat i o )  i t  i s  po s s i bl e  to  ca l cu l ate a 
meas ure of  the  aff i  n i  ty of the  antagon i st . I f  the  antagon i sm i s  
compet i t i ve then  the  d i s s oc i at i on constant  ( K D ) = [ antagon i s t j /dose  
rat i o  - 1 .  The pAz , a number u sed to measure rel at i ve aff i n i ty of 
d i fferent an tagon i s t s ,  can  be ca l cu l ated , ( pAz = - l og KD ) ·  The pAz , 
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TABLE  1 0  
The D i s s oc i at i on Constant  and  Rel at i ve Potency (Atrop i ne 1 0 0 )  
for a Number of Ant i muscar i n i c  Agent s  
on Smooth Musc l e of  G u i nea  P i g I l eum 
Compound pA2 KD ( nM )  Rel at i ve Potency 
29  1 0 . 09 0 . 08 1 600 
79  9 . 80 0 . 1 6 8 1 0  
46* 9 . 3 1 0 . 49 260 
3 5* 9 . 29 0 . 5 1 2 50 
47* 9 . 28 0 . 54 240  
76 9 . 1 7 0 . 67 1 90 
48* 9 . 03 0 . 93 1 4 0  
6 0  9 . 00 1 . 0 1 3 0 
Atro p i ne  8 . 88 1 . 3 1 00 
36* 8 . 7 7 1 . 7 76 
2 0* 8 . 74 1 . 8 72  
8 2  8 . 5 2 3 . 0  43 
11 8 . 48 3 . 3  39  
26 8 . 40 4 . 0  3 2  
70 8 . 3 3 4 . 7  28 
74 8 . 28 5 . 3  2 5  
68 8 . 2 1 6 . 2  2 1  
73 8 . 1 9 6 . 4  20  
II 8 . 1 3  7 . 5  1 7  
44* 7 . 99 1 0 . 3  1 3  
1 1 0  
TABLE  1 0  ( Cont i nued ) 
Compound pA2 Ko ( nM )  Rel at i ve Potency 
3 7* 7 . 96 1 1 . 0 1 2  
4 5* 7 . 9 1  1 2 . 4  1 0  
5 9  7 . 86 1 3 . 8  9 
4f 7 . 80 1 6 . 0  8 
69 7 . 7 6 1 7 . 4  8 
1 8" 7 . 4 7 34 . 3  4 
34* 7 . 46 34 . 6  4 
I t  7 . 4 5 3 5 . 7  4 
38* 7 . 4 2 38 . 5  3 
6 5  7 . 3 7 43 . 0  3 
63  7 . 20 6 2 . 5  2 
66 6 . 94 1 1 6 
1.£* 6 . 93 1 1 8 
58 6 . 92 1 1 9 
78 6 . 90 1 2 7 
64  6 . 87 1 3 4  
2 4  6 . 86 1 3 7  
Zl 6 . 7 1 1 94 0 . 7  
80 6 . 2 7 536  0 . 2  
7 5  5 . 82 1 500 0 . 08 
§l 5 . 69 2040 0 . 06 
67  5 . 6 2 2380 0 . 0 5 
1 1 1  
TABL E  1 0  ( Cont i n ued ) 
Compound pA2 Ko ( n M )  Rel at i ve Potency 
62  5 . 43 3700  0 . 03 
49* < 5 . 00 > 1 0 , 000 < 0 . 0 1 
.ll* < 5 . 00 > 1 0 , 000 < 0 . 0 1 
Ko and the  rel at i ve potency of the  antagon i s t s  compared to  atrop i ne 
( 1 00 )  are g i ven i n  Tabl e 1 0  i n  order of  decreas i ng act i v i ty .  As can 
be seen the  aff i n i ty of the  d i fferent antagon i s t s  for muscar i n i c  
receptors  i n  the  g u i nea  p i g  i l eum was qu i te var i abl e .  A number of 
the  aprophen ( 4 6 ,  4 7 ,  4 8 )  and caram i phen ( 2 0 ,  3 5 , 3 6 )  ana l ogs  were 
appro x i mate l y equal  to or better t h an atrop i ne i n  t h i s  a s s ay .  I t  i s  
i n terest i ng t o  note  caram i phen C�) and aprophen (.ill ) ,  wh i c h are 
better a n t i dotes  t h an atrop i ne ,  exh i b i ted o n l y  4% of the rel at i ve 
act i v i ty o f  atrop i ne .  Compound 43 , t he  i ndane  ana l og wh i c h conta i n s 
feature s  of  .ill and � ,  was a better antagon i s t than e i ther  compound , 
a l though  s t i l l  much weaker rel at i ve to atrop i ne ( 8%) . Brea k i ng the 
bond i n  the  i ndane  r i ng system ( compound 4 2 )  re s u l ted i n  s i g n i f i cant 
l o s s  of act i v i ty .  Al s o ,  compound 44 , an aprophen anal og w i th  one 
hyd rogen ated aromat i c  r i ng ,  res u l ted i n  an i n crease i n  act i v i ty 
rel at i ve t o  atrop i ne .  N , N , N ' , N ' - tetramethyl - N , N ' - b i s [ 3 - ( 2 - phtha l -
1 1 2  
i m i do ) propy l ] - 1 , 6 - hexaned i ammon i um brom i de (11) and the  corre spond i ng 
tert i ary ami ne 49 were not effect i ve at the  h i g hest  dose  tes ted . 
The compounds  have been eval u ated for aff i n i ty at CNS muscar i n i c  
receptors  by exami nat i on for ab i l i ty t o  d i sp l ace tr i t i ated q u i nuc l i ­
d i nyl benz i l ate ( Q N B )  from spec i f i c  b i nd i ng s i t e s  i n  mou se bra i n  
homogenates 1 9 3 . Three concentra t i ons  of  antagon i s t s  were run i n  
d up l i c ate . The concentrat i on req u i red i n  order to  d i sp l ace one - h al f 
( I C s o ) of  the  spec i f i ca l l y  bound QNB ( 5 . 0  nM concent rat i on )  and 
rel at i ve aff i n i ty ( atrop i ne = 1 0 0 )  of  the  antagon i st s  tested i s  shown 
i n  Tab l e 1 1 .  Becau se  QNB h a s  a h i g h aff i n i ty for muscar i n i c  recep­
tors , a h i g h  concentrat i on of  some antagon i s t s  i s  needed to d i sp l ace 
i t ,  and a n umber of  compounds  d i d  not d i sp l ace 50% of  the QNB at t he 
h i g h e s t  concentrat i on u sed ( l . 0 }4 M ) . Therefore the  concentrat i on of  
QNB  was  reduced to  0 . 5  nM , wh i c h l owers the  I C s o for  the  antagon i s t .  
The  resu l t s  o f  the  compounds  wh i c h were eval uated a t  t h i s concentra ­
t i on are s hown i n  Tabl e 1 2 .  I t  i s  obv i ou s  t hat  atrop i ne and scopol ­
am i ne ( 26 )  b i nd w i th h i g h affi n i ty from t h i s  b i n d i ng a s s ay .  Caram i ­
phen exh i b i ted on l y 5% of  the  rel at i ve aff i n i ty of  atrop i ne for bra i n  
muscar i n i c  receptors  a l though i t  i s  a better ant i dote . Some o f  the  
ana l og s of  c arami phen wh i c h were synthes i zed d i d  i mprove on the 
aff i n i ty of  the  parent mol ecul e .  The best  anal og i n  b i nd i ng was  the 
4 - hydroxy - N -methyl p i perd i nyl  der i vat i ve 20 . The b i s N - s ubst i t uted 
1 , 6 - hexaned i ammon i um compound 11 and the correspond i ng tert i ary ami ne 
49 were we ak antagon i s t s  ( 0 . 3% and 0 . 4% respec t i ve l y )  rel at i ve to 
atrop i ne .  
TABLE  1 1  
The  I C�o and Rel at i ve Potency (Atro p i ne = 1 0 0 )  o f a Number of Ant i mu scar i n i c  Agents  
i n  D i s p l ac i ng Rad i ol abe l ed Q u i nuc l i d i nyl Benz i l ate 
from Spec i f i c  B i nd i ng S i tes  i n  Mouse Bra i n Homogenates  
( QNB  Concent rat i on = 5 . 0  nM )  
1 1 3  
Compound  I C 5 0 ( n M )  Rel at i ve Aff i n i ty 
26  36  1 2 5  
Atrop i ne 4 5  1 00 
2 9  50 90 
60  65 59 
73  1 00 4 5  
2 0* I I I  4 1  
7 0  1 3 3 34  
3 5* 1 4 7  3 1  
7 2  1 70 26 
1 8* 273  16  
38* 330 1 4  
2 4  380 1 2  
59  402  1 1  
63  5 1 0  9 
69 535 8 
36* 645 7 
ll.* 800 6 
.ul.* 9 1 5  5 
6 5  930 5 
1 1 4 
TABLE  1 1  ( Con t i nued ) 
Compound l Cs o ( n M )  Rel at i ve Affi n i ty 
64  1 000  4 
58 > 1 000 < 4 
§.l > 1 000 < 4 
6 2  > 1 000 < 4 
66 > 1 000 < 4 
6 7  > 1 000 < 4 
Il > 1 000 < 4 
74  > 1 000 < 4 
24  > 1 000 < 4 
TABLE  1 2  
The I C �o and Rel at i ve Potency (Atrop i ne = 1 0 0 )  ot  a Number of  Ant i muscar i n i c  Agent s 
i n  D i s p l ac i ng Rad i ol abel ed Q u i nuc l i d i nyl Ben z i l ate  
from Spec i f i c  B i nd i ng S i tes  i n  Mou s e  Bra i n  Homogenates  
( QNB  Concentrat i on = 0 . 5  nM )  
1 1 5  
Compound I C s o ( nM )  Rel at i ve Aff i n i ty 
2 6  1 . 9 560 
29 7 . 9  1 3 4  
7 0  1 0 . 1  1 0 5  
Atrop i ne 1 0 . 6  1 0 0  
46* 1 1 .  1 9 5  
7 2  7 7  1 4  
68  100  1 1  
74  1 1 0 1 0  
1.2* 1 2 4  9 
4 5* 1 3 6  7 
3 4* 1 92 6 
58 228 5 
49* 2380 0 . 4  
11* 3 550 0 . 3  
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Tabl e 1 3  s hows a compar i son of  rel at i ve act i v i t i e s  of  compound s 
i n  the  g u i nea  p i g  i l eum ( per i pheral ) and QNB b i nd i ng ( centra l ) a s s ays 
re l at i ve to  atrop i ne .  I f  the  rel at i ve aff i n i t i e s o f  antagon i s t s  are 
e s sent i a l l y  the s ame for muscar i n i c  receptors  at both s i tes , then 
t h i s  may i nd i cate  that  the d i fference i n  the i n  v i vo effec t i vene s s  i s  
a refl ect i on of d i fferences i n  d i s t r i but i on .  As  can be seen , for 
some of the compounds  the rat i o  i s  near 1 ,  show i ng the aff i n i ty of 
the  compound i n  the  d i fferent a s s ays  var i e s i n  the  s ame way the  
aff i n i ty of  atrop i ne var i es . Scopol ami ne ( 2 6 ) , aprophen  (.lli ) and  
t r i fl upromaz i ne ( 24 )  appear to  have a rel at i ve l y  s t ronger affi n i ty 
for t h e  bra i n  muscar i n i c  receptors  than  for t hose  i n  the  i n test i n a l  
smooth musc l e .  
There i s  e v i dence that  muscar i n i c  receptors i n  the  bra i n  are not 
homogeneou s . Both  M 1  and M2 receptors  are present and uneven l y  
d i s t r i buted . The M 1  receptors  predom i nate i n  t h e  forebra i n  and the 
M2 receptors  are l ocated p r i mar i l y  i n  the  cerebe l l um and med u l l a .  
Therefore b i nd i ng va l ues  of a compound obt a i ned on a whol e bra i n  
homogenate refl ect a m i xed affi n i ty for both s ubtypes . To addres s 
t h i s  d i fference some of  the  antagon i s t s  have been eva l uated for 
ab i l i ty to  d i sp l ace QNB from b i nd i ng s i tes  prepared separat e l y  from 
rat forebra i n  ( p redom i nant l y  M 1 ) or rat medu l l a  ( predom i nant l y  M2 ) .  
The re su l t s  are g i ven i n  Tabl e 1 4 . I t  can be s een the  1 ( 5 0 va l ues  
vary i n  the  d i fferent bra i n  reg i on s . Both aprophen ( .lli ) and  carami -
phen (l2.) have a h i gher  affi n i ty for s i tes  i n  the  forebra i n  than i n  
the  medu l l a . 
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TABL E  1 3  
Compar i son  of t he Rel at i ve Potenc i e s (Atrop i ne = 1 00 )  
of  Sel ected Ant i muscar i n i c  Agents  
on  Muscar i n i c  Receptors of  Mouse Bra i n  and  Gu i nea P i g  1 1  eum 
Mou se  G u i nea P i g  Rat i o  o f  
Compound Bra i n  I l  eum Act i v i t i e s 
2 6  1 2 5 3 2  3 . 9 1 
Atrop i ne 1 00 1 0 0  1 .  0 0  
60  69  1 3 0  0 . 53 
73  45  20  2 . 2 5 
2 0* 4 1  7 2  0 . 5 7 
7 0  34  28  1 .  2 1  
11. 26  39  0 . 6 7 
�* 1 6  4 4 . 00 
24  1 2  1 2 . 0  
59  1 1  9 1 .  2 2  
63  9 2 4 . 50 
69  8 8 1 .  00  
l2.* 5 4 1 .  25  
6 5  5 3 1 .  67 
64 4 4 . 00 
TABLE  1 4  
The 1 C5 0 Va l ues  and Rel at i ve Potency (Atro p i ne = 1 0 0 )  
o f  a Number of  Ant i mu scar i n i c  Agent s 
i n  D i sp l ac i ng Rad i o l abe l ed Q u i nuc l i d i nyl Benz i l ate  
from Spec i f i c  B i nd i ng S i tes  
i n  Homogenates  of  Rat  Forebra i n  and Medu l l a  
1 1 8  
Forebra i n  Medul l a  
Re l at i ve Rel at i ve 
Compound  1 C 5 0 Potency 1 C5 0 Potency 
2 6  1 5  590 44 50 
2 9  2 5  3 50 6 7  33 
7 0  86  1 0 2  1 30 1 6  
Atrop i ne 88 1 00 2 2  1 0 0  
l§.* 1 30 68 340 6 
58 230 38 1 000  2 
u* 360  25  330  6 
1 1 9  
I n h i b i t i on o f  oxotremor i ne - i nduced tremors , wh i ch was  conducted 
by Dr . U .  E s trad a ,  Department of Pharmacol ogy , Med i ca l  Co l l ege of 
V i rg i n i a ,  i s  a s t andard a s s ay for in v i vo ant i mu scar i n i c  act i v i ty .  
Oxot remo r i ne i s  a potent non - q u aternary chol i nerg i c  agent that  
produces  t remors  a s  a resu l t of s t i mu l at i ng central  muscar i n i c  
receptors . I n  a prel i m i nary s t udy oxotremor i ne was i nj ected subcuta ­
neo u s l y  i n to  grou p s  of  1 0  m i ce at  doses  rang i ng from 0 . 1 - 0 . 8  mg/kg . 
The n umber of  m i ce w i t h t remors at  var i ou s  t i me i nterval s was  noted . 
The data  are presented i n  Tabl e 1 5 .  The  peak effect o f  oxotremor i ne 
appeared to  occur between 10 and 20 m i nutes . E ffec t s  of  al l doses  
had cea sed i n  90 m i nute s .  F rom t h i s  data  an opt i mum t i me and dose  of  
oxotremor i ne were c ho sen  for eval uat i ng the  i n h i b i tory potency of  the  
ant i mu s c a r i n i c  agent s .  
1 2 0 
TABLE  1 5  
The Percent age o f  M i ce Exh i b i t i ng Tremor 
at  D i fferent T i mes  After Subcutaneous  I nj ect i on 
of  the  I nd i cated Dose of  Oxotremori ne 
Dose (mg/ kg ) * 
T i me (m i n )  
5 1 0  2 0  3 0  60 90 
0 . 1  1 0  1 0  1 0  0 0 0 
0 . 2  1 0  40 50 1 0  0 0 
0 . 4  40 80 1 0 0  80 1 0  0 
0 . 6  50 90 1 00 80 1 0  0 
0 . 8  70 1 00  1 00 1 0 0  6 0  0 
*Dose  i s  mg/ kg of  oxotremor i ne ba se . Ten m i ce were u sed at each dose  1 eve 1 . 
The met hod of  Atk i n son et al . I 0 7 was  u sed for a s s ay i ng the 
muscar i n i c  antagon i st s . I n  one ser i e s of  expe r i ments  each of  the 
antagon i s t s  was  admi n i stered s ubcutaneou s l y  to groups of m i c e  30 
m i nutes  p r i o r  to cha l l enge w i t h a 0 . 48 mg/kg dose of oxot remor i ne . 
The n umber of  m i ce w i t h  tremors at 1 0  and 20  m i nutes  after the 
oxotremor i ne i nj e c t i on was  observed . Th i s  was  repeated u s i ng three 
d i fferent concentrat i on s  of the ant agon i s t i n  groups of 6 a n i mal s 
un t i l  a graded i n h i b i t i on of tremors was observed . From t h i s data  
the  effect i ve dose  ( EDs o ) reduc i ng the  number of  m i ce w i t h  tremor by 
50% was  ca l cu l ated at  each t i me po i n t .  The res u l t s  of the antago -
n i s t s  te s ted and the  potency rel at i ve to  at rop i ne are shown i n  Tabl e 
1 2 1  
1 6 .  Th i s  method demon strates an antagon i s t ' s  effi cacy to protect i n  
prophyl act i c  t reatment of organophosphate po i s on i ng .  I n  a chemi ca l  
warfare s i t uat i o n ,  pO i son i ng w i l l  have al ready occurred and t reatment 
w i l l  then  be requ i red . Therefore i n  a paral l e l s er i e s of exper i ment s  
the  antagon i s t s  were adm i n i s tered one  m i nute  after the  dose  of 
oxotremo r i n e .  The n umber of  m i ce w i t h  t remors at  1 0  and 20  m i nutes  
was  observed , and an EDs o for  antagon i sm of the  tremors was ca l c u l a ­
ted . T hese  resu l t s  are shown i n  Tabl e 1 7 .  
For a compound to be an effect i ve pretreatment agent for 
protect i ng ag a i n s t  organophosphate po i s on i ng ,  i t  w i l l  requ i re a l ong 
d u rat i on of act i on .  Re su l t s  i n  Tabl e 16 s how that  at 20 m i nutes  ( 50 
m i nutes  after g i v i ng the  antagon i s t )  t he  effec t i venes s  of  mos t  of the  
ant agon i s t s  i s  dec l i n i ng ( EDs o r i ses ) compared to  10  m i nutes  ( 40 
m i n u t e s  after admi n i s trat i on ) . Atrop i ne i n  contrast  i s  about equal l y  
effect i ve a t  both t i mes , mak i ng t h e  rel at i ve potency of  mo st  com­
pounds  even l e s s  favorabl e at 20 m i nutes  than at 1 0  m i nute s . An al ogs 
1 2 2 
TABLE  1 6  
The ED( o Val ue and Rel at i ve Potency (Atrop i ne = 1 0 0 )  
or Antagon i sm of  Tremors I nduced i n  M i ce 
When the  Antagon i s t Compound i s  Adm i n i stered 
30  M i n utes  Before Oxotremor i ne 
EDs o (mgj kg ) Potency (Atrop i ne = 1 0 0 )  
Compound At  10  M i n  At 20  M i n At 1 0  M i n At 2 0  M i n  
2 6  0 . 005  0 . 0 1 4  7 560 2 500 
29 0 . 0 23  0 . 06 1  1 640 574 
3 5* 0 . 065  0 . 2 5 582 1 3 8  
7 2  0 . 1 5 0 . 2 7 2 5 5  1 3 2  
46* 0 . 2 2 0 . 62 1 7 3  5 6  
69  0 . 2 5 0 . 6 7 1 4 9  5 2  
2 0* 0 . 3 2 0 . 50 1 1 9 7 0  
Atro p i ne  0 . 38 0 . 35  100  1 00 
2 4  0 . 4 3 0 . 60 88 58 
7 9  0 . 46 0 . 67 82 53 
68 0 . 9 5 0 . 84 40 4 2  
1 8* 1 . 1 6 4 . 9 1 33  7 
7 0  1 .  3 1  2 . 63 2 9  1 3  
36* 1 .  54 1 .  99  25  18  
4 5* 1 .  59  2 . 2 2 24  16  
7 4  1 .  7 2  1 .  8 1  2 2  1 9  
7 3  1 .  94  2 . 6 9 20  13  
1.2* 2 . 1 2 3 . 3 4 1 8  1 0  
6 5  2 . 4 3 6 . 1 0 1 6  6 
1 2 3  
TABL E  1 6  ( Cont i nued ) 
EDs o ( mgjkg ) Potency (Atrop i ne = 1 00 )  
Compound At 10 M i n  At 2 0  M i n At 10 M i n  At 20 M i n 
8 2  2 . 56 3 . 39 1 5  1 0  
38* 2 . 89 5 . 44 1 3  6 
34* 3 . 1 7 7 . 7 1 1 2  5 
64 3 . 40 3 . 2 5 1 1  1 1  
37* 3 . 4 2 3 . 36 1 1  1 0  
11. 3 . 52 5 . 62 1 1  6 
6 6  4 . 96 8 . 1 8 8 4 
59 6 . 3 2 8 . 1 7 6 4 
63  6 . 4 4 1 0 . 6  6 3 
78  7 . 5 2 1 1 .  7 5 3 
§.l 1 0 . 8  2 5 . 6  4 
58 > 20 . 0  > 20 . 0  < 2 < 2 
6 2  > 20 . 0  > 20 . 0  < 2 < 2 
6 7  > 2 0 . 0  > 20 . 0  < 2 < 2 
Il > 20 . 0  > 20 . 0  < 2 < 2 
80 > 20 . 0  > 20 . 0  < 2 < 2 
49* > 20 . 0  > 20 . 0  < 2 < 2 
11* > 2 0 . 0  > 20 . 0  < 2 < 2 
76 > 20 . 0  > 20 . 0  < 2 < 2 
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TABLE  1 7  
The ED( o Val ue and Rel at i ve Potency (Atro p i ne = 1 00 )  
o r  Antagon i sm of  Tremors I nduced i n  M i ce 
When the  Antagon i s t Compound i s  Adm i n i stered 
1 M i nute After Oxotremor i ne 
EDs o (mgj kg ) Potency (Atrop i ne = 1 00 )  
Compound At 10 M i n  A t  2 0  M i n At 1 0  M i n  At 20 M i n 
2 6  0 . 0 50 0 . 02 2  3 9 1 0  2690 
69  0 . 2 3 0 . 3 1  869 1 0 9 1  
2 9  0 . 3 0 0 . 1 6 64 1  38 1  
7 2  1 .  08  0 . 3 5 1 8 1  1 6 7  
7 0  1 .  2 7  0 . 59 1 54 1 00 
82  1 .  54  1 . 1 5 1 2 7  5 1  
59  1 .  7 9  2 . 0 1  1 0 9  2 9  
Atro p i ne  1 .  9 6  0 . 59 1 00 1 00 
7 3  2 . 1 6 1 .  36  9 1  43 
68 2 . 3 1  1 . 30 85 46 
.lli* 2 . 49 1 . 87  78  3 2  
7 4  2 . 93 1 .  33  67  44 
l2.* 3 . 29 1 .  87 59  32  
3 7* 3 . 8 1  2 . 90 5 1  2 0  
6 5  3 . 83 3 . 1 7 5 1  1 9  
4 5* 4 . 50 4 . 26 43 1 4  
38* 4 . 86 5 . 3 2  4 0  1 1  
§.l 5 . 1 0 3 . 3 9 38 1 7  
2 4  6 . 29 2 . 1 4 3 1  28 
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TABLE  1 7  ( Cont i n ued ) 
ED5 0 ( mg/ kg ) Potency (Atrop i ne = 1 0 0 )  
Compound At 1 0  M i n  At 20  M i n  At 1 0  M i n At 2 0  M i n 
II 7 . 89 6 . 2 2 2 5  1 0  
3 4* 8 . 26 5 . 3 9 2 4  1 1  
6 6  8 . 7 0 6 . 3 3 2 2  9 
58 8 . 88 1 1 .  3 2 2  5 
78  1 5 . 2  1 2 . 2  1 3  5 
Zl > 2 0 . 0  > 20 . 0  < 1 0  < 3 
7 6  > 2 0 . 0  > 20 . 0  < 1 0  < 3 
2 0 ,  3 5 ,  and 4 6  are more e ffect i ve than atrop i ne a t  1 0  m i nutes , and 
compound  35 i s  s t i l l  s i gn i f i cant l y better than atrop i ne at 20  
m i n u te s . Caram i phen � and aprophen � are both l e s s  e ffect i ve than  
a trop i n e .  Compounds  11 and 4 9  d i d  not antagon i ze the  tremors even at 
the h i g he s t  do se s  t e sted  ( 20 mg/kg ) . A key factor i s  t hat  an agent 
mu s t  h ave a protect i ve effect at a dose  that i s  not too tox i  c .  
Compounds  w i t h  l e s s  antagon i st i c  potency t h an atrop i ne m i ght  be 
u sefu l  pretreatment agents  i f  t hey can be g i ven  i n  h i g her  doses  
w i thout  tox i c  e ffec t s . 
For a compound to be an effect i ve ant i dote for organophosphate  
po i s on i ng when i t  i s  g i ven after po i son i ng occurs  i t  mu s t  have a 
rap i d  onset  of act i on so a s  to bl ock t he  muscar i n i c  receptors before 
t he  r i s i ng l evel s of ACh are l e tha l . The effects  of the i n h i b i t i on 
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of tremors for the  antagoni  s t s  g i  ven one m i  nute  after oxotremor i  ne 
are s hown i n  Tabl e 1 7 .  I t  can be seen i n  t h i s  s i tuat i on the  potency 
i s  general l y  r i s i ng between 1 0  and 20  m i nutes  ( EDs o decl i n i ng ) . 
C aram i p hen (�)  and aprophen (18 )  are more effec t i ve i n  a n  ant i dote 
s i t uat i on than i n  a pret reatment s i tuat i on ( Tabl e 1 6 )  rel at i ve to 
atrop i ne .  
Another a s s ay wh i c h was u sed to  determ i ne CNS act i v i ty of the 
antagon i s t s  was  the  d i s cr i m i n at i ve s t i mu l u s  a s s ay wh i c h has been 
devel oped for detect i ng drug - i nduced s ubj ec t i ve sensat i on s  i n  
a n i ma l s .  Th i s  a s s ay was conducted by Dr . J .  Rosecran s ,  Department of 
Pharmaco l ogy , Med i c a l  Col l ege of  V i rg i n i a .  I f  a drug w i l l  produce a 
s u i t abl e cue  upon admi n i s trat i on ,  then an an i ma l  can be tra i ned to 
recogn i ze the cue  and to  d i st i ng u i sh  among drugs wh i c h w i l l  or w i l l  
not produce the  s ame cue  to the  dose  of  a drug wh i c h the  a n i mal can 
detect . To carry out  the  a s s ay a group of  a n i mal s must  be tra i ned on 
a part i c u l ar drug . One i nj ec t s  e i ther  the  tra i n i ng drug or s a l i ne 
and p l aces  t he an i mal  i n  an operant chambe r .  The chamber cont a i n s  
two l evers , one arb i trar i l y  d e s i gnated the  drug l ever and the  other 
the  s a l i ne l ever . When the  a n i ma l  has  been adm i n i stered drug , a 
certa i n  number of  pushes  on the  drug l ever re su l t s  i n  the  d i spen s i ng 
of  a food pel l e t reward ( s a l i n e l ever produces no resu l t ) . When 
s a l i ne h a s  been adm i n i stered , the  oppos i te l ever re s u l t s  i n  reward . 
I f  the  drug i s  capabl e of s t i mu l at i ng detectabl e cues , the  a n i mal s 
w i  1 1  i n  t i me 1 earn to  pre s s  the proper 1 ever i n  the chamber 80% or 
more of  the t i me . Once the a n i mal s are tra i ned , d i fferent drugs  can 
be u sed to s u b s t i tute  for or to bl ock the l e arned cue . 
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Th i s  a s s ay was  u s ed as  a measure o f  centra l  ant i mu scar i n i c  
act i v i ty by t he  method descr i bed by G l ennon  e t  a 1 . 1 9 4 . Rats  were 
tra i ned  on the muscar i n i c  agon i s t arecol i n e ( 1 . 1 6 mg/kg ) p l u s  
methyl  atrop i ne a s  a cue . I t  was  found rat s l e arned to d i s cr i m i nate  
between arecol i n e and s a l i n e ,  but  th i s  was  then  b l ocked by both  
atrop i ne and methy1 atrop i n e .  S i nce  methy 1 atrop i ne i s  a quatern ary 
compound  t h a t  does  not  act central l y ,  the  a n i ma l s must  have been 
dete c t i ng  a per i pheral  c ue . By admi n i s ter i ng methy 1 atrop i n e i n  the  
t ra i n i ng s e s s i on ,  any per i pheral  cue  s hou l d be b l ocked . After 
tra i n i ng the a n i mal s on  the  agon i s t ,  the  antagon i s t s  were admi n i s ­
tered a l ong w i t h the  do se  o f  arecol i ne .  I f  t he  antagon i s t effect i ve ­
l y  b l o c k s  the  cue , the rats  s h ou l d p u s h  the  s a l i n e l ever . The 
res u l t s  for atrop i ne  and the  other  antagon i sts  t e s ted are s h own i n  
Tab l e 1 8 .  A s a l i n e - l i ke response  ( antagon i sm )  i s  ach i eved when the  
an i ma l  responds  l e s s  than  20% on the  drug l ever . An  80% or  greater 
re spon se  o n  the  drug l ever i s  con s i dered a drug - l i ke respon s e . That 
i s ,  t he  an i ma l  s t i l l  s e n s e s  a cue , and the  antagon i sm fa i l s . 
Atro p i ne b l oc ked t he  arecol i n e cue  at a d o s e  o f  1 2  mg/kg . Aprophen 
(�) effec t i ve l y  bl oc ked t he centra l  cue  at a dose of  4 5  mg/ kg , 
wherea s  c aram i phen (12)  d i d  not bl ock  at a do se  o f  75 mg/kg . An 
appropr i ate  d o s e  cou l d not be found for a l l compounds  exam i ned . I n  
genera l , t he  n umber o f  an i ma l s respond i ng and t h e  rate of  respon se on 
the l evers  dec1 i ned w i t h i ncrea s i ng do se s  of antagon i s t s . The 
a n t i muscar i n i c  agent s  may be i n terfer i ng w i th  the memory proce s s e s  
n ec e s s ary for  respond i  ng . As can  be seen i n  the  resu 1  t s  for many 
compound s , the h i g her do se s  seemed to i n terfere w i th  re spond i ng 
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TABLE  1 8  
Effect o f  Ant i mu scari n i c  Agents  on Drug D i s cr i m i nat i on 
i n  Areco l i ne -Tra i ned Rats  
Dose  Average Average 
Compound ( mg/kg ) N/T* % DL** Rate*** 
Atrop i ne 1 2  6/ 1 0  1 3  0 . 34 
1 8* 30 3/6 53 0 . 0 3 
45  5/ 1 2  8 0 . 1 0 
58 50 5/7 80 0 . 2 1 
2 0* 1 2  5/8 39  0 . 06 
5 9  30  3/ 1 0  33 0 . 0 7 
60 0/6 
60  0 . 2 5 5/6 62  0 . 2 1  
0 . 50 5/8 60  0 . 0 1  
0 . 7 5 6/ 1 7  3 2  0 . 0 1 
63  60 0/6 
64 60 3/6 83 0 . 08 
2 9  7/8 57 0 . 2 6 
2 5/7 63 0 . 1 6 
4 9/ 1 2  4 7  0 . 0 5 
6 5  40 4/6 5 1  0 . 1 8 
7 5  8/ 1 7  43 0 . 09 
1 00 3/6 5 0 . 1 3 
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TABL E  1 8  ( C o n t i nued ) 
Dose  Average Average 
Compound (mg/kg ) N/T* % DL** Rate*** 
68 30 7/8 33 0 . 1 1  
4 5  6/9 8 0 . 02 
�* 50 8/ 1 5  54 0 . 1 4 
60 3/ 1 1  77  0 . 0 7 
7 5  3/ 1 3  78 0 . 008 
69 8 5/ 1 6  2 0 . 006 
70 40 4/6 77 0 . 08 
60 7/ 1 3  40 0 . 1 0 
II 60 7/9 87 0 . 1 3 
7 2  5 5/ 1 2  1 00 0 . 03 
8 1/6  50  0 . 008 
24 0 . 2 5 7/7 1 00 0 . 03 
0 . 50 8/9 83 0 . 0 5 
0 . 7 5 6/9 3 2  0 . 02 
34* 60  5/6 92  0 . 08 
3 5* 2 6/ 1 7  63 0 . 0 1 
3 1/8 1 5  0 . 0 1 
36* 60 2/7 67  0 . 0 2 
3 7* 4 5  2/6 80 0 . 1 0 
60 1/6  0 0 . 03 
TABLE  1 8  ( C on t i n ued ) 
Dose  Average 
Compound (mg/ kg )  N/T* % DL** 
79 1 0  3/8 5 1  
1 5  3/ 1 0  3 9  
4 5* 60 4/7 50 
46* 8 8/ 1 5  2 5  
*Number o f  rat s  res pond i ng o f  the  n umber t e sted . 
**Average % o f  re spo n s e s  on the  drug l ever .  
***Average n umber o f  l ever  pre s s e s/ second dur i ng t h e  t r i a l . 
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Average 
Rate*** 
0 . 03 
0 . 0 2 
0 . 1 4 
0 . 03 
before i t  t o t a l l y  b l ocked the  areco l i n e cue . The cho l i nerg i c  effect s 
o n  l e arn i ng and memory h ave been wel l documented2 0 2 , a l though  other  
factors  cou l d be respon s i bl e  for the  l ac k  o f  respond i ng .  I t  ha s  been 
reported a n i mal s t ra i ned on a l earned t a s k  have been s i gn i f i c an t l y  
i mp a i red t o  perform t h e  t a s k  after treatment  w i t h  a n  a n t i cho l i n erg i c  
agent  s u c h  a s  s copo l am i ne 1 9 6 • 
The  N - s u b s t i tuted - 1 , 6 - h exaned i ammon i um compound s ,  N - s ub s t i t u ted -
1 , 6 - hexaned i am i ne s  and N - ( 4 - d i ethy l am i no - 2 - butynyl ) p htha l i m i d e  were 
eva l uated for muscar i n i c  receptor b i nd i ng affi n i ty and s ubtype 
s e l ec t i v i ty by Dr . H . ! .  Yamamu ra , Department of  Pharmaco l ogy , 
U n i vers i ty o f  Ar i zona 1 9 5 . The resu l t s  of  t h e  compound s '  ab i l i ty to  
separate l y d i s p l ace rad i o l abe l ed p i renzep i n e from rat  cortex  ( M 1  
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receptor s ubtype ) and rad i o l abel ed QNB from rat heart (M2  receptor 
s u btype )  are g i ven i n  Tabl e 1 9 .  Each dose was run i n  t r i p l i c ate . 
Atrop i ne does  not  d i s t i ng u i sh  between these  receptor s ubtype s . The 
b i s - quatern ary N , N , N '  , N ' - tetramethyl - N , N ' - b i s [ 3 - ( 2 - p htha l i m i d o ) pro ­
pyl ] - 1 , 6 - h exaned i ammon i um compound 11 ,  though  weaker than atrop i ne 
s howed moderate  potency i n  b i nd i ng to  muscar i n i c  receptors . Compound 
II had a two fol d h i gher  aff i n i ty for the M2 s i te than the M 1  
receptor s ubtype . 
approx i mate l y  equa l  
The correspond i ng b i s - tert i ary am i ne 49 had 
aff i n i ty for the  M2 receptor s ubtype a s  the  
quatern ary compound , but l o st  b i nd i ng aff i n i ty for  t he  M 1  receptor 
s ubtype . Compound 49 showed nearl y a f i ve fol d h i gher  affi n i ty for 
t he  M2 receptor . I t  i s  general l y  accepted for a compound to  be 
c l a s s i f i ed as se l ect i ve for one subtype i t  s hou l d demon strate  at 
l e a s t  a ten fo l d  exce s s  i n  b i nd i ng affi n i ty for one receptor s ubpop u ­
l at i on .  Al t hough t h e s e  compounds  a r e  n o t  se l ect i ve ,  t hey do s how a 
preference for t he  M 2  receptor . S i  nce the  quaternary compound II 
does  not  penetrate  t he  bra i n ,  t he  correspond i ng tert i ary am i ne 49 may 
funct i on as a CNS act i ve muscar i n i c  agent . An exami nat i on of the  
data  reve a l s i n format i on on the  SAR  of  t h i s  s er i e s of  compound s .  As 
can  be seen w i th  the  un symmetr i ca l  quaternary compound ( 50 ) , the 
removal  of  one 3 - ( 2 - p htha l i m i d o ) propyl port i on of the  mo l ecu l e 
resu l t s  i n  l o s s  of  both affi n i ty and receptor subtype se l ect i v i ty 
( preference ) .  The  l o s s  of b i nd i ng affi n i ty and receptor s ubtype 
pre ference i s  even more drast i c  w i th  the corres pond i ng tert i ary am i ne 
(�) . T hu s  i n  compar i son of  the  symmetr i ca l  w i th  the  un symmetr i ca l  
compound s ,  i t  appears that  for  good ant i muscar i n i c  act i v i ty ( pos s i bl y  
Compound 








TABLE  1 9  
B i nd i ng Affi n i t i e s and Subtype Sel ect i v i t i e s 
for Sel ected Muscar i n i c  Antagon i s t s  
K [ ( nM )  
M2  M l  
[3H ] QNB [3H ] P i renze p i ne  
( Rat  Heart ) ( Rat Cortex ) 
0 . 7 0 0 . 2 5 
1 2  2 5  
1 8  87 
80 1 60 
73 95 
409 2B3 
69 29  
Not Tested 
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Rat i o  
M l/M2 
0 . 4  
2 . 1  
4 . 8  
2 . 0  
1 . 3 
0 . 7  
0 . 4  
a n t i dota l  act i v i ty )  both 3 - ( 2 - phtha l i m i d o ) propyl port i on s  contr i bute 
i n  b i nd i ng .  When t he  3 - ( 2 - phtha l i m i do ) propyl port i on o f  the  mol ecu l e 
i s  s u b s t i t uted w i t h  t he  b i s - [ 4 - ( 2 - p htha l i m i do ) - 2 - butynyl ] mo i ety 
( compound 5 5 )  a s u b s t an t i a l  l o s s  o f  b i nd i ng aff i n i ty i s  o b served . N -
( 4 - d i ethy l ami no - 2 - butynyl ) p htha l i m i de ( 54 )  showed a h i gher  affi n i ty 
for t he  M l  receptor than t he M2 s i t e .  
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The compound s  are a l s o  be i ng eval uated for ab i l i ty to bl ock  the  
l et h a l  effc t s  o f  s oman in  m i ce .  T h i s work i s  be i ng done by the  U . S .  
Army Med i c a l  Re s earch and Devel opment  Command through  the  D i v i s i on of  
Exper i menta l  Therapeut i c s ,  WRA I R ,  WRDMC , W a s h i ngton , DC . The  
compound s are te sted  aga i n s t  2 x LDs o o f  s oman and s urv i va l  rate  
noted after 24  h vers u s  control . The antagon i s t s  are admi n i n stered 
at 1/4 and  1/2  the  LDs o of the  antagon i s t ,  one m i nute  after an i . m .  
i nj ect i on o f  s oman . The effect i vene s s  o f  the  antagon i s t a s  an 
ant i dote  i s  f i r s t  te s ted a l one . I t  i s  then eval u ated a l ong w i t h  the 
ox i me react i v ator 2 - PAM ( 2 5  and 50 mg/ kg ) . Add i t i ona l l y ,  the  novel  
antagon i s t s  are eva l uated a s  ant i dotes  i n  conjunct i on w i th  atrop i ne 
and 2 - PAM . The re s u l t s  o f  t h i s  s t udy have not  yet been re l ea sed . 
I V .  CONCLUS I ONS 
The  goal o f  t h i s  research was  t o  synthe s i ze novel  an t i mu scar i n i c  
agen t s  for i mproved t reatment  o f  po i s on i ng by organopho s phate 
c ho l i n e s terase  i n h i b i tors . Correl at i on s  are  to  be sought  between the  
re l at i ve ab i l i ty o f  the  compounds  t o  protect  aga i n s t  s oman p o i s on i ng 
and a ct i v i ty i n  the other  pharmacol.og i ca l  t e s t s . Ant i mu s c ar i n i c  
act i v i ty was  mea sured o n  g u i nea  p i g  i l eum and o n  t he  ab i l i ty to 
d i s p l ace  rad i ol abel ed QNB from s pec i fi c  b i n d i ng s i te s  o f  mou s e  bra i n  
h omogenates  i n  order to  compare centra l  versu s  per i pheral  mu scar i n i c  
act i v i ty .  I n format i on from the  g u i nea  p i g  i l eum a s s ay i s  a rel i abl e 
t e s t  o f  a compound ' s  ab i l i ty to act a s  an ant i mu s c ar i n i c  agent . The 
compound s i n  t h i s  a s s ay are d i re c t l y  b l ock i ng e ffect s  o f  ACh . The 
QNB  b i nd i ng a s s ay may be l e s s  rel i abl e o f  a compound ' s  aff i n i ty for 
muscar i n i c  receptors  because  of the var i ab i l i ty i n  the a s s ay .  Both 
M l  and M2  receptors  are present  i n  the  bra i n ,  but t hey are not even l y  
d i s tr i buted . There fore , b i nd i ng va l ues  o f  a compound obta i ned on a 
whol e bra i n  homogenate  are a mi xed funct i on o f  the  affi n i ty for the 
separate  s ubtype s .  The compound s were exami ned for centra l  mu scari ­
n i c  act i v i ty i n  v i vo by ab i l i ty to  b l ock  oxot remor i ne - i nduced tremors 
and to  bl ock  the areco l i n e cue i n  a drug d i s cr i m i n at i o n a s s ay . The 
bl o c k  of  an ago n i s t  cue  w i t h  an antagon i s t i n  a drug d i s c r i m i n at i on 
parad i gm h a s  never  been reported i n  the  l i terature w i t h t he  
1 3 4 
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muscar i n i c  receptor sys tem . Several  compounds  d i d  show a d o s e ­
response  re l at i on s h i p  t o  b l ock  t he  cue . A n  appropr i a te d o s e  cou l d  
n o t  b e  found for a l l compounds  exami ned . The number of  an i ma 1 s 
res pond i ng and t he  rate o f  response  on the  1 evers  dec l  i ned w i t h 
i ncreas i ng d o s e s  of  antagon i s t s .  The re s u l  t s  o f  the  compounds  I 
ab i l i ty to  protect i n  s oman po i s on i ng h a s  not  been rel ea sed a s  yet . 
The  reason  a battery o f  pharmaco l og i c a l  a s s ay s  was  empl oyed i n stead 
o f  one  repre sentat i ve a s s ay o f  ant i mu s c ar i n i c  effect i vene s s  i s  
bec a u s e  i t  i s  nec e s s ary to  determ i n e  i f  there i s  a pharmaco l og i ca l  
property i n  an  antagon i st wh i c h correl ates  w i th  i t s a b i l i ty to  act as  
an  a n t i dote . Aprophen and caram i phen have been reported to  be 
s i g n i f i cant l y  better ant i dotes  than  atrop i ne ,  yet t hey were much 
weaker antagon i s t s  rel at i ve t o  atrop i ne i n  the pharmaco l og i ca l  
a s s ay s . At t h i s po i nt i t  appears  from t h i s research that  the  
ant i dota l  p ropert i e s  can  not  be expl a i ned based s o l e l y  on the 
ant i mu s car i n i c  act i v i ty o f  t he  compound s from t he  var i o u s  pharmaco l o ­
g i c al a s s ay s . T he  be s t  ant i dotes  are not  t he  best  antagon i s t s  i n  the  
ant i mu s c ar i n i c  a s s ay s . The pr i mary ph armaco l og i c a l  effect i s  the 
central  ant i mu scar i n i c  act i v i ty to  b l ock  t he  response to  the  exc e s s  
ACh .  Beyond that  po i n t ,  compounds  1 i ke carami phen and aprophen may 
be act i ng by an add i t i ona l  mechan i sm to g i ve added ant i dota l  protec ­
t i on .  Po s s i b l y  t he  o n l y  reason  atrop i ne i s  a better ant i mu scari n i c  
but  a l e s s  e ffec t i ve ant i dote  i s  becau se  i t s  on l y  mechan i sm for 
protec t i on i s  an  ant i mu scar i n i c  effect . Th i s  add i t i ona l  mechan i sm 
may be operat i ng o n l y  w i t h  cert a i n  s tructural  type s of  ant i mu scar i ­
n i c s  at  t he  extreme l y  h i g h d o s e s  wh i ch are u s ed i n  t h i s  ant i dota l  
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s i t uat i on .  Even at  h i g h doses  atro p i ne may on l y be exh i b i t i ng 
ant i mu s c ar i n i c  act i v i ty wh i c h wou l d expl a i n  why i t s max i mum protec ­
t i on l eve l s off  even  w i t h  i ncrea s i ng doses . Caram i phen con t i nues  to 
g i ve added protec t i on at  exces s i ve l y  i ncrea s i ng doses . 
A .  Caram i phen and aprophen compounds . 
A n umber o f  s tructura l  var i  at  i on s  of  carami  phen and aprophen 
were synthes i zed . The purpose o f  t h i s  set  of  compounds  was  to 
determ i ne i f  there was any paral l e l pattern o f  c hange i n  ph armaco l o ­
g i c a l  act i v i ty i n  the  var i o u s  a s s ays  w i t h  the  ab i l i ty to  protect 
a n i mal s p o i soned by soman . Many o f  these ana l ogs  were better 
antagon i s t s  i n  the  pharmac o l og i ca l  a s s ays  t han the  parent c ompound s .  
I n  general , i ncorporat i on o f  a qu i nuc l i d i ny l , trop i nyl , o r  N - methyl -
4 - p i pe r i d i ny l  mo i ety i n  t he ami no - al coho l  port i on o f  the  mo l ecu l e 
resu l ted i n  more potent compounds . Mod i f i c at i on s  o f  the  ac i d  port i on 
o f  aprophen al s o  s how c hanges  i n  the  act i v i ty o f  the  compounds .  
Reduc i ng one o f  the  aromat i c  r i ng s  t o  the  phenyl cycl ohexyl mo i ety 
resu l ted i n  i n creased act i v i ty .  E l ongat i on o f  the  a l kyl port i on of  
the  ac i d  ( methyl  t o  ethyl ) res u l ted i n  decreased act i v i ty .  However 
when the ethyl  g roup  was i n  a r i g i d  conformat i on form i ng an i ndane 
r i ng system , enhanced act i v i ty was observed . 
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B .  N - s u b s t i tuted - l , 6 - h exaned i ammon i um compounds ; N - s ub s t i tuted - l , 6 -
hexaned i am i n e s ; and N - ( 4 - d i a l kyl ami n o - 2 - butynyl ) phtha l i m i de s . 
N , N , N '  , N ' - t e t ramet hy l - N , N ' - b i s [ 3 - ( 2 - p h t h al i m i do ) propyl ] - 1 , 6 -
hexaned i ammon i um was  prev i ou s l y  reported to  b e  a more e ffec t i ve 
ant i dote  t h a n  atrop i ne .  We determ i ned u s i ng a b i n d i ng a s s ay that  
t h i s  compound b i nd s  w i t h  moderate aff i n i ty to  the  muscar i n i c  receptor 
w i t h  a two fo l d  h i gher  affi n i ty for the  M2 s i te than the Ml  receptor 
s u btype . I n  order to  determ i  n e  i f  t he  quatern ary s tructure was 
mandatory for the  mu scar i n i c  b i n d i ng affi n i ty t he  corre s pond i ng 
tert i ary am i ne was  synthe s i zed . The tert i ary am i ne had appro x i mate l y  
equa l  a ff i n i ty for t he  M2  s ubtype a s  t h e  quaternary compound , but 
l o s t  b i nd i ng aff i n i ty for the Ml receptor s ubtype . N , N ' - d i methyl ­
N , N ' - b i s [ 3 - ( 2 - phtha l i m i do ) propyl ] - 1 , 6 - hexaned i am i ne  s hows nearl y a 
f i ve fol d  h i g her  aff i n i ty for t he  M2  recepto r .  S i nce  t h e  quatern ary 
c ompound does  not  penetrate  t he  bra i n ,  t he  c orrespond i ng tert i ary 
am i ne may funct i on a s  a eNS act i ve mu scar i n i c  agent . The  un symmetr i -
ca l  c ompounds  were synthe s i zed to  determ i ne  i f  both  3 - ( 2 - phtha l ­
i m i do ) propyl port i on s  o f  the  mol ecu l e are necessary for b i n d i ng 
aff i n i ty .  T he  removal  o f  one  3 - ( 2 - phtha l i m i d o ) propyl  port i on 
resu l ted  i n  drast i c  l o s s  of  act i v i ty .  The N - ( 4 - d i al kyl am i no - 2 -
butynyl ) ph tha l i mi de s howed moderate aff i n i ty and a preference for the  
M l  receptor s ubtype . When the  4 - ( 2 - phtha l i m i do ) - 2 - butynyl mo i ety was  
i n corporated i n to  the  1 , 6 - hexaned i am i ne s tructure , dra s t i c  l o s s  of  
b i nd i ng aff i n i ty was observed . I t  h a s  not yet been determ i  ned i f  
t h e s e  type s o f  s tructures  are effec t i ve a s  a n t i dotes  for soman 
po i s on i ng .  
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c .  Para s u b s t i tuted caram i phen anal og s ( four  corners approac h ) . 
The purpose  of  t h i s  set  was  to  determ i ne i f  any po s s i bl e  
rel a t i on sh i p  of  ant i mu scar i n i c  or ant i dotal  act i v i ty ex i s t s  wi t h  
s u b s t i tuent  parameters  s uch a s  Hammett ' s  s i gma or Hansch ' s  p i  val ue s .  
These  compounds  have not been tes ted a s  yet . L arge quant  i t  i e s  of 
compound are nec e s s ary for compl ete pharmaco l og i ca l  te s t i ng .  The 
ami no  ( -<r, -II' ) and I - pyrrol i d i ny l  (-<r. +11") anal ogs  were synthe s i zed 
i n  5 g quant i t i e s .  The I - tetrazol y l  ( +  0:-, - II )  was  synthes i zed , but 
because  of the d i ff i cu l ty of the  synthes i s ,  cou l d not be obt a i ned i n  
l arge enough quan t i ty for compl ete whol e an i mal  te s t i ng .  The 
t r i fl uoromethyl (+ 0-, + II ) der i vat i ve proved very d i ffi cu l t to 
obt a i n i n  a n a l yt i ca l l y  pure form . There are other s u b s t i tuents  wh i c h 
m i g h t  a l so  f i t i nto  t h i s  part i cu l ar ser i e s . For examp l e ,  the 
met h anesu l fonyl (+ 0 . 7 2 0- ;  - 1 .  6 3  II and the  t r i fl uoromethanes u l ­
fonyl ( +  0 . 93 <r; + 0 . 55 7( ) mo i et i e s con ta i n  the  requ i red s i gn s  and 
s u ff i c i en t  va l ues  of s i gma and pi to  be u sed i n  comb i nat i on w i t h  the 
am i no and pyrrol i d i ny l  compounds to  te s t  t h i s  SAR approach . The 
syn t he s i s of the methanesu l fonyl and tr i fl uoromethanesu l fonyl 
der i vat i ve s  are curren t l y  i n  progre s s . 
D .  Add i t i ona l  compounds  cho sen for te s t i ng .  
A n umber of  l i terature compounds  and current l y  manufactured 
ant i mu s c ar i n i c s were chosen to be te sted as ant i dotes  and screened i n  
the  var i ous  i n  v i t ro and i n  v i vo a s s ays . Some of  the  compounds  were 
chosen bec ause  of the prev i ou s l y  reported effec t i venes s  aga i n st  the 
l et h a l  effect s of  organophosph ate chol i nesterase  i n h i b i t ors . Others 
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were c h o sen j u s t  t o  prov i de a set  o f  agents  w i t h d i verse s tructural  
feature s . Both  ester  and non - e s ter type ant i muscar i n i c s were se l ect ­
ed . Other  compound s were i nc l uded wh i ch had been prev i ou s l y  reported 
to  be s e l ect i ve for mu scar i n i c  receptor subpopul at i on s . When a l l 
t e s t i ng i s  comp l eted correl at i on s  can  then be sought  between the  
eff i c acy as  an  ant i dote  and the  potency i n  the  var i o u s  in  v i t ro and  
i n  v i vo t e s t s  that  we have emp l oyed . It  w i l l  be  o f  i nterest  t o  see  
i f  any part i c u l ar pattern o f  s t ructural  features  or  pharmaco l og i ca l  
propert i e s emerge s  a s  a key to  an effect i ve ant i dote . 
V .  EXPERI MENTAL 
Proton nuc l ear  magnet i c  resonance ( NMR)  spectra were recorded on 
e i ther  a H i tach i / Perk i n - E l mer R - 2 4  h i g h resol ut i on spectrometer or a 
Var i an EM - 360A -60  MHz spectromete r ;  chem i ca l  sh i ft s  are reported 
rel at i ve to  tetramethyl s i l ane ( TMS ) or sod i um 2 , 2 - d i methyl - 2 - s i l apen ­
tane - 5 - s u l fonate ( OSS ) . I n frared ( I R ) spectra were obta i ned on 
e i t her  a Bec kman Accu l ab 8 grat i ng spectrophotometer or a Beckman FT 
1 300  spectrophotomete r .  Mel t i ng po i nt s  were determi ned on a Thomas ­
Hoover mel t i ng po i n t apparat u s . Al l mel t i ng p o i n t s  and bo i l i ng 
po i n t s  are uncorrected . E l ementa l  ana lyses  were performed by 
At l an t i c  M i crol ab , I nc . , At l anta , GA . 
2 - (O i e t hyl ami nolethyl I - Phenyl cyc l opentanecarboxyl ate Hydro­
c h l or i de (12) . Method A .  To a so l u t i on of 1 - phenyl cyc l open tanecar­
boxyl i c  ac i d  (84)  ( 5 . 0  g ,  26 mmo l ) i n  2 5  mL of  sod i um- dr i ed benzene 
was added 25 mL of  t h i onyl ch l or i de , and the  so l ut i on was  s t i rred at 
refl u x  for 12 h .  The so l ut i on was  concentrated under reduced 
pre s s u re ,  then  reconcentrated w i th  t hree 25 mL port i on s  of  benzene to 
remove any rema i n i ng t h i onyl ch l or i de .  The re s i due was d i s so l ved i n  
5 0  m L  o f  dry benzene and decol or i zed w i th  ch arcoa l . Then 6 . 2 9 9 
( 52 . 6  mmo l ) of  fresh l y d i s t i l l ed 2 - d i ethyl ami noethanol  was  added 
dropw i se i n  50  mL of benzene , and the mi xture was s t i rred at refl ux 
for 1 2  h .  The so l u t i on wa s coo l ed to room temperature , then poured 
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i n to  250  m L  o f  water and bas i f i ed w i t h  1 0% Na2 C03 so l u t i on .  The 
l ayers  were separated , and the  aqueous  pha se  was  extracted twi ce  w i th  
50 mL  o f  ether . The combi ned organ i  c extracts  were concentrated 
under reduced pre s s u re .  The re s i d ue was  d i s so l ved i n  about 100 mL of 
d i e t hy l  ether and extracted three t i me s  w i t h  1 00 -mL port i on s  of 
water . The  ether  l ayer was  d r i ed over anhydrou s magne s i um s u l fate . 
The  d ry i ng agent was  removed by f i l trat i on ,  and the  hydroch l o r i de 
s a l t w a s  prepared by treat i ng the  ether  s o l u t i on of  t he  base  w i t h  
g a s eou s  HC l . Recry s t a l l i zat i on from acetone y i el ded 5 . 8  g ( 68% ) of 
li as  wh i te needl e s ,  mp 1 4 2 - 1 4 4  C ( L i t 1 6 2 mp 1 4 2 - 1 4 4  C ) . I R  
( n uj o l ) :  1 7 2 0  cm- 1 ( C =O ) . l H  NMR ( D2 0 ) : 0 1 . 3  ( t ,  6 ,  - C H2 CH3 ) ;  1 . 85  
( broad , 6 ,  cpentyl ) ;  2 . 3 - 2 . 8  ( comp l ex ,  2 ,  cyc l openty l ) ;  3 . 2  (q ,  4 ,  
- N - CH2 CH3 ) ;  3 . 6  ( t ,  2 ,  - CH2 NEt2 ) ;  4 . 6  ( t ,  2 ,  - O - CH2 ) ;  7 . 6  ( s ,  5 ,  
Ar- H ) . Ana l . Ca l cu l ated for C 1 8 H2 8 N02 C l : C ,  66 . 55 ;  H ,  8 . 69 ; N ,  
4 . 3 1 . Found : C ,  66 . 3 9 ;  H ,  8 . 68 ;  N ,  4 . 26 .  
Method B .  To a s t i rred so l ut i on of  1 - pheny l cycl opentanecarbox -
y l i c  ac i d  ( 8 4 )  ( 2 . 0  g ,  1 0 . 5  mmo l ) i n  2 5  mL  of  dry 2 - propanol  was  
added 1 . 63  g ( 1 2 . 0  mmo l ) o f  fre s h l y - prepared 2 - d i e thy l ami noethy l  
c h l or i de  ( 86 )  i n  10  mL of  2 - propanol . The  react i on was  heated to  
refl ux  for  4 h .  The  wh i te crysta l l i ne prec i p i t ate  formed upon 
coo l i ng on an i ce bath was  co l l ected by fi l trat i on and was hed w i th  
d i e t hy l  e ther . Recrysta l l i zat i on from acetone y i e l ded 1 . 7 7  g ( 52%) 
of li as wh i te need l e s ,  mp 1 4 2 - 1 44  C .  Th i s  compound was i dent i c a l  
i n  i t s  phys i c a l  and spectral  propert i e s  to  li prepared from the  ac i d  
c h l or i de  of  1 - pheny l cyc l opentanecarboxyl i c  ac i d  ( Method A ) . 
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Method C .  To a s t i rred so l u t i on o f  pota s s i um I - pheny1 cyc 1 0pe n ­
tanecarboxy1 a t e  ( 87 )  ( 2 . 0  g ,  8 . 8  mmo 1 )  i n  2 5  mL of  absol ute  ethanol  
was  added i n  one  port i on 1 . 42  g ( 1 0 . 5  mmo 1 ) of  fre s h l y  prepared 2 -
d i ethy1 ami noethy1  c h l o r i de ( 86 )  i n  2 5  m L  of  ethanol . The reac t i on 
i mmed i ate l y became turb i d ,  and a prec i p i tate beg an to  separat e .  The 
m i  x t ure was  heated at  ref1 ux  for 12 h .  After the  so l u t i on was  
cool ed , the prec i p i t ated i norgan i c  s al t was  removed by fi l trat i on and 
d i scarded . The  f i l trate was  evaporated to drynes s  at  reduced 
pre s s ure , and the resu l t i ng o i l  was d i s so l ved i n  7 5  mL of  d i ethy1 
ether . The so l u t i on was  washed w i t h  three 50 mL port i on s  of wate r ,  
then  d r i ed o v e r  anhydrou s  magne s i um s u l fate . T h e  hydroch l or i de s a l t 
was  p repared by treat i ng an ethereal  so l u t i on of the  base w i t h  
g a seous  HC l . Recrysta l l i zat i on from acetone y i e l ded 1 . 6 g ( 56%) of 
� a s  col orl e s s  needl e s , mp 1 4 2 - 1 4 4  C .  T h i s compound was i dent i cal  
i n  i t s phy s i ca l  and spectral  propert i es to  � prepared from Method A 
or Method B .  
2 - D i et hy1 ami noethy1 Ch l or i de (86) . The  method descr i bed by 
Bre s l ow et a 1 . 1 6 9 was  used . An i ce - co l d aqueou s  ( 2 5  mL )  s o l ut i on of 
2 - d i ethy 1 ami noethy 1 ch 1 0r i de hydroch l o r i de ( 5 . 0  g ,  29 . 4  mmo 1 ) was  made 
ba s i c  w i t h  1 0% sod i um hydro x i de and s t i rred v i gorou s l y  w i t h  i ce - co l d  
ether ( 50 mL ) for 5 m i n .  The l ayers were separated , and the  aqueou s 
pha se  was extracted three t i mes  w i t h  2 5  mL of d i ethy1 ether . The 
comb i ned extrac t s  were d r i ed 4 h at 5 - 1 0  C over anhydrous  magnes i um 
s u l fate . The dry i  ng agent was removed by f i  l t rat i on ,  and the  ether 
l ayer was  concentrated at reduced pre s s ure , y i e l d i ng 3 . 2 2 g ( 82%) of 
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a co l or l e s s  o i l . No at tempt was made to ch aracter i ze the  product , 
and i t  was  u sed i mmed i at e l y  for ester i f i c at i o n .  
Pot a s s i um I - Phenyl cycl opent anecarboxyl ate (87) . A so l ut i on of  
1 . 7 g ( 1 0 mmo l ) I - phenyl cycl opentane c arboxyl i c  ac i d  ( 8 4 )  i n  50 mL  of 
abso l ute  ethano l  was  t i trated w i th  1 0% ethanol i c  pot a s s i um hydrox i de 
u s i ng phenophtha l e i n  a s  external  i nd i cator . The so l vent was  evapora ­
ted under reduced pres s ure fol l owed by recrysta l l i z at i on from ethanol  
- e t h e r ,  y i e l d i ng 2 . 2  g ( 9 7%)  a s  co l orl e s s  needl e s , mp > 350  e 
( L i t 1 6 0  mp > 350  e ) . 
N -Methyl - 4 -piper i dyl I - Phenyl cyc l opent anecarboxyl ate Hydroch l or ­
i de (20) . Th i s  compound was  prepared by the  s ame general  procedure 
a s  � (Method A )  u s i ng 5 . 0  g ( 26 . 3  mmol ) of  84 and 6 . 0 5 g ( 52 . 6  mmo l ) 
of  4 - hydroxY - N - methyl p i per i d i ne .  The hydroch l or i de s a l t was  prepared 
by t reat i ng an etherea l  so l u t i on of  base w i t h  gaseous  He l . Recrys ­
t al l i z at i on from acetone y i e l ded 4 . 4 5 g ( 52%) of  20  a s  wh i te need l es , 
mp 1 7 5 - 1 7 6  C ( L i t 1 6 1 mp 1 7 7 . 5 - 1 78 . 5  C ) . I R  ( n u jo l ) :  1 72 0  cm- l 
( C=O ) . I H NMR ( 02 0 ) : 8 1 . 8 ( broad , 6 ,  cpentyl ) ;  2 . 6  ( broad , 2 ,  
N - C H ) ; 2 . 9  ( s ,  3 ,  N - CH3 ) ;  3 . 2 5 ( broad , 2 ,  - N - C H - ) ;  5 . 0  ( broad , s ,  I ,  
- O - CH ) ; 7 . 5  ( s ,  5 ,  Ar - H ) . Anal . Ca l cu l ated for C 1 8 H2 6 N02 C l : C ,  
6 6 . 7 5 ;  H ,  8 . 09 ;  N ,  4 . 33 .  Found : C ,  66 . 7 5 ;  H ,  8 . 1 0 ;  N ,  4 . 3 2 .  
N -Methyl - 3 -piper i dyl I - Phenyl cyc l opent anecarboxyl ate Hydroch l or ­
i de (34) . T h i s  compound was prep ared by the  s ame general  procedure 
a s  � ( Method A )  u s i ng 5 . 0  g ( 26 . 3  mmo l ) of 84 and 6 . 0 5 g ( 52 . 6  mmo l ) 
of  3 - hydroxy - N -methyl p i per i d i ne .  The hydroc h l or i de s a l t was  prepared 
by t reat i ng an ethereal  so l u t i on of the  base  w i th  gaseous  Hel . 
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Recrysta l l i z at i on from acetone y i e l ded 4 . 9  g ( 58%) of  34  a s  wh i te 
need l es ,  mp 1 84 - 1 85  C .  IR ( n ujo l ) :  1 72 0  cm- l ( C=O ) . I H NMR 
( 02 0 ) : E 1 . 8 ( broad , 1 0 ,  - CH2 - ) ; 2 . 4 - 2 . 8  ( comp l ex m,  2 ,  cpentyl ) ;  3 . 1  
( s ,  3 ,  - N - CH3 ) ;  3 . 5  ( broad m ,  4 ,  N - C H2 ) ;  5 . 2  ( s ,  1 ,  -OCH ) ; 7 . 5  ( s ,  5 ,  
Ar - H ) . Anal . Ca l c u l ated for C 1 8 H2 6 N02 C l : C ,  66 . 7 5 ;  H ,  8 . 09 ;  N ,  
4 . 3 3 .  Found : C ,  66 . 59 ;  H ,  8 . 1 0 ;  N ,  4 . 24 .  
3 -Qu i nuc l i d i nyl I - Phenyl cycl opentanecarboxyl ate Hydroch l o r i de 
� To a s o l u t i on of  5 . 0  g ( 26 . 2  mmol ) of  I - phenyl cyc l opent anecar­
boxy l i c  ac i d  i n  25  mL of sod i um -dr i ed benzene was added 25  mL of 
t h i onyl c h l o r i d e ,  and the  so l ut i on was  s t i rred at  refl ux for 1 2  h .  
The  so l u t i on was  concentrated under reduced pres s ure , then  recon ­
centrated w i t h  t hree 2 5  mL port i on s  of  benzene to  remove any rema i n ­
i ng t h i onyl c h l or i de .  The res u l t i ng o i l was  d i s s o l ved i n  50  mL of 
d ry c h l oro form . Then , 6 . 7  g ( 5 2 . 8  mmo l ) of  3 - q u i nuc l i d i no l  i n  50 mL 
of  dry c h l oroform was added , and the so l ut i on was  s t i rred at  refl ux 
for t h ree days . After the  react i on was  cool ed to  room temperature , 
t he  so l i d  prec i p i tate  was  co l l ected by fi l trat i on and d i sc arded . The 
org an i c  l ayer was  evaporated at  reduced pres s ure , then d i s so l ved i n  
1 00 mL d i ethyl  ether  and washed three t i mes  w i t h  1 0 0  mL o f  water . 
The  ether  l ayer was  then  dr i ed over anhydrous  magnes i um s u l fate . The 
hydroc h l or i de s a l t was  prepared by treat i ng the  ethereal so l u t i �n of 
the  base  w i t h  gaseous HC 1 . Recrysta l l i z a t i on from meth anol  - ethyl 
acetate  y i e l ded 3 . 1  g ( 3 5%)  of 35 a s  wh i te fl a kes , mp 2 0 5 - 207 C 
( L i t 1 6 1 mp 2 06 - 2 07  C ) . I R  ( n u jo l ) :  1 7 2 0  cm- l ( C = O ) . I H  NMR 
( 02 0 ) : � 1 . 8 ( broad s ,  6 ,  cpentyl ) ;  1 . 8 - 2 . 3 5 ( m ,  5 ,  - C H2 - ) ; 2 . 4 - 2 . 8  
( comp l ex m ,  2 ,  c pentyl ) ;  3 . 3  ( m ,  6 ,  - CH2 N ) ; 5 . 1  ( q ,  1 ,  O - C H ) ; 7 . 4  ( s ,  
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5 ,  Ar - H ) .  Ana l . Ca l cu l ated for C 1 9 H2 6 N02 C l : C ,  68 . 3 5 ;  H ,  7 . 5 5 ;  N ,  
4 . 20 .  Found : C ,  68 . 33 ;  H ,  7 . 8 1 ; N ,  4 . 94 .  
3 - Tropi nyl 1 - Phenyl cyc l opent anecarboxyl ate Hydroch l or i de (36) . 
Th i s  compound was prepared by the  s ame general  procedure a s  � 
( Method A )  u s i ng 5 . 0  g ( 2 6  mmo l ) of  1 - phenyl cycl opentanecarboxyl i c  
ac i d ,  and 7 . 4 2 g ( 52 . 6  mmo l ) o f  trop i ne .  The hydroch l o r i de sa l t was 
p repared by treat i ng an ethereal sol u t i on of  the base w i t h  gaseous  
HC l . Recry s t a l l i z at i on from methanol  - ethyl acetate y i el ded 3 . 9  g 
( 43%) of  3 6  a s  a wh i te so l i d ,  mp 2 2 6 - 228  C .  I R  ( n ujo l ) :  1 7 1 0  cm- l 
( C=O ) . l H  NMR ( 02 0 ) : 6 1 . 8 ( broad s ,  6 ,  cpentyl ) ;  2 . 05 ( broad , 4 ,  
- C H2 - ) ;  2 . 3 - 2 . 7  ( comp l ex m ,  6 ,  - CH2 - ,  cpentyl ) ;  2 . 8  ( s ,  3 ,  N - CH3 ) ;  
3 . 8  ( p ,  2 ,  - N - CH - ) ;  5 . 1  ( m ,  1 ,  - O - CH ) ; 7 . 4  ( s ,  5 ,  Ar- H ) . Ana l . 
C a l c u l ated for C2 o H2 8 N02 C l : C ,  68 . 65 ;  H ,  8 . 07 ;  N ,  4 . 00 .  Found C ,  
68 . 7 5 ;  H ,  8 . 1 0 ;  N ,  3 . 98 .  
3 - (O i ethyl am i no) - 1 -propyl 1 - Phenyl cyc l opentanecarboxyl ate Hydro-
c h l o r i de (37) . Th i s  compound was prepared by the  s ame general  
procedure as � (Method A )  u s i ng 5 . 0  g ( 2 6 . 3  mmo l ) of  1 - phenyl cyc l o ­
pentanec arboxyl i c  ac i d  and 6 . 94 ( 5 2 . 6  mmol ) of fre s h l y  d i s t i l l ed 3 -
( d i ethy l ami n o ) - l - propanol . The hydroch l or i de s a l t was prepared by 
treat i ng an ethereal  so l u t i on of  the base  w i t h  gaseous  HC1 . Recrys ­
t al l i z a t i on from acetone y i e l ded 4 . 3  g ( 48%) of  37  a s  wh i te need l es , 
mp 1 39 - 1 40 C ( L i t l 6 l mp 1 4 0 - 1 40 . 5  C ) . I R  ( n u jo l ) ;  1 7 1 0  cm- l ( C =O ) . 
l H  NMR ( 02 0 ) : J 1 . 2  ( t ,  6 ,  - CH2 CH3 ) ;  1 . 7 ( broad , 6 ,  cpentyl ) ;  1 . 9 ( p ,  
2 ,  - CH2 - ) ; 2 . 4 - 2 . 8  ( compl ex m ,  2 ,  cpentyl ) ;  3 . 1  ( compl ex m ,  6 ,  
- C H2 - N ) ; 4 . 2  ( t ,  2 ,  0 - CH2 - ) ; 7 . 4  ( s ,  5 ,  Ar - H ) . Ana l . Ca l cu l ated for 
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C 1 9 H3 0 NOz C l : C ,  67 . 1 4 ;  H ,  8 . 90 ;  N ,  4 . 1 2 .  Found : C ,  67 . 2 2 ;  H ,  8 . 90 ;  
N ,  4 . 0 7 .  
2 - (O i et hyl ami no1ethyl I - Phenyl cycl ohexanecarboxyl ate Hydroch l or ­
i de (381 . Th i s  compound was prepared by the  s ame general  procedure 
a s  1.2 ( Method A )  u s i ng 4 . 0  g ( 20 mmol ) o f  I - phenyl cyc l ohexanecar­
boxyl i c  ac i d  and  4 . 64 g ( 3 9 . 0  mmol ) o f  fre s h l y  d i s t i l l ed 2 - d i ethyl ­
ami noethano l . The hydroch l o r i de s a l t was  prepared by treat i ng an 
ethereal  s o l u t i on of the free base  w i t h  gaseous  HC l . Recrysta l l i za ­
t i on from acetone y i e l ded 4 . 3  g ( 66%) o f  38 a s  a wh i te so l i d ,  mp 
1 58 - 1 60 C ( L i t 1 6 Z  mp 1 59 - 1 6 1  C ) . I R  ( n ujo l ) :  1 7 2 0  cm- 1 ( C =O ) . I H 
NMR ( Oz O ) : � 1 . 2  ( t ,  6 ,  - CHz CH3 ) ;  1 . 4 - 1 . 8 ( broad , 1 0 ,  c hexyl ) ;  3 . 2  
( q ,  4 ,  N - CHz CH3 ) ;  3 . 6  ( t ,  2 ,  CHz N ) ; 4 . 6  ( t ,  2 ,  - O - CHz - ) ; 7 . 4  ( s ,  5 ,  
Ar - H ) . Ana l . Ca l c u l ated for : C 1 9 H3 0 NOz Cl : C ,  67 . 3 3 ;  H ,  8 . 92 ;  N ,  
4 . 1 3 .  Found : C ,  67 . 09 ;  H ,  8 . 94 ;  N ,  4 . 1 0 .  
N -[2 - (O i ethyl am i no1ethyl l I - Phenyl cycl opentanecarboxam i de Hydro -
ch l or i de (391 . Th i s  compound was prepared by the  s ame general  
proced ure as 1.2 (Method A )  u s i ng 4 . 0  g ( 2 1  mmol ) o f  I - phenyl cyc l ope n ­
t anecarboxyl i c  ac i d  and 4 . 9  g ( 42 mmol ) of  N , N - d i ethyl ethyl ened i ­
ami n e . The hydroch l or i de sa l t was  prepared by treat i ng an  ethereal  
s o l u t i on o f  the  free base w i th  ga seou s HC l . Recrysta l l i z at i on from 
met h ano l  - ether  y i el ded 2 . 8  g ( 4 1%)  39 as a wh i te so l  i d ,  mp 1 3 8 - 1 40 
C .  I R  ( neat , b a se ) : 33 1 0  cm- 1  ( - NH ) ; 1 700 cm - l  ( C =O ) . I H NMR 
( COC 1 3 , b a se ) : & 1 . 1  ( t ,  6 ,  - CHz CH3 ) ;  1 . 8 ( broad , 6 ,  cpentyl ) ;  2 . 6  
( q ,  6 ,  - CHz ) ;  3 . 2  ( broad , 2 ,  - CHz - N ) ; 3 . 8  ( t ,  2 ,  - NH - CHz ) ;  7 . 0  ( s ,  1 ,  
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N H ) ; 7 . 4  ( s ,  5 ,  Ar - H ) . Anal . Ca l cu l ated for : C I 8 Hz 8 N z OC1 : C ,  66 . 3 5 ;  
H ,  9 . 0 ;  N ,  8 . 62 .  Found : C ,  66 . 1 1 ;  H ,  8 . 96 ;  N ,  8 . 62 . 
1 - Methyl - 4 - ( l -phenyl cyc l opentanecarbonyl ) piperaz i ne Hydroch l or­
i de (40) . Th  i s  compound was prepared by the  s ame general  procedure 
a s  � ( Method A )  u s i ng 2 . 5  g ( 1 3 . 2  mmo l ) of 1 - phenyl cyc l opentanecar­
boxyl i c  ac i d  84 and 2 . 64 g ( 2 6 . 4  mmo l ) of fre s h l y  d i s t i l l ed N - methyl -
p i peraz i n e .  The  hydroch l or i de sa l t was prepared by t reat i ng an 
etherea l  s o l ut i on of  the base  w i t h  gaseous HC1 . Recrysta l l i zat i on 
from methano l  - ethyl  acetate y i e l ded 2 . 3  g ( 58%) of 40 a s  wh i te 
needl e s , mp 2 4 2 - 244  C .  I R  ( n u jo l ) :  1 700 cm- l ( C =O ) . I H NMR 
( Oz O ) : � 1 . 8 ( broad , 6 ,  cpentyl ; 2 . 2 - 2 . 6  ( compl ex m, 2 ,  cyc l opentyl ) ;  
3 . 0 ( s ,  3 ,  NCH3 ) ;  3 . 3  ( m ,  4 ,  CHz NMe ) ; 3 . 85 ( m ,  4 ,  N - CH3 ) ;  7 . 5  ( s ,  5 ,  
Ar - H ) . Ana l . C a l cu l ated for C 1 7 Hz s N z OC l  . 0 . 5  Hz O :  C ,  64 . 23 ;  H ,  
8 . 2 5 ;  N ,  8 . 8 1 . Found : C ,  64 . 1 9 ;  H ,  8 . 1 2 ;  N ,  8 . 73 .  
N - [ 2 - ( O i e t hyl am i n o) e t hyl l 1 - P h e nylcyc l o h e x a n e c a rb o x am i d e  
Hydroch l or i de (4 1 ) .  T h i s compound was prepared by the  s ame general  
procedure a s  � ( Method A)  u s i ng 5 . 0  g ( 24 . 4  mmo l ) of  1 - phenyl cyc l o ­
hexanecarboxyl i c  ac i d  and 5 . 7  g ( 48 . 8  mmo l ) N , N - d i ethyl ethyl ened i ­
ami ne . The  hydroch l o r i de s a l t was prepared by treat i ng an ethereal 
so  1 ut  i on  of  the base  w i th  gaseous HC1 . Recrysta  1 1  i zat  i on from 
met h ano l  - ethyl  acetate y i e l ded 4 . 9  g ( 59%) of 11 as a wh i te sol i d ,  
mp 1 66 - 1 68 C ( L i t I S 7 mp 1 66 . 5 - 1 6 7 C ) . I R  ( n eat , b a se ) : 3320  cm- l 
( - NH ) ; 1 700  cm- l  ( C =O ) . I H NMR ( COC1 3 , base ) : � 1 . 0 ( t ,  6 ,  - CHz CH3 ; 
1 . 4 - 1 . 8 ( broad , 1 0 ,  chexyl ) ;  2 . 1 - 2 . 6  ( m ,  6 ,  CHz N - ) ; 3 . 3  ( t ,  2 ,  
- N H - CHz ) ;  6 . 2  ( s ,  1 ,  - NH ) ; 7 . 4  ( s ,  5 ,  Ar- H ) . 
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2 , 2 - 0 i phenyl butyron i tr i l e  (89) . To a s t i rred s u spen s i on of 4 . 0 2 
( 1 03  mmo l ) of  NaNH2 i n  1 50 mL of  anhydrou s  ether , ma i n t a i ned under 
n i t rogen at about - 50 C,  was  added dropw i se 20 . 0  g ( 1 03 mmo l ) of 
d i phenyl aceton i tr i l e  in  1 00 mL of ether . The m i xture was s t i rred for 
one  hou r . Then 2 4 . 0  g ( 1 5 5 mmo l ) of ethyl i od i de i n  7 5  mL of  ether 
was  added dropw i se  over a 30  mi n peri  od . The react i on m i  xture was 
a l l owed to  warm to room temperature , then s t i rred at refl ux for 4 h .  
The s o l u t i on was  then poured i n to 250  mL of crus hed i ce and water . 
The  l ayers  were separated , and the  aqueou s  phase  was extracted twi ce 
w i t h  5 0  mL of  d i ethyl  ether . The comb i ned extracts  were washed w i th  
200  mL water , t hen dr i ed over anhydrou s  magnes i um s u l fate . The 
dry i ng agent was removed by f i l trat i on and the s o l vent removed under 
reduced pre s s ure , to  g i ve an o i l .  Th i s  o i l was  d i s t i l l ed under 
vacuum to  y i e l d  2 1 . 2  g ( 93%) of 89 as  a co l orl e s s  o i l ,  bp 1 2 0 - 1 2 5 
C/0 . 2  mm ( L i t 1 7 3 bp 1 4 5 - 1 4 7  C/0 . 3  mm ) . I R  ( neat ) :  2 2 1 0  cm- 1  
( - C=N ) . I H NMR ( COC 1 3 ) :  5 1 . 0 ( t ,  3 ,  - CH2 CH3 ) ;  2 . 3 5  ( q ,  2 ,  - C H2 CH3 ) ;  
7 . 3  ( s ,  1 0 ,  Ar - H ) . 
2 - Cyc l ohexyl - 2 -phenyl propi on i t r i l e (9 1 ) .  To a s t i rred s u spen -
s i on of  4 . 4  g ( 1 1 3 mmol ) of  NaNH2 i n  1 50 mL of anhydrous  ether , ma i n ­
t a i ned under n i t rogen a t  about - 30 C ,  was  added dropw i se 1 9 . 0  g 
( 7 5 . 4  mmol ) of cyc l ohexyl phenyl aceton i tr i l e  i n  1 00 mL of ether . The 
m i xture was s t i rred for 1 h .  Then 1 5 . 9  g ( 1 1 3 mmol ) of methyl  i od i de 
i n  7 5  mL  of  ether  was added dropwi s e .  The m i  xture was a l l owed to 
warm to room temperature , then brought to  refl ux for 4 h .  The 
s o l u t i o n was poured onto 250 mL of  cru s hed i ce wate r .  The l ayers 
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were separated and the  aqueous phase  extracted tw i ce w i th  d i ethy1 
ether  ( 50 mL ) . The comb i ned extracts  were was hed w i t h  200 mL of 
wat e r ,  then  d r i ed over anhydrou s magnes i um su l fate . The sol vent was 
removed under reduced pres sure , g i v i ng an o i l .  The o i l  was  d i s t i l l ed 
under  vacuum to  y i el d 1 3 . 7  g ( 86%) of  II a s  a col orl e s s  o i l , bp 
1 2 2 - 1 2 4 C/0 . 2 5 mm ( L i t 1 7 4 bp 1 6 6  C/ 1 1  mm ) . I R  ( neat ) : 2 2 20  cm- 1 
( - C=N ) . l H  NMR ( CDC1 3 ) : , 1 . 2 - 1 . 6  ( broad , 1 1 ,  chexy 1 ) ;  1 . 6 5  ( s ,  3 ,  
- CH3 ) ;  7 . 4 5 ( s ,  5 ,  Ar - H ) . 
2 , 2 - D i pheny1 butyr i c ac i d  (92) . A s u spen s i on of  1 0 . 0  g ( 4 5 . 3  
mmo 1 ) o f  89 i n  7 5  mL of 48% HBr was s t i rred v i goro u s l y  at refl ux for 
ten d ay s . The react i on m i xture was cool ed to  room temperature ,  then 
poured onto  300  mL of  crus hed i ce .  The so l i d  mater i al wh i ch prec i p i -
t ated  was  co l l ected by f i l t rat i on and washed repeated l y  w i t h  water to 
l eave a wh i te product . The crude ac i d  was  d i s so l ved i n  a col d 5% 
NaOH  s o l ut i on . The so l u t i on was  f i l tered to  remove any i n sol ubl e 
mater i a l . The  crude ac i d  was  prec i p i t ated by the  s l ow add i t i on of  a 
5% HC 1  so l ut i on . The product was co l l ected by f i l trat i on .  Reprec i ­
p i t a t i on from a 5% NaOH so l ut i on w i th  a 5% HC 1  so l ut i on y i e l ded 4 . 3  g 
( 40%) o f  92  a s  a wh i te so l i d ,  mp  1 7 2 - 1 74 C ( L i t 1 7
3 mp  from benzene 
1 7 4 - 1 7 5 C ) . I R  ( nujo l ) :  1 680 cm- 1  ( C =O ) . l H NMR ( CDC 1 3 ) :  � 1 . 0 ( t ,  
3 ,  - CH2 CH3 ) ;  3 . 1  ( q ,  2 ,  - CH2 CH3 ) ;  7 . 3  ( s ,  1 0 ,  Ar - H ) ; 1 2 . 2  ( s ,  1 ,  
- COOH ) . 
2 - Methyl - 2 -pheny1cyc1 0hexaneacet i c  ac i d  (93) . A suspen s i on of 
1 0 . 0  g ( 46 . 9  mmo 1 ) of  90 i n  75  mL of 48% HBr was s t i rred v i gorou s l y  
at  refl ux for t e n  days . The react i on mi xture was cool ed to  room 
t emperature , then  poured onto 300 mL of crus hed i ce and wate r .  The 
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so l i d  mater i a l wh i c h prec i p i t ated was  col l ected and tr i t urated 
repeated l y  w i t h  water to  l eave a wh i te product . The crude ac i d  was 
d i s so l ved i n  a co l d 5% NaOH so l u t i on . The so l ut i on was f i l tered to  
remove any i n sol ub l e mater i a l . The crude  ac i d  was prec i p i t ated by 
t h e  s l ow add i t i on of  a 5% HC 1  so l ut i on .  The product  was col l ected by 
f i l trat i on and reprec i p i tated from a col d 5% NaOH so l u t i on wi th  a 5% 
HC 1  so l u t i on ,  y i e l d i ng 9 . 4  g ( 86%) of  93 a s  a wh i te so l i d ,  mp 1 28 - 1 3 0  
C ( L i t 1 7 5 m p  1 3 0 - 1 3 1  C ) . I R  ( n ujo 1 ) :  1 6 70 cm- 1  ( C=O ) . l H  NMR 
( CDC 1 3 ) :  & 1 . 1 - 1 . 4  ( broad , 1 1 ,  chex ) ; 1 . 5  ( s ,  3 ,  - CH3 ) ;  7 . 3  ( s ,  5 ,  
Ar- H ) ; 1 2 . 1 5  ( s ,  1 ,  COOH ) . 
2 - (Di ethy1 ami no)ethy1 2 , 2 - D ipheny1 butyrate Hydroch l o r i de (42) . 
To a s o l u t i on of  3 . 9  g ( 1 6 . 3  mmo l ) 92  i n  2 5  mL of  s od i um dr i ed 
benzene was  added 2 5  mL of t h i onyl c h l or i de and the  so l u t i on s t i rred 
at refl ux  under n i trogen for 1 2  h .  The reac t i on was cool ed to room 
temperature , t hen concentrated under reduced pre s s ure . The resu l t i ng 
o i l  was  washed w i t h  three 2 5 -mL port i on s  of  benzene to  remove any 
rema i n i ng t h i ony1 ch l or i d e .  The res i due was  d i s so l ved i n  50 mL of 
dry benzene and the  s o l u t i on was deco 1 0r i zed w i t h  charcoal . Then 
3 . 8  g ( 3 2 . 5  mmo 1 ) of  fre s h l y  d i s t i l l ed 2 - d i ethyl ami noethano1  i n  50 mL 
of  d ry benzene was added dropw i se and the so l ut i on s t i rred at refl ux 
for 1 2  h .  The reac t i on mi xture was cool ed to  room temperature ,  
poured i n to  2 5 0  m L  o f  water and bas i f i ed w i th  a 1 0% Na2 C03 so l ut i on .  
The l ayers were separated and the  aqueou s phase  extracted twi ce w i t h  
50 mL of  d i ethyl  ether . The comb i ned organ i c  l ayers were concen­
trated under reduced pre s s u re . The re s i due was d i s so l ved in  1 00 mL 
d i ethy1  ether  and extracted w i th  four  1 00 mL port i on s  of water .  The 
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ether  l ayer was  s eparated and dr i ed over anhydrous  magnes i um su l fate . 
The  d ry i ng agent was removed by f i l trat i on .  The  hydroch l or i de sa l t 
was  prepared by treat i ng the  ethereal s o l ut i on of  the  base  w i th 
g a seous  HC l . Recrysta l l i zat i on from ethyl acetate y i e l ded 4 . 1  g 
( 66%) 4 2  a s  a wh i te s o l i d ,  mp 1 1 8 - 1 20 C ( L i t l 7 3 mp 1 2 4 - 1 2 6 C ) . I R  
( n u jo l ) :  1 7 2 0  cm- l ( C =O ) . l H  NMR ( 02 0 ) : & 0 . 8  ( t ,  3 ,  - CH2 CH3 ) ;  1 . 1 5 
( t ,  6 ,  - NCH2 CH3 ) ;  2 . 5  ( q ,  2 ,  - CH2 CH3 ) ;  3 . 0  ( q ,  4 ,  - NCH2 CH3 ) ;  3 . 4  ( t ,  
2 ,  - CH2 N Et2 ) ;  4 . 5  ( t ,  2 ,  - OCH2 - ) ; 7 . 3 5 ( s ,  1 0 ,  Ar - H ) . Anal . 
C a l c u l ated for C2 2 H3 0 N02 C l : C ,  70 . 28 ;  H ,  8 . 04 ; N ,  3 . 73 .  Found : C ,  
7 0 . 00 ;  H ,  8 . 1 1 ;  N ,  3 . 70 .  
2 - (O i ethyl ami no)ethyl 2 - Cyc l ohexyl - 2 -phenylpropi onate Hydrogen 
Oxa l ate (44) . To a so l ut i on of 5 . 85 g ( 2 5 . 2  mmo l ) 93 i n  2 5  mL of  
s od i um d r i ed benzene was  added 2 5  mL  of  t h i onyl ch l or i de a nd  the 
s o l u t i on was  s t i rred at  refl ux under n i trogen for 12 h .  The mi xture 
was  coo l ed to  room temperature , then concentrated under reduced 
pres s ure . The resu l t i ng o i l was washed w i t h  t hree 2 5 -mL port i on s  of  
benzene to remove the  rema i n i ng t h i onyl c h l or i de . The res i due was 
d i s so l ved i n  50  mL of  dry benzene , and the  so l ut i on was decol or i zed 
w i t h  ch arcoal . Then 6 . 0  g ( 50 . 4  mmol ) of  fresh l y d i st i l l ed 2 -
d i ethyl ami noethano l  was  added dropw i se i n  7 5  m L  o f  benzene ,  and the  
m i xture was  s t i rred at  refl ux for  12  h .  The so l u t i on was cool ed to 
room t emperature , poured i nto  250  mL water and ba s i f i ed w i t h  1 0% 
Na2 C 03 s o l  ut  i on . The 1 ayers were separated and the  aqueous phase 
was hed tw i ce w i th  5 0  mL of d i ethyl ether . The comb i ned organ i c  
extrac t s  were concentrated under reduced pre s s ure , g i v i ng an o i l .  
Th i s  o i l  was  d i s so l ved i n  about 1 00 mL of d i ethyl ether and extracted 
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w i th  four 1 0 0 - mL port i on s  of water . The ether l ayer was dr i ed over 
anhydrous  magnes i um s u l fate . The dry i ng agent was removed by 
f i l trat i on ,  and the  so l vent was removed under reduced pres sure , 
y i e l d i ng 6 . 6 5 g ( 80%) of  44 as a gol den o i l .  The oxal ate s a l t was 
prepared by treat i ng an ethereal sol ut i on of  oxal i c  ac i d  wi t h  an 
ethereal  s o l ut i on of  the base . Recrysta l l i zat i on of the  crude sa l t 
from met h anol  - d i ethyl ether y i el ded a wh i te so l i d ,  mp 1 1 7 - 1 1 9  C .  
I R  ( ba s e , neat ) : 1 72 0  cm- 1  ( C=O ) . l H  NMR ( d60MSO ) : & 1 . 1  ( t ,  6 ,  
- CH z CH3 ) ;  1 . 1 - 1 . 6  ( broad , 1 1 ,  chexyl ) ;  1 . 2  ( s ,  3 ,  - C H3 ) ;  3 . 05 ( q ,  4 ,  
- CHz CH3 ) ;  3 . 3  ( m ,  2 ,  - CHz NEtz ) ;  4 . 3  ( t ,  2 ,  - OCHz ) ;  7 . 3  ( s ,  5 ,  Ar - H ) . 
Ana l . C a l cu l ated for C2 3 H3 4 N06 • 0 . 5  Hz O :  C ,  64 . 1 6 ;  H ,  8 . 43 ;  N ,  
3 . 2 5 .  Found : C ,  64 . 3 6 ;  H ,  8 . 4 1 ; N ,  3 . 26 .  
2 , 4 - 0 iphenyl butyron i tr i l e  (95) . To a s t i rred s u spen s i on of  4 . 1 7 
g ( 1 0 7  mmo l ) of  sod i um am i de i n  200  mL of anhydrous  ether ma i nt a i ned 
at  - 50 C under n i t rogen was  added dropwi se  1 2 . 5  g ( 1 07  mmo l ) of 
phenyl  aceton i tr i l e  in  100 mL of  d i ethyl ether over a 30  m i n  peri od . 
The m i xture was  s t i rred for an add i t i ona l  2 h .  Then 1 9 . 9  g ( 1 07  
mmol ) of  phenethyl  brom i de in  1 00 mL of d i ethyl ether was added 
dropw i se . The  reac t i on was cont i n ued for an add i t i onal  2 h .  Th i s  
so l ut i on was  a l l owed to  warm to room temperature , then brought  to  
s l ow ref l  ux for 4 h .  The mi  xt ure was then poured over about 400 mL 
of i ce -water , and the  l ayers were separated . The aqueous phase  was 
extracted tw i ce w i t h  d i ethyl ether ( 50 mL ) . The extrac t s  were 
comb i ned  and d r i ed over anhydrous  magne s i um su l fate . The ether 
s o l u t i o n was concen trated under reduced pres sure , y i e l d i ng a c l ear 
o i l . Th i s  o i l  was  d i s t i l l ed under vacuum to g i ve 1 7 . 2 5 g ( 74%) 95  as  
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a co l orl e s s  o i l ,  bp 1 2 0 - 1 2 2 C/0 . 2 5 mm ( L i t 1 7 6 bp 1 3 2  C/0 . 1 6 mm ) . 
I R  ( neat ) : 2 2 2 0  cm- 1 ( - C=.N ) . l H  NMR ( CDC1 3 ) :  S 2 . 2  ( m ,  2 ,  
HC - CH2 - CH2 - ) ;  2 . 7  ( t ,  2 ,  Ar - CH2 - ) ; 3 . 7 5 ( t ,  1 ,  Ar-CH - CN ) ; 7 . 4  ( d ,  1 0 ,  
Ar- H ) . 
2 - Bromo - 2 , 4 - d i pheny1 butyron i tr i l e  (96) . To a s t i rred so l ut i on 
o f  9 . 2 5 g ( 4 1 . 9  mmo 1 ) of  9 5  i n  1 00 mL of methyl ene ch l o r i de was  added 
dropw i se  7 . 1 5 g ( 44 . 7  mmo 1 ) of brom i ne i n  50  mL CH2 C 1 2 over a 2 h 
per i od . The so l u t i on was brought to  s l ow refl ux for an add i t i onal  2 
h ,  t hen  poured i n to  2 50 mL of  a col d 1 0% Na2 C03 so l u t i on .  The l ayers 
were separated , and the  aqueou s phase was extracted tw i ce w i t h  CH2 C 1 2 
( 50 m L ) . The  extracts  were d r i ed over anhydrou s magne s i um s u l fate . 
The  s o l vent  was  removed under reduced pre s s ure , g i v i ng 1 0 . 85 g ( 87%) 
of a crude d ar k  o i l . I R  ( neat ) : 2 200 cm- 1 ( - C=.N ) . l H  NMR ( CDC1 3 ) :  
2 . 8 ( m ,  4 ,  - CH2 - ) ;  7 . 3  ( d ,  1 0 ,  Ar - H ) . T h i s compound was not further 
ana l yzed , but  was  i mmed i atel y u sed i n  t he next  step . 
1 - Cyano - l - Pheny1 i ndane  (97) . To a s t i rred so l ut i on of  1 0 . 85 g 
( 3 6 . 2  mmo 1 ) of  96 at  - 1 0 C i n  500 mL of  dry 1 , 2 - d i c h 1 0roethane under 
a n i t rogen atmosphere was added 6 . 0  g of  pu l veri zed so l i d  a l um i n um 
c h l o r i de  port i onwi se  over 1 h .  The mi xture was s t i rred at - 1 0  C for 
an add i t i on a l  6 h ,  then  al l owed to warm to room temperature and kept 
for 36 h .  Th i s  mi  xture was then poured onto 300 mL of col d 1 0"10 HC1  
so l u t i on and  the  l ayers were separated . The aqueou s l ayer was 
extracted tw i ce w i t h  CH2 C 1 2 . The comb i ned organ i c  l ayers were dr i ed 
over anhydrous  magnes i um s u l fate . The so l vent was removed under 
reduced pre s s u re , g i v i ng an o i l .  The o i l was d i s t i l l ed under vacuum 
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g i v i ng 4 . 5 5 g ( 58%) of  97 a s  a gol den col ored o i l , bp 1 50 - 1 5 5 C/0 . 6  
mm ( L i t 1 7 6 bp  1 2 2  C/0 . 2  mm ) . I R  ( neat ) : 2 2 1 0  cm- 1  ( - C.=N ) . l H  NMR 
( COC 1 3 ) :  & 2 . 3 - 3 . 1  ( comp l ex m, 4 ,  - CH2 ) ;  7 . 3  ( broad s ,  9 ,  Ar - H ) . 
I - Phenyl i ndane - l - c arboxyl i c  ac i d  (98) . A s u spen s i on of  4 . 5  g 
( 2 0 . 6  mmo l ) of  9 7  i n  40 mL of 48% HBr was s t i rred at v i gorou s refl ux 
for f i ve  days . The reac t i on mi xture was coo l ed to room temperature , 
then  poured onto  250  mL of  crushed i ce .  The resu l t i ng semi - s o l  i d  
mater i a l was  co l l ected by f i l trat i on and washed repeated l y  w i th  
wate r .  T h e  c rude ac i d  was  d i s so l ved i n  a co l d 5% NaOH so l u t i on , t hen 
f i l tered to remove the i n so l ubl e mater i al . The ac i d  was prec i p i t ated 
by the s l ow add i t i on of  a 5% HCl  so l ut i on ,  to y i e l d  3 . 7  g ( 7 5%) of  a 
t h i c k  1 i g h t  brown o i l .  I R  ( n eat ) : 1 680 cm- 1 ( C =O ) . 1 H NMR ( COC1 3 ) :  
& 2 . 5  ( broad , 3 ,  - C H - ) ;  3 . 5  ( broad s ,  1 ,  - CH - ) ;  7 . 3  ( d , 9 ,  Ar - H ) ; 
1 2 . 1  ( s ,  1 ,  COOH ) . Al l attempts  to  obt a i n  a crysta l l i ne mater i al 
were un succe s s fu l . Therefore t h i s compound was u sed i mmed i at e l y  i n  
the  next  s tep . 
2 - (O i ethyl ami no)ethyl I - Phenyl i ndane - l - carboxyl ate Hydroch l or i de 
� To a so l u t i on of 4 . 0  g ( 1 6 . 8  mmol ) 98 i n  25 mL of sod i um d r i ed 
benzene was  added 2 5  mL of  t h i onyl ch l or i de  and the s o l ut i on s t i rred 
at refl ux under a n i t rogen atmosphere for 1 2  h .  The react i on was 
coo l ed t o  room temperature , then concen trated under reduced pres sure . 
The resu l t i ng o i l  was  washed w i th  th ree 2 5 -mL port i on s  of benzene to 
remove any rema i n i ng t h i onyl c h l or i de . The dark res i due was d i s s o l ­
ved i n  about 50  mL of  dry benzene ,  and the s o l u t i o n was decol or i zed 
w i t h c harcoa l . Then 4 . 0  g ( 33 . 6  mmo l ) of  fre s h l y  d i s t i l l ed 2 -
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d i ethyl ami noethanol  i n  50  mL of  dry benzene was added dropw i se and 
the m i xture was s t i rred at  refl ux for 24  h .  The reac t i on mi xture was 
coo l ed to  room temperature , poured i n to 250 mL of water and bas i f i ed 
w i t h  a 1 0% sod i um c arbonate so l ut i on .  The l ayers were separated , and 
the aqueous  phase  was  extracted twi ce w i t h  50 mL of  d i ethyl ether . 
The  comb i ned organ i c  phases  were concentrated under reduced pres sure , 
g i v i ng an o i l .  Th i s  o i l was  d i s s o l ved i n  about 1 0 0  mL of d i ethyl 
ether  and  extracted w i t h  four 1 00 -mL por i tons  of water . The ether 
l ayer was separated and d r i ed over anhydrous magnes i um s u l fate . The 
d ry i ng agent was removed by f i l trat i on .  The hydroch l o r i de s a l t was 
p repared by treat i ng the  ethereal  so l ut i on of  the  base  w i t h  g aseous  
HC l . Recry s t a l l i z at i on from meth anol - ethyl acetate y i el ded 2 . 88 g 
( 46%) 43 a s  a wh i te so l i d ,  mp 1 4 5 - 1 4 7  C .  I R  ( n ujo l ) :  1 7 20  cm- 1 
( C:O ) . l H  NMR ( 02 0 ) :  & 1 . 2  ( t ,  6 ,  - CH2 CH3 ) ;  2 . 3  ( broad s ,  2 ,  - CH2 - ) ;  
3 . 0  ( broad , m ,  6 ,  - N - CH2 CH3 , ArCH2 - ) ; 3 . 4  ( broad , 2 ,  - CH2 NEt2 ) ;  4 . 5  
( broad s ,  2 ,  - OCH2 ) ;  7 . 3  ( s ,  8 ,  Ar- H ) ; 7 . 5  ( s ,  1 ,  Ar - H ) . An a l . 
Ca l c u l ated for C2 2 H2 8 N02 C l : C ,  70 . 66 ;  H ,  7 . 5 5 ;  N ,  3 . 7 5 .  Found : C ,  
70 . 43 ;  H ,  7 . 60 ;  N ,  3 . 7 1 . 
1 - Phenyl - 1 - i ndanol  ( 1 00) . The phenyl Gr i gn ard reagent was 
prepared by treat i ng bromo benzene ( 7 . 06 g ,  45  mmo l ) i n  1 50 mL of 
anhydrous ether  under a n i trogen atmo sphere w i th  1 . 07  g (45  mmol ) of 
magne s i um .  A c rysta l  of  i od i de was added and the  m i xture was al l owed 
to s t and unt i l  a l l the  magnes i um reacted . 1 - I ndanone ( 5 . 0  g ,  37 . 8  
mmo 1 )  i n  7 5  mL o f  ether was added dropwi se  and the  react i on was 
s t i rred for 4 h .  Saturated ammon i um ch l or i de so l ut i on ( 200 mL )  was 
then  added and  the m i xture was a l l owed to st i r  for 30  m i n .  After the 
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l ayers  were separated , the  aqueou s  phase  was extracted twi ce w i t h  50 
mL o f  ether . The  comb i ned ether extrac t s  were d r i ed over anhydrou s 
magne s i um s u l fate , then  evaporated at reduced pre s s ure to y i el d a 
co l orl e s s  o i l .  The y i e l d  of crude 1 00 was 7 . 8  9 ( 98%) . I R  ( neat ) : 
3 450  cm- l ( - OH ) . l H  NMR ( COC1 3 ) :  & 2 . 2 5 ( t ,  2 ,  - CH2 - ) ; 2 . 8  ( t ,  2 ,  
Ar- CH2 ) ;  2 . 7 5 ( s ,  1 ,  - OH ) ; 7 . 1 5 ( s ,  9 ,  Ar - H ) . 
N,N,N ' ,N ' - Tetramethy1 -N,N ' - b i s[3 - ( 2 -phtha 1 i m i do)propy1 1 - l ,6 - hex -
aned i ammon i um Brom i de (3 1 a) . A so l u t i on of 1 0 . 0  9 ( 58 mmo 1 ) of  
N , N , N '  , N ' - tetramethy 1 - 1 , 6 - h exaned i ami ne a nd  34 . 3  9 ( 1 28 mmo 1 ) of 
N - ( 3 - bromopropy1 ) phtha 1 i m i de in  3 50 mL of  dry methanol  was s t i rred at  
refl ux  under a n i trogen atmosphere for  24  h .  The reac t i on was then  
cool ed to  room temperature and  the  heavy wh i te prec i p i tate  wh i ch 
formed was  co l l ected by f i l trat i on .  Mu l t i p l e  recrysta 1 1 i z a t i ons  from 
met hano l  - d i ethy1  ether y i el ded 1 8 . 5 9 ( 4 5%) of 3 1 a  as a wh i te 
so l i d ,  mp 2 6 6 - 268  C ( L i t l 0 3 mp 266 - 268 C ) . I R  ( n ujo 1 ) :  1 7 1 0 - 1 760 
cm- l ( C=O ) . l H  NMR ( 02 ° ) : � 1 . 5 - 2 . 3  ( broad m, 1 2 ,  - CH2 - ) ;  3 . 1  ( s ,  
1 2 ,  - NCH3 ) ;  3 . 1 - 3 . 4 ( compl ex m ,  8 ,  - NCH2 - ) ; 3 . 7 5 ( t ,  4 ,  ( CO ) 2 N - CH2 ) ;  
7 . 8  ( s ,  8 ,  Ar - H ) . Ana l . Ca l c u l ated for C3 2 H4 4 N4 04 Br2 . H2 0 :  C ,  
52 . 86 ;  H ,  6 . 38 ;  N ,  7 . 7 5 .  Found : C ,  52 . 85 ;  H ,  6 . 4 2 ;  N ,  7 . 67 .  
N ,N, N '  ,N ' - Tetramethy1 - N ,N ' - b i s[3 - ( 2 -phtha 1 i m i do)propy1 1 - 1 ,6 -
hexaned i ammo n i um I od i de (3 1 b) .  To a so l ut i on of 1 . 5 9 ( 2 . 9  mmo 1 ) of 
49a  i n  15  mL of  s od i um dr i ed benzene was added 3 mL of methyl i od i de .  
The react i on was s toppered and a l l owed to s i t  at room temperature for 
24  h .  The heavy prec i p i tate  wh i c h formed was co l l ected by fi l tra ­
t i on ,  was hed w i t h  benzene , and d r i ed under vacuum . Recrysta l l i zat i on 
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from d i l ute  methanol  y i e l ded 2 . 1  g ( 90%) of  ill as a l i gh t  yel l ow 
s o l  i d ,  mp 2 7 4 - 2 7 5  C .  I R  ( n u jo l ) :  1 7 2 0 ,  1 760 cm- 1 ( C = O ) . An a l . 
C a l cu l ated for C3 z H4 4 N4 04 I z : C ,  47 . 89 ;  H ,  5 . 53 ;  N ,  6 . 98 .  Found : C ,  
4 7 . 74 ;  H ,  5 . 4 5 ;  N ,  6 . 9 1 . 
N, N ' - O i me t hyl - N , N ' - b i s [3 - ( 2 -ph tha l i m i do)oropyl ] - 1 ,6 - hexaned i ­
am i ne (49a) . To a s o l ut i on o f  N - ( 3 - bromopropyl ) phtha l i m i de 1 0 2  ( 8 . 0  
g ,  3 0  mmo l ) i n  5 0  m L  dry acetone was added 1 . 96 g ( 1 5 mmo l ) of  
N , N ' - d i methyl - 1 , 6 - hexaned i am i ne 1 04 i n  2 0  mL acetone . The m i x ture 
was s t i rred at  refl ux  under n i trogen for 4 h ,  then cool ed to  room 
t emperature . Tr i ethyl ami ne was then rap i d l y  added ( 3 . 0 2 g ,  30 mmol ) 
and  the  h e a t i ng con t i n ued for 1 2  h .  After cool i ng the  m i xture on an 
i ce bat h ,  t he  s o l  i d  prec i p i tate  wh i ch formed was  removed by f i  l t ra ­
t i on .  The mother  l i quor was  concentrated at  reduced pres sure , 
y i e l d i ng a yel l ow i s h  v i scous  o i l .  Th i s  o i l  was  t r i turated repeated l y  
w i t h  benzene , resu l t i ng i n  a semi - so l i d  wh i te product wh i c h was  
d i sc arded . The  benzene so l ut i on was  was hed w i t h  t hree 50 mL port i on s  
o f  wate r .  T h e  benzene w a s  then evaporated at  reduced pre s s ure , 
l eav i ng a wh i te so l i d .  Mu l t i p l e  recrysta l l i z at i on s  from methano l ­
water y i el ded 4 . 2  g ( 2 7%) of  49a  a s  a wh i te so l  i d ,  mp 80 -82  C .  I R  
( n u jo l ) :  1 72 0 , 1 760  cm- 1 ( C=O ) . l H  NMR ( COC1 3 ) :  5 1 . 4 ( broad s ,  8 ,  
- C Hz - ) ;  1 . 85 ( m ,  4 ,  - CHz - ) ; 2 . 2  ( s ,  6 ,  - N - CH3 ) ;  2 . 35  ( t ,  8 ,  - N - CHz ) ;  
3 . 8  ( t ,  4 ,  ( CO ) z - N - CHz ) ;  7 . 8 ( d ,  8 ,  Ar - H ) . Anal . Ca l cu l ated for 
C3 0 H3 8 N4 04 . 0 . 5  Hz O :  C ,  68 . 29 ;  H ,  7 . 44 ;  N ,  1 0 . 62 .  Found : C ,  68 . 5 1 ;  
H ,  7 . 3 4 ;  N ,  1 0 . 6 1 . 
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N,  N '  - 0 i me t hy 1 - N ,  N '  - b i s [3 - ( 2 -ph th al i mi do) propyl J-l, 6 - hexaned i -
am i ne O i hyd roch l or i de (49b) . The d i hydroch l or i de sa l t of 49a was 
prepared by d i s so l v i ng 2 . 0  9 ( 3 . 9  mmol ) of  49a  in  about  20  mL of  dry 
met hanol  and treat i ng w i t h  gaseous  HC1 . The methano i c  so l u t i on was 
concentrated under vacuum to  a t h i ck  wh i te prec i p i tate . Mu l t i p l e  
recry s t a l l i z at i on s  from methanol  - ethyl acetate y i e l ded 1 . 65 9 ( 7 2%) 
of 49b as a f i ne wh i te powder , mp 248- 250  C .  I R  ( n ujo l ) :  1 7 2 0 ,  1 760 
cm- 1 ( C =O ) . I H NMR ( 02 0 ) : � 1 . 6 - 2 . 4  ( compl ex m ,  1 2 ,  - CH2 - ) ; 3 . 1  ( s ,  
6 ,  NCH3 ) ;  3 . 3 5 ( q ,  8 ,  N - CH2 ) ;  3 . 9  ( t ,  4 ,  ( CO ) 2 - N - CH2 ) ;  7 . 9  ( s ,  8 ,  
Ar - H ) . Ana l . Ca l cu l ated for C3 0 H4 o N4 04 C 1 2 :  C ,  60 . 90 ;  H ,  6 . 82 ; N ,  
9 . 4 7 .  Found : C ,  60 . 5 5 ;  H ,  6 . 86 ;  N ,  9 . 2 4 .  
N , N '  - O i me t hyl - N , N ' - b i s[3 - ( 2 -ph tha l i mi do)propyl J- 1 ,6 - hexaned i ­
am i ne O i hydrobromi de  (49c) . To a so l u t i on of  1 1 . 1  9 ( 4 1 . 7  mmo l ) of 
N - ( 3 - bromopropyl ) phtha l i m i de (ill) in  100 mL of dry methanol  was 
added 3 . 0  9 ( 2 0 . 8  mmo l ) of N , N ' - d i methyl - 1 , 6 - hexaned i ami ne i n  2 5  mL 
of methano l . The react i on mi xture was s t i rred at refl ux under 
n i t rogen for 2 4  h .  The so l u t i on was then c h i l l ed on an i ce bath and 
f i l t ered to  remove any i n sol ubl e product s .  The so l vent was removed 
at reduced pre s s u re to gi ve a vi scous  oi 1 .  Th i s oi 1 was tr i turated 
repeated l y  w i t h  ethyl  acetate unt i l  a wh i te prec i p i tate formed . The 
crude product  was  col l ected by fi l trat i on and washed w i t h  ethyl 
acetate . Mu l t i pl e  recrysta l l i z a t i ons  from methanol  - d i ethyl ether 
y i e l ded 6 . 5  9 ( 46%) of 49c as  a wh i te sol i d ,  mp 1 1 7 - 1 1 9 C .  I R  
( n u j o l ) :  1 7 1 0 ,  1 760 cm- 1 ( C =O ) . I H NMR ( °2 0 ) : � 1 . 4 - 2 . 3  ( broad , 1 2 ,  
- CH2 - ) ;  3 . 0  ( s ,  6 ,  - N - CH3 ) ;  3 . 1 - 3 . 4  ( m ,  8 ,  N - CH2 ) ;  3 . 6 - 4 . 0  ( m ,  4 ,  
( CO ) 2 - N - C H2 ) ;  7 . 9  ( s ,  1 0 ,  ArH ) . Anal . Ca l cu l ated for 
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C3 0 H4 0 N4 04 Brz · 2  Hz O :  C ,  50 . 2 7 ;  H ,  6 . 1 8 ;  N ,  7 . 82 . Found : C ,  50 . 0 5 ;  H ,  
6 . 2 2 ; N ,  8 . 0 1 . 
N ,  N '  - 0 i m e t  h y 1 - N - [3 - ( 2 -ph t h a l  i m i d  0) pro p y 1 1 - I , 6 - h e x  a ned i ami ne 
( 1 05), A so l ut i on of  8 . 5  g ( 59 . 0  mmol ) of N , N ' - d i methyl - l , 6 - hex­
aned i am i n e  ( 1 0 4 )  and 3 . 1 6 g ( 1 1 . 8  mmol ) of  N - ( 3 - bromopropyl ) phtha l i m ­
i de (10 2 ) i n  7 5  mL of  dry THF was s t i rred at  refl ux under n i t rogen 
for 20  h .  The so l ut i on was  coo l ed to  room temperature . The so l i d  
wh i ch prec i p i tated was  removed by f i l trat i on and washed w i t h  2 0  mL of 
THF . The comb i ned THF s o l ut i on s  were concentrated at  reduced 
pres s ure to  y i e l d  a crude o i l . The rema i n i ng N , N ' - d i methyl - 1 , 6 - hex ­
aned i am i ne was  d i s t i l l ed from t h i s  o i l under v acuum ( 60 C/0 . 2  mm) . 
The  v i scous  o i l  wh i ch rema i ned was  d i s sol ved i n  50 mL of  ether and 
extracted w i t h  three 50 -mL port i on s  of wate r .  The ether l ayer was 
concentrated at reduced pre s sure to y i e l d  2 . 6 1  g ( 67%) of  1 05 a s  a 
v i scous  go l den  o i l .  I R  ( n eat ) : � 7 1 0 ,  1 760 cm- 1 ( C =O ) . l H NMR 
( COC1 3 ) :  � 1 . 1 - 1 . 5  ( broad , 8, - CHz - ) ;  1 . 6 - 2 . 0  ( m ,  2 ,  - C Hz - ) ;  2 . 1 - 2 . 6  
( m ,  6 ,  - CHz ) ;  2 . 2  ( s ,  3 ,  - N - CH3 ) ;  2 . 4 5 ( s ,  3 ,  - N - CH3 ) ;  3 . 0  ( s ,  1 ,  
N - H ) ; 3 . 5 - 3 . 9  ( m ,  2 ,  - N - CHz ) ;  7 . 8 ( s ,  4 ,  ArH ) . Th i s  compound was not 
further ana l yzed , but u sed i mmed i at e l y  i n  the  next  step . 
N - [3 - ( 2 - Ph tha l i m i do)propyl l - N ,N ' , N ' - t r i methyl - 1 , 6 - hexaned i am i ne 
O i hydroch l or i de ( 5 1 ) .  To a so l u t i on o f  3 . 5  g ( 1 0 . 6  mmol ) o f  ill 
d i s so l ved i n  5 mL of  form i c  ac i d  was added 5 mL of 3 7% forma l dehyde . 
The m i  xture was heated on a s team bath for 6 h ,  then poured onto 
crus hed i ce .  Th i s  so l ut i on was  made strong l y  bas i c  w i t h  so l i d  sodi um 
hydrox i de ,  then  extracted w i th  t hree 1 0 0 - mL port i on s  of ether . The 
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comb i ned ether 1 ayers  were d r i  ed over anhydrous magnes i um su l fate . 
The d ry i ng agent was  removed by f i l trat i on and the ether was removed 
at  reduced pres sure to y i e l d  2 . 8  g ( 7 7%) of 1 06 a s  an amber o i l .  The 
d i hydrochl or i de sa l t (�) was prepared by t reat i ng an ether so l ut i on 
o f  the  base  w i t h  an ether so l ut i on s aturated w i t h  HCl gas . Mul t i p l e  
recry s t a l l i zat i on s  o f  the  sa l t from methanol  - ether y i el ded 1 . 9 g 
( 43%) of  � as  a wh i te so l i d ,  mp 1 76 - 1 78 C .  I R  ( n ujol ) :  1 7 1 0 ,  1 7 60 
cm- 1 ( C =O ) . l H  NMR ( 02 0 ) : � 1 . 5 - 2 . 4  ( m ,  8 ,  - CH2 - ) ;  3 . 0  ( s ,  9 ,  
- N - CH3 ) ;  3 . 1 - 3 . 5  ( m ,  8 ,  - N - CH2 ) ;  3 . 7 - 4 . 1  ( m ,  2 ,  - N - CH2 ) ;  7 . 8  ( s ,  4 ,  
ArH ) . Anal . C a l cu l ated for C2 o H3 3 N3 02 Cl : C ,  5 7 . 4 1 ; H ,  7 . 9 5 ; N ,  
1 0 . 04 .  Found : C ,  5 7 . 3 2 ;  H ,  7 . 96 ;  N ,  9 . 99 .  
N , N , N '  , N '  , N ' - P e n  t am e t hy 1 - N - [ 3 - (2 -ph t ha l  i m i do) pro p y 1 1  -1. 6 - hex ­
aned i ammon i um I od i ne (50) . To a so l ut i on of  1 . 5  g ( 4 . 4  mmol ) of lQQ 
i n  1 5  mL o f  s od i um d r i ed benzene was added 3 mL of  methyl i od i de .  
The  react i on m i xture was  stoppered and al l owed t o  s i t  a t  room 
temperature for 24 h .  The heavy prec i p i tate  wh i c h formed was 
co l l ected by f i l trat i on and then washed w i t h  benzene . Recry s ta l l i z a ­
t i on of  t h e  product  from methanol  y i e l ded 1 . 85  g ( 74%) of  5 0  a s  a 
l i g h t  yel l ow so l i d ,  mp 206 - 208 C .  I R  ( n ujol ) :  1 7 1 0 ,  1 760 cm- 1  
( C =O ) . l H  NMR ( 02 0 ) : � 1 . 4 - 2 . 3  ( m ,  8 ,  - CH2 - ) ; 3 . 1  ( s ,  1 5 ,  N - CH3 ) ;  
2 . 8 - 3 . 4  ( m ,  8 ,  - N - CH2 ) ;  3 . 6 - 3 . 9  ( m ,  2 ,  N - CH2 ) ;  7 . 8  ( s ,  4 ,  ArH ) . 
Anal . Ca l cu l ated for C2 2 H3 7 N302 I 2 : C ,  4 1 . 98 ;  H ,  5 . 93 ;  N ,  6 . 68 .  
Found : C ,  42 . 08 ;  H ,  5 . 93 ;  N ,  6 . 63 .  
N - ( 2 - Propynyl )phtha l i m i de ( 1 1 0) .  To a so l ut i on of  20 . 0  g ( l 08 
mmo l ) of  potas s i um phtha l i mi de i n  2 50 mL of dry methanol  was added 
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dropw i se 2 5 . 7  g ( 2 1 6 mmo l ) of propargyl brom i de i n  7 5  mL of methano l . 
The  m i  xture was  s t i rred at refl ux under n i t rogen for 24  h .  After 
coo l i ng to  room temperature , the so l ut i on was  f i l tered and the 
s o l vent  was  removed under reduced pres s ure to  g i ve a crude tan  s o l i d .  
M u l t i p l e  recrysta l l i zat i on s  from d i l ute  methanol  y i e l ded 1 6 . 8  g ( 84%) 
of 1 1 0  as a wh i te so l i d ,  mp 1 48 - 1 49  C ( L i t 1 5 5  mp 1 4 7 - 1 50 C ) . I R  
( n u j o l ) :  3 2 60  cm- 1  ( C�CH ) ; 2 1 3 0 cm- 1  ( - C�C - ) ; 1 7 00 , 1 760 cm- 1 ( C=O ) . 
l H  NMR ( d60MSO ) : b 2 . 9  ( s ,  1 ,  - C�CH ) ;  4 . 2  ( s ,  2 ,  N - CHz ) ;  7 . 7  ( s ,  4 ,  
Ar - H )  . 
N - (4 - 0 i methyl am i no - 2 - butynyl )phtha l i m i de Hydroch l o r i de (53) . To 
a s o l u t i on o f  6 . 0  g ( 3 2 . 4  mmo l ) of  N - ( 2 - propynyl ) phtha l i m i de ( llQ )  i n  
6 0  mL o f  ethano l  was  added 2 0  mL of 3 7% forma l dehyde and 5 . 23 g ( 6 5  
mmo l ) o f  d i methyl  ami ne hydroch l or i de . Cuprous c h l or i de ( 0 . 3  g )  was 
added , and  the  so l ut i on was  s t i rred at refl ux  for 12 h .  The m i xt ure 
was coo l ed to  room temperature and 2 50 mL of  water was added . The 
mi xture  was  a c i d i f i ed w i t h a 1 0% HC l so l u t i on and extracted tw i ce 
w i t h  5 0  mL o f  d i ethy l  ethe r .  The aqueou s phase was made a l kal i ne 
w i t h  a 1 0% NaZ C03 s o l u t i on w i th cool i ng and ext racted exhaust i ve l y  
w i t h  s i x  50  m L  port i on s  of  CHC1 3 • The comb i ned CHC1 3 extracts  were 
d r i ed over anhydrous magnes i um s u l fat e .  The dry i ng agent w a s  removed 
by f i l t rat i on and the  s o l vent was evaporated under reduced pres s ure ,  
y i e l d i ng a n  o i l .  The hydroch l or i de sa l t was  prepared by treat i ng an 
ethereal  so l ut i on of  the o i l w i th  gaseous  HC1 . Mu l t i p l e  recrysta l l i ­
z at i on s  from acetone - ether y i e l ded 4 . 7  g ( 6 5% )  of 53 a s  a wh i te 
s o l i d ,  mp 1 8 5 - 187  C .  I R  ( nu jo l ) :  1 70 0 ,  1 7 60 cm- 1  ( C =O ) . l H  NMR 
( Oz O ) : � 3 . 1  ( s ,  6 ,  - NMez ) ;  4 . 3  ( s ,  2 ,  - CHz C�C - ) ;  4 . 6  ( s ,  2 ,  
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- C=.C - CH2 - N ) ; 7 . 8  ( s ,  4 ,  Ar - H ) . Anal . Ca l c u l ated for C I 4 H l S N2 02 Cl : 
C ,  6 0 . 3 3 ;  H ,  5 . 4 2 ;  N ,  1 0 . 0 5 .  Found : C ,  60 . 4 2 ;  H ,  5 . 4 3 ;  N ,  1 0 . 0 5 .  
N - (4 - 0 i e t hyl ami no - 2 - bu tynyl lphtha l i m i de Hydrochl o r i de (54) . To 
a so l u t i on o f  llQ ( 5 . 5  g ,  30 mmo l ) i n  60 mL of ethanol  was added 20  
mL o f  37% forma l dehyde and 6 . 5 1 g ( 60  mmo l ) of  d i ethyl ami ne hydro­
ch l o r i d e .  Cuprou s  c h l or i de ( 0 . 3  g )  was  added , and  the  so l ut i on was 
s t i rred a t  refl ux for 12 h .  The m i xture was  cool ed to  room tempera­
t ure , and 250  mL of  water was added . The mi xture was ac i d i f i ed wi t h  
a 1 0% HC l  s o l u t i on and extracted t w i c e  wi t h  50 m L  of  d i e thyl ether . 
The  aqueous  phase  was  made a l kal i ne w i th  a 1 0% Na2 C03 so l u t i on wi t h  
cool i ng a n d  ext racted exhau s t i ve l y  w i th s i x  50 -mL port i on s  of  CHC1 3 •  
T he  comb i ned CHC 1 3  extract s  were dr i ed over anhydrous magnes i um 
s u l fate . The  dry i ng agent was removed by fi l t rat i on ,  and the  so l vent 
was  evaporated at  reduced pre s s u re ,  y i e l d i ng an o i l . The hydroch l or ­
i de s a l t was  prepared by treat i ng i n  ethereal  s o l u t i on of  the  o i l  
w i t h  g a seous  HC l . Mu l t i p l e  recry s t a l l ; za t i ons  from acetone y i e l ded 
4 . 1 2 g ( 45%) of 54 as a wh i te so l i d ,  mp 1 74 - 1 7 5 . 5  C .  I R  ( nu jo l ) :  
1 700 , 1 7 60 cm- 1  ( C =O ) . I H NMR ( Oz O ) : � 1 . 4 5  ( t ,  6 ,  - CH2 CH3 ) ;  3 . 5  ( q ,  
4 ,  - CHz CH3 ) ;  4 . 3  ( 5 ,  2 ,  - CHz C=.C ) ; 4 . 6  ( 5 ,  2 ,  C=.C - CH2 - N ) ; 7 . 8  ( s ,  4 ,  
Ar - H ) . Ana l . Ca l c u l a ted for C 1 6 H 1 9 N2 02 C l : C ,  62 . 64 ;  H ,  5 . 93 ;  N ,  
9 . 1 6 .  Found : C ,  62 . 6 5 ;  H ,  6 . 03 ; N ,  9 . 07 .  
N ,N ' - O i methyl - 1 ,6 - hexaned i ami ne O i hydroch l or i de ( I l l ) .  Th i s  
compound  was  prepared by trea t i ng 2 . 3  g ( 1 6 . 0  mmol ) o f  N , N ' - d i methyl -
1 , 6 - hexaned i am i n e  i n  20  mL of  methanol  w i t h  g a seous  HC l and prec i p i ­
t at i ng t he  s a l t w i t h  d i e thyl ether . The so l i d  prec i p i t ate  was 
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co l l ected by f i l trat i on ,  washed w i t h  d i ethyl ether and then dr i ed . 
Recry s t a l l i z at i on from methanol  - d i ethyl ether y i e l ded 3 . 3  9 ( 9 7%) 
of  III a s  a wh i te s o l i d ,  mp 240 - 242  C ( L i t 1 8 1 mp 240 - 2 4 1  C ) . 
N ,  N '  - 0 i m e  t hy 1 - N , N '  - b i s  [ 4 - (2  -pht h a  1 i m i  do)  - 2 - butynyll-l. 6 - hexan ­
ed i am i ne ( 55a) . To a s o l ut i on of  7 . 1  9 ( 38 . 0  mmo l ) of N - ( 2 - propyn ­
y l ) ph t h a l i m i de ( 1 1 0 )  i n  50 mL of ethanol  was added 2 5  mL of 37% 
formal dehyde and 2 . 7 5 9 ( 1 9 . 1  mmol ) of N , N ' - d i methyl - 1 , 6 - hexaned i ­
am i ne d i hydroch l or i de (lll ) .  Cuprous c h l or i de ( 0 . 6  g )  was  added , and 
the s o l ut i on was  s t i rred at refl ux for 6 h .  The  m i xture was coo l ed 
to room temperature , and 2 50 mL of  water was added . The m i xture was 
ac i d i f i ed w i t h  a 1 0% HCl  so l ut i on and extracted tw i ce w i t h  50 -mL 
port i on s  of  ether . The aqueous  phase  was made a l kal i ne w i t h  a 1 0% 
Na2 C03 so l ut i on ,  then  extracted exhau s t i ve l y  w i t h  s i x  5 0  mL port i on s  
of  CHC1 3 . The  comb i ned CHC 1 3  extract was  dr i ed over anhydrous 
magn e s  i urn s u l fate . The  dry i  ng agen t was removed by f i  l trat i on and 
the so l vent  was  removed under reduced pre s sure to  y i el d  an o i l ,  wh i ch 
so l i d i f i ed upon stand i ng .  The product was  recrysta l l i zed from 
met h ano l  - water to y i e l d  5 . 4 5 g ( 53%) of 55a  as a tan so l i d ,  mp 
1 2 1 - 1 24 C .  I R  ( nujo l ) :  1 7 1 0 ,  1 7 60 cm- l  ( C= O ) . I H  NMR ( COC1 3 ) :  � 
1 . 3  ( broad , 8 ,  - CH2 - ) ;  2 . 1 - 2 . 6  ( broad , 1 0 ,  - N - CH ) ; 3 . 3  ( broad , 4 ,  
N - CH2 - C=C ) ; 4 . 5  ( s ,  4 ,  ( CO ) 2 - N - CH2 ) ;  7 . 85 ( s ,  8 ,  ArH ) . Anal . 
C a l c u l ated for C3 2 H3 4 N4 04 . H2 0 :  C ,  69 . 0 5 ;  H ,  6 . 5 1 ;  N ,  1 0 . 07 .  Found : 
C ,  69 . 3 0 ;  H ,  6 . 4 1 ; N ,  1 0 . 04 .  
N , N ' - 0 i m e t  h y 1 - N , N '  - b i s [ 4 - ( 2 - ph t h a l  i m i d  0 )  - 2 - bu t yn y 1 J - 1 ,6 - hex-
aned i am i ne O i hydroch l or i de (55b) . The d i hydroch l or i de s a l t was 
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prepared by treat i ng a sol ut i on of 55a  i n  methano l  w i t h  a methanol ­
g a seou s  HC l  s o l u t i on and prec i p i tat i ng the s a l t w i th  ethyl  acetate . 
Recry s ta l l i z a t i on from methanol  - ethyl  acetate  y i e l ded 55b as  a 
l i g h t  tan  s o l i d ,  mp 1 1 4 - 1 1 5 C .  Ana l . 
. 2 H2 0 :  C ,  5 9 . 3 5 ;  H ,  6 . 0 7 ;  N ,  8 . 65 .  
8 . 68 .  
Ca l cu l ated for C3 2 H3 6 N4 04 C1 2 
Found : C ,  59 . 48 ;  H ,  6 . 1 0 ;  N ,  
N - ( 2 - Propynyl ) succ i n i m i de (1 1 3) .  To a so l u t i on o f  2 . 3  9 of 
sod i um ( 0 . 1  mol ) i n  200  mL absol ute  e thano l  was  added 1 0 . 0  g ( 0 . 1  
mol ) o f  so l i d  s u cc i n i m i de port i onw i se . Propargyl brom i de ( 1 2 . 0  g ,  
1 0 1  mmo l ) i n  50  mL ethanol  was  added dropw i se , and the  m i xture was 
s t i rred a t  refl ux  under a n i trogen atmo sphere for 15 h .  The reac t i on 
m i x t u re was  then  coo l ed to room temperature , and the  s a l t wh i c h 
prec i p i t ated  was  removed by f i l trat i on .  The so l vent  was  evaporated 
under reduced pre s s ure to g i ve a c rude yel l ow o i l .  The re s i due wa s 
d i s t i l l ed under  vacuum to  y i e l d  1 0  . 9 ( 79%) o f  111 a s  a gol den o i l , 
bp 9 5 - 1 0 0  C/0 . 2 5 mm ( L i t 1 5 5 bp 9 5  C/0 . 5  mm) . I R  ( n eat ) : 3260  cm- 1 
( C=.CH ) ; 2 1 3 0  cm- 1 ( - C=.C - ) ; 1 7 1 0 ,  1 7 70 cm- 1  ( C = O ) . I H  NMR ( COC 1 3 ) :  & 
2 . 6 5 ( s ,  1 ,  C=.CH ) ;  2 . 85 ( s ,  4 ,  - C H2 - ) ;  4 . 3  ( d , 2 ,  ( CO ) 2 N - CH2 - ) '  
N , N '  - 0 i me  t h y 1 - N , N '  - b i s [ 4 - ( 1 - s u c c i n i m i d  0 ) - 2 - bu t yn y 1 1  - 1 ,6  - hex -
aned i am i ne  O i hydrobrom i de (56) . To a so l u t i on of  5 . 0  9 ( 3 6 . 4  mmol ) 
o f  N - ( 2 - propynyl ) s u cc i n i m i de (111) i n  40 mL of  d i oxane  was  added 20 
mL of  a 3 7% formal dehyde so l u t i on and 3 . 84 9 ( 1 8 . 2  mmo l ) of 
N , N ' - d i methyl - 1 , 6 - hexaned i am i n e  d i hydroch l or i de ( ill ) .  Cuprou s  
c h l o r i de ( 0 . 2  g )  w a s  added , a n d  the  so l u t i on w a s  s t i rred at  refl ux 
for 6 h .  The  m i x t ure was  cool ed to room temperature , and 2 50 mL of 
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water was  added . The  mi xture was  ac i d i f i ed w i t h  a 1 0% HC l  so l ut i on 
and extracted tw i ce w i t h  50 mL of  ether . The aqueou s phase  was made 
a l kal i ne w i t h  a 1 0% Na2 C03 so l u t i on ,  then extracted exhau s t i ve l y  w i th  
s i x  5 0 -mL  port i on s  of  CHC1 3 . The comb i ned CHC 1 3  extract was d r i ed 
over anhydrous magnes i urn s u l fate . The  dryi ng agent was removed by 
f i l trat i on ,  and t he so l vent was  removed under reduced pre s s ure to  
y i e l d  an o i l .  Th i s  o i l  was  d i s so l ved i n  20  mL of  methanol  s aturated 
w i t h  g a s eou s H B r .  The  d i hydrobrom i de sa l t was prec i p i tated w i th  
ethyl  acetate . Mu l t i p l e  recrysta l l i z a t i ons  from methanol  - ethyl 
acetate  y i el ded 1 . 5  g ( 1 4% )  of 56 a s  a tan sol i d ,  mp 1 68 - 1 70 C .  I R  
( n u jo l ) :  1 70 7 ,  1 7 70  cm- 1 ( C=O ) . I H  NMR ( 02 ° ) : � 1 . 2 - 1 . 9  ( broad , 8 ,  
- CH2 - ) ; 2 . 8  ( s ,  6 ,  - N - CH3 ) ;  2 . 9  ( s ,  8 ,  - CO - CH2 ) ;  3 . 1 - 3 . 3 5  ( m ,  4 ,  
- N - CH2 ) ;  4 . 0 5 ( m ,  4 ,  - ( CO ) 2 N - CH2 - C,=C - ) ;  4 . 4  ( m ,  4 ,  - C =C - CH2 - N ) . 
Ana l . C a l c u l ated for C2 4 H3 6 N4 04 Br2 : C ,  47 . 69 ;  H ,  6 . 0 0 ; N ,  9 . 2 7 .  
Found : C ,  47 . 50 ;  H ,  6 . 1 0 ;  N ,  9 . 2 1 . 
1 - (p- N i  t rophenvl lcycl opent anecarboxyl i c  ac i d  ( 1 1 4  l .  1 - Phenyl -
cyc l opentanecarboxyl i c  ac i d  ( 5 . 0  g ,  2 6 . 3  mmo l ) 84 was added port i on ­
w i s e  w i t h  s t i rr i ng to  7 5  m L  of  fumi ng n i tr i c  ac i d  a t  - 1 0 C .  
St i rr i ng w a s  con t i n ued at  0 C for 2 h .  The m i xture was  a l l owed to 
warm to  room temperature for 1 h ,  then poured onto crus hed i ce .  The 
resu l tant  prec i p i t ate  was  co l l ected by fi l trat i on and recrysta l l i zed 
from methano l , y i el d i ng 5 . 1 5 g ( 87%) of ill as l i ght  tan pl atel et s ,  
mp 1 7 9 - 1 8 1  C ( L i t l 6 0 mp 1 79 - 182  C ) . I R  ( n ujo l ) :  1 695 cm- 1  ( C=O ) . 
I H NMR ( COC 1 3 ) : ' 1 . 85 ( s ,  6 ,  - CH2 - ) ;  2 . 5 - 2 . 8  ( compl ex m ,  2 ,  cyc l o ­
pentyl ) ;  7 . 6 - 8 . 2  ( compl ex m ,  4 ,  Ar - H ) ; 1 1 . 5 5 ( s ,  1 ,  - COOH ) . 
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2 - (O i ethyl ami no)ethyl l - (p- N i trophenyl )cycl opentanecarboxyl ate 
Hydroc h l o r i de ( 1 1 5). Method A .  T o  a so l u t i on of  5 . 0  g ( 2 2 . 6  mmol ) 
o f  1 1 4 i n  2 5  mL of  sod i um-dr i ed benzene was  added 2 5  mL of  t h i onyl 
c h l or i de . The so l u t i on was  s t i rred at  refl ux  for 1 2  h .  The so l u t i on 
was  concen trated under reduced pres s ure ,  then reconcentrated w i t h  
t hree 2 5 -mL port i on s  of  benzene to  remove the  rema i n i ng t h i onyl 
c h l o r i de . The  re s i due  was d i s so l ved i n  40 mL of  dry benzene and 
decol o r i zed w i t h  c harcoal . Then , 5 . 38 g ( 4 5 . 3  mmol ) of  fresh l y  
d i s t i l l ed 2 - d i ethyl ami noethanol  was added i o  7 5  m L  of  dry benzene , 
and t h e  m i  xture was  heated under refl ux for 1 2  h .  The so l  u t  i on was 
coo 1 ed to  room temperature , poured i n to 250  mL water and made bas  i c 
w i t h  1 0% Naz C03 so l u t i on .  The l ayers were separated , and the  aqueou s 
p h a s e  was  washed tw i ce ( 50 -mL port i on s )  w i t h  d i ethyl  ether . The 
comb i ned organ i c  l ayers were concentrated under reduced pres sure ,  
d i s so l ved i n  about  1 0 0  m L  of  d i ethyl ether and extracted four t i mes  
w i t h  1 00 - m L  port  i on s  of  water . T he  e ther  1 ayer wa s  dr i  ed  over 
anhydrou s magne s i um s u l fate . The dry i ng agent was removed by 
f i l t r a t i on and the  hydroch l or ide  sa l t was  prepared by treat i ng the  
ethereal  so l u t i on of  the  base  w i t h  gaseou s HCl . Recry s ta l l i z at i on 
from met hanol  - d i ethyl  ether y i el ded 6 . 53 g ( 78%) of  ill a s  a wh i te 
so l i d ,  mp 1 8 0 - 1 8 2  C ( L i t 1 6 0  mp 1 8 2 - 1 82 . 5  C ) . I R  ( n u jo l ) :  1 7 20  cm- 1 
( C=O ) . l H  NMR ( Oz O ) : � 1 . 3 5  ( t ,  6 ,  -CHz CH3 ) ;  1 . 8 ( broad s ,  6 ,  
cpentyl ) ;  2 . 4 - 2 . 8  ( compl ex m ,  2 ,  cycl opentyl ) ;  3 . 2  ( q ,  4 ,  - CH2 CH3 ) ;  
3 . 5  ( m ,  2 ,  CHz NEtz ) ;  4 . 5  (m ,  2 ,  - OCHz - ) ; 7 . 55 ( d ,  2 ,  Ar- H ) ; 8 . 0 5 ( d ,  
2 ,  Ar - H ) . 
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Method B .  Pota s s i um l - ( p - n i trophenyl ) cycl opentanecarboxyl ate 
( 1 1 6 )  ( 2 . 3  g ,  8 . 4  mmo l ) d i s s ol ved i n  2 5  mL of  absol ute  eth anol was 
added i n  one port i on to  fresh l y prepared 2 - d i ethyl ami noethyl ch l or i de 
( 8 6 )  ( 1 . 68 g ,  1 2 . 4  mmol ) d i s sol ved i n  10 ml of absol ute  eth anol . The 
so l u t i on i mmed i at e l y  became turb i d ,  and a prec i p i tate  began to  
separate . The m i xture was then s t i rred at refl ux for 1 6  h .  After 
the s o l u t i on was  cool ed , the prec i p i tated i norgan i c  sa l t was removed 
by f i l trat i on and d i s carded . The f i l trate was evaporated to drynes s  
at  reduced pres s ure . The resu l t i ng o i l was d i s so l ved i n  d i ethyl 
ether  ( 1 0 0  mL ) , washed w i t h  three 50 -mL port i on s  of  water and d r i ed 
over anhydro u s  magnes i um s u l fate . The hydroch l o r i de sa l t was 
prepared by treat i ng the  ethereal  sol u t i on of  the  base w i th  gaseous  
HC l . Recry s t a l l i z at i on from methanol  - d i ethyl ether y i el ded 1 . 8 g 
( 58%) of  1 1 5  a s  a wh i te so l  i d ,  mp 1 8 2 - 1 84 C ( L  i t 1 6 0 mp 1 82 - 1 82 . 5  
C ) . T h i s compound was i dent i ca l  i n  i t s p hy s i ca l  and spectral  
propert i e s to  1 1 5  prepared from 1 - ( 4 - n i trophenyl ) cycl opentanecarboxy­
l i c ac i d  ( Method A ) . 
Pot a s s i um l - (p- N i t rophenvl )cyc l opentanecarboxyl ate ( 1 16) . A 
s o l u t i on o f  2 . 6  g ( 1 1 . 1  mmo l ) of  1 1 4 i n  50 mL of absol ute  ethano l  was 
t i t rated w i t h 1 0% ethanol i c  potas s i um hydrox i de u s i ng phenol phtha l e i n  
a s  a n  external  i nd i cator .  The so l vent was evaporated under reduced 
pre s s u r e ,  fol l owed by recrysta l l i z at i on of the  product from ethanol  -
ether , y i e l d i ng 2 . 95 g ( 97%) of ill as wh i te need l e s ,  mp 2 2 2 - 224  C 
( L i t 1 6 0  mp 2 2 5  C ) . 
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2 - (O i ethvl ami nolethyl l - (p-Am i nophenyl lcycl opentanec arboxyl ate 
Hydroch l or i de (57al . A dry methanol  so l u t i on ( 60 mL )  of  5 . 9 5 g ( 1 6 . 1  
mmol ) 1 1 5  was  cata l yt i ca l l y  reduced w i th  1 0% pl at i num on carbon under 
a hydrogen atmosphere on a Parr apparat u s . When the  t heoret i ca l  
q u a n t i ty o f  hydrogen had been  absorbed , t he  cata l yst  was removed by 
f i l trat i on .  The so l vent was evaporated under reduced pres s ure ,  
y i el d i ng a crude yel l ow so l i d .  Recrysta l l i zat i on from methanol  -
ethyl  acetate  y i el ded 4 . 3 5 g (80%)  of  57a  a s  a l i g h t  tan  so l i d ,  mp 
1 3 5 - 1 3 7  C .  I R  ( n ujo l ) :  3460 , 3360 , 3200  cm- 1 ( - NH2 ) ; 1 72 0  cm- 1 
( C=O )  . 
cpentyl ) ;  2 . 2 - 2 . 7  ( comp l ex m ,  2 ,  cyc l opentyl ) ;  3 . 0 5  ( q ,  4 ,  - CH2 CH3 ) ;  
3 . 4  ( broad , 2 ,  CH2 NEt2 ) ;  4 . 4  ( broad , 2 ,  - OCH2 - ) ;  6 . 85 ( d , 2 ,  Ar - H ) ; 
7 . 2 5  ( d ,  2 ,  Ar- H ) . Anal . Ca l cu l ated for C l s H2 9 N2 02 C l  
. 0 . 5  H2 0 :  C ,  
6 1 . 78 ;  H ,  8 . 64 ;  N ,  8 . 0 1 . Found : C ,  6 1 . 76 ;  H ,  8 . 48 ;  N ,  7 . 97 .  
Methyl l - (p- N i trophenyl lcyc l opentanecarboxyl ate 0 1 7al . To a 
s o l u t i on of  6 . 2 5 g ( 26 . 6  mmo l ) of l - (p - n i trophenyl ) cycl opentanecar ­
boxyl i c  ac i d  (11 4 )  i n  2 5  m L  o f  s od i um -dr i ed benzene was added 2 5  mL 
of t h i onyl c h l or i de and the  so l u t i on was heated at refl ux for 1 2  h .  
The s o l u t i on was  concentrated under reduced pres s ure ,  then reconcen-
trated w i t h three 2 5 -mL port i on s  of benzene . The re s i due was 
d i s s o  1 ved i n  40 mL of  benzene and deco 1 ori zed w i t h  charcoaL The 
s o l u t i on was then heated at refl ux w i th  7 5  mL of dry methanol  for 1 2  
h .  After t h e  so l u t i on was cool ed , t h e  so l vent was removed at  reduced 
pre s s u re .  The resu l t i ng crude tan so l i d  was recrystal l i zed from 
methano l  y i e l d i ng 5 . 1 4 g ( 78% ) of 1 1 7a  as l i ght  tan  need l e s ,  mp 72 - 73 
C .  I R  ( n u j o l ) :  1 7 1 0  cm- 1 ( C=O ) . l H  NMR ( COC 1 3 ) :  & 1 . 8 ( broad , s ,  
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6 ,  cpentyl ) ;  2 . 5 - 2 . 8  ( compl ex m ,  2 ,  cyc l opentyl ) ;  3 . 55 ( s ,  3 ,  - CH3 ) ;  
7 . 4 5 ( d ,  2 ,  Ar - H ) ; 8 . 1  ( d ,  2 ,  Ar - H ) . Anal . Ca l cu l ated for 
C I 3 H 1 S N04 : C ,  6 2 . 6 2 ;  H ,  6 . 07 ;  N ,  5 . 64 .  Found : C ,  62 . 6 3 ;  H ,  6 . 1 1 ;  N ,  
5 . 60 .  
Et hyl l - (p- N i t rophenyl )cyc l opentanecarboxyl ate ( 1 1 7b) . To a 
s o l u t i on o f  3 . 5  g ( 1 4 . 2  mmol ) of l - (p - n i t rophenyl } cycl opentanecar­
boxyl i c  ac i d  ( 1 1 4 )  in  2 5  mL sod i um -dr i ed benzene was  added 2 5  mL of 
t h i onyl c h l o r i d e ,  and the  so l ut i on was  heated at refl ux  for 12  h .  
The  m i x ture was  concentrate.d at  reduced pre s s ure and then reconcen -
trated w i t h three 2 5  mL port i on s  of benzene . The re s i due was  
d i s s o l ved i n  4 0  mL of  benzene and decol or i zed w i t h  charcoal . The 
s o l u t i on was  then  heated at refl ux w i t h  7 5  mL of  anhydrous  ethanol  
for 1 2  h .  The  s o l u t i on was  then  coo l ed to  room temperature . 
Evaporat i on of  the  so l vent under reduced pre s s u re y i e l ded an amber 
o i l . The  o i l  wa s  d i st i l l ed under vacuum y i e l d i ng 2 . 8  g ( 7 5%) of  an 
amber o i l ,  bp 1 1 0 - 1 1 5  C/0 . 2 5 mm . I R  ( n e at ) : 1 7 20 cm- 1 ( C =O ) . l H  
NMR ( CDC 1 3 ) :  � 1 . 2 ( t ,  3 ,  - OCH2 CH3 ) ;  1 . 85 ( broad , 6 ,  cpentyl ) ;  
2 . 4 - 2 . 8  ( compl ex m ,  2 ,  cyc l opentyl ) ;  4 . 1  ( q ,  2 ,  OCH2 CH3 ) ;  7 . 4 5 ( d ,  2 ,  
Ar - H ) ; 8 . 1 5 ( d ,  2 ,  Ar - H ) . Anal . Cal cu l ated for :  C I 4 H 1 7 N04 : C ,  
63 . 86 ;  H ,  6 . 5 1 ; N ,  5 . 3 2 .  Found : C ,  63 . 97 ;  H ,  6 . 56 ;  N ,  5 . 28 .  
Methyl l - (p-Am i nophenyl )cycl opentanecarboxyl ate ( 1 18a) .  A 
met hanol  s o l u t i on ( 60 mL )  of 2 . 2 5 g ( 9 . 0  mmol ) of 1 1 7a was  catal yt i ­
ca l l y  reduced w i t h 1 0% pl a t i num on carbon under a hydrogen atmosphere 
on a Parr apparat u s . When the theoret i ca  1 quant i ty of hydrogen had 
been absorbed , the  cata l y s t  was removed by f i l t ra t i on . The so l vent 
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was  evaporated under reduced pre s s u re .  Recrysta  1 1  i zat  i on o f  the  
re s i due  from met h anol  y i e l ded 1 . 4 5  g ( 7 7%) of I l Ba a s  wh i te need l es ,  
mp 1 29 . 5 - 1 3 1  C .  I R  ( n ujo 1 ) :  3 2 1 0  cm- I , 3360  cm- I , 3430 cm- I  ( - NH2 ) ;  
1 7 1 0  cm- I  ( C =O ) . I H NMR ( COC1 3 ) :  � 1 . 7 ( broad , 6 ,  - CH2 - ) ; 2 . 3 - 2 . 7  
( comp l ex m ,  2 ,  cyc 1 0pentyl ) ;  3 . 5  ( s ,  3 ,  - OCH3 ) ;  6 . 6  ( d ,  2 ,  Ar - H ) ; 
7 . 1 5 ( d ,  2 ,  Ar- H ) . Anal . Ca l cu l ated for C I 3 H 1 7 N02 : C ,  7 1 . 2 0 ;  H ,  
7 . B2 ; N ,  6 . 3 9 .  Found : C ,  7 1 . 2 6 ;  H ,  7 . BB ;  N ,  6 . 34 . 
E thyl 1 - (p- Ami nopheny1 )cyc1 0pentanecarboxy1 ate ( l l Bb) . An 
ethano l  so l u t i on ( 6 0  mL )  of  2 . 2  g ( B . 4  mmo 1 ) of 1 1 7b  was cata l y t i ca l ­
l y  reduced w i t h  1 0% p l a t i num on carbon under a hydrogen atmosphere on 
a Parr apparat u s . When the theore t i ca l  quant i ty of  hydrogen had been 
absorbed , the cata l yst  was removed by f i l trat i on .  The so l vent was 
evaporated under reduced pre s sure , y i e l d i ng a yel l ow o i l .  The o i l  
was  d i s t i l l ed under vacuum , y i el d i ng 1 . 46  g ( 7 5%)  o f  a yel l ow o i l ,  bp 
1 2B - 1 3 2  C/0 . 2  mm , wh i c h so l i d i f i ed on s t and i ng to yel l ow pr i sms , mp 
6 2 - 63 C .  I R  ( neat ) : 3 2 1 0 ,  3360 , 3430 cm- I ( - NH2 ) ;  1 7 1 0  cm- I  ( C=O ) . 
I H NMR ( COC1 3 ) :  � 1 . 1  ( t ,  3 ,  - OCH2 CH3 ) ;  1 . 7  ( broad s ,  6 ,  - C H2 - ) ;  
2 . 3 - 2 . 7  ( comp l ex m ,  2 ,  cyc 1 0penty1 ) ;  4 . 0  ( q ,  2 ,  - OCH2 CH3 ) ;  6 . 5  ( d ,  2 ,  
Ar - H ) ; 7 . 0 5 ( d ,  2 ,  Ar- H ) . Anal . Ca l cul ated for C I 4 H I 9 NOz : C ,  72 . 0 7 ;  
H ,  B . 2 1 ; N ,  6 . 00 .  Found : C ,  72 . 1 7 ;  H ,  B . 2 2 ;  N ,  5 . 99 .  
M e t hyl 1 - [p ( 1 - Pyr ro 1 i d i ny1 ) ph e nyl ] eyc 1 ope n t a n e c a r b o xy1 ate  
( 1 1 9 a) . To a so l ut i on of  2 . 7  g ( 1 2 . 3  mmo l ) 1 1 8a i n  40 mL of dry DMF , 
con t a i n i ng 3 . 0  g of  anhydrous  pot a s s i um carbonate , under a n i trogen 
atmo sphere , was added 2 . 66 g ( 1 2 . 3  mmo l ) of  1 , 4 - d i bromobut ane 
dropw i se  over a 1 5  m i n per i od .  The react i on m i xture was then s t i rred 
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at  7 5 - 80 C for 1 2  h .  The so l ut i on was  poured over crus hed i ce ,  and 
the prec i p i tate  was  col l ected by f i l trat i on .  Recrysta l l i zat i on from 
met h anol  y i e l ded 2 . 1  9 ( 63%) 1 1 9a  as l i gh t  tan  need l e s , mp 1 1 5 - 1 1 7  
C .  I R  ( n ujol ) :  1 7 1 0  cm- 1  ( C = O ) . l H  NMR ( CDC 1 3 ) :  � 1 . 7 ( broad , 6 ,  
cpentyl ) ;  1 . 9 ( q ,  4 ,  N - CH2 - ) ; 2 . 3 - 2 . 8  ( compl ex m ,  2 ,  cyc l opentyl ) ;  
3 . 2  ( t ,  4 ,  N - CH2 CH2 ) ;  3 . 55 ( s ,  3 ,  - OCH3 ) ;  6 . 5  ( d ,  2 ,  Ar - H ) ; 7 . 2  ( d ,  
2 ,  Ar - H ) . Anal . C a l cu l ated for C 1 7 H2 3 N02 : C ,  74 . 69 ;  H ,  8 . 48 ;  N ,  
5 . 1 2 .  Found : C ,  74 . 55 ;  H ,  8 . 52 ;  N ,  5 . 06 .  
E t hyl 1 - [p- (1 - Pyrro 1 i d i nyl ) ph e nyl 1 cyc l ope n t an e c a r boxyl a te  
( 1 1 9b) . To a s o l ut i on of  1 . 6 9 ( 6 . 9  mmol ) of  1 1 8b i n  2 5  mL of  d ry 
DMF , conta i n i ng 2 . 0  9 anhydrou s potas s i um carbonate , was  added 
d ropwi s e  1 . 5  9 ( 6 . 9  mmol ) of 1 , 4 - d i bromobutane i n  5 mL of DMF over a 
1 5  m i n per i od . The  reac t i on mi xture was  s t i rred under n i t rogen at 
7 5 - 80 C for 1 2  h .  The so l ut i on was  then poured over crushed i ce ,  
and  the  prec i p i tate was  col l ected by f i l trat i on .  Recrysta l l i z at i on 
from met hanol  y i e l ded 1 . 3 9 ( 66%) of  � a s  a wh i te so l i d ,  mp 78 - 79 
C .  I R  ( n ujo l ) :  1 7 2 0  cm- 1  ( C=O ) . l H  NMR ( CDC 1 3 ) :  & 1 . 2 5  ( t ,  3 ,  
- CH2 CH3 ) ;  1 . 7 - 2 . 2  ( m ,  1 0 ,  - CH2 - ) ;  2 . 5 - 2 . 8  ( m ,  2 ,  - C H2 - ) ;  3 . 3  ( t ,  4 ,  
- N - CH2 ) ;  4 . 1 ( q ,  2 ,  - CH2 CH3 ) ;  6 . 5  ( d ,  2 ,  Ar- H ) ; 7 . 2  ( d ,  2 ,  Ar - H ) . 
Ana l . Ca l cu l ated for C I 8 H2 S N02 : C ,  7 5 . 2 2 ;  H ,  8 . 7 7 ;  N ,  4 . 87 . Found : 
C ,  7 5 . 3 4 ;  H ,  8 . 79 ;  N ,  4 . 86 . 
2 - ( D i e t hyl am i n o) e t hyl l - [p- ( l - Pyr ro l i d i nyl )phenyl lcyc l open -
t anecarboxyl ate Hydroch l or i de (57c) . A m i xture of  4 . 0  9 ( 1 4 . 7  mmol ) 
of  1 1 9 a ,  3 . 43  9 ( 29 . 3  mmol ) of fre s h l y  d i s t i l l ed 2 - d i ethyl am i noetha ­
n o l  a n d  0 . 1  9 sodi um i n  1 2 5  m L  of dry to l uene w a s  heated under refl ux 
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w i t h  s t i rr i ng for 20 h ,  dur i ng wh i c h mas s i ve prec i p i t at i on occurred . 
After the  reac t i on was  cool ed to  room temperature , the  so l i d  was 
co l l ected by f i l trat i on ,  was hed w i t h  benzene and d i s s o l ved i n  water . 
The  to l uene s o l ut i on was extracted three t i mes  w i t h  1 00 -mL port i on s  
of  1 0% HCl  so l ut i on .  T he  aqueous  l ayer was  made bas i c  w i t h  the 
add i t  i on  of so l  i d  sod i  um carbonate i n  port i on s , combi ned w i th  the  
aqueous  so l ut i on of  the  prec i p i tate , and  extracted four  t i me s  w i th  
d i ethyl  ether ( 50 mL port i on s ) .  The ether extract was dr i ed over 
anhydro u s  magnes i um s u l fate . The hydroch l o r i de s a l t was prepared by 
t h e  s l ow add i t i on of  an ethereal so l ut i on of  g aseous  HCl  to the  base 
i n  d i ethyl  ether . Recrysta l l i zat i on from ch l oroform - ether y i el ded 
2 . 7 5 g ( 4 9%) of 57c as a tan so l i d ,  mp 208- 2 1 1  C .  IR ( n ujo l ) :  1 7 20 
cm- 1 ( C=O ) . I H NMR ( 02 0  . C F3 COOO ) : � 1 . 2  ( t ,  6 ,  - CH2 CH3 ) ;  1 . 8 
( broad , 6 ,  - cpentyl ) ;  2 . 0- 2 . 4  ( m ,  6 ,  - CH2 ) ;  3 . 1  ( q ,  4 ,  - CH2 CH3 ) ;  
3 . 2 - 3 . 8  ( m ,  6 ,  - N - CH2 ) ;  4 . 2 - 4 . 5  ( m ,  2 ,  - 0 - CH2 ) ;  7 . 4  ( s ,  4 ,  ArH ) . 
Ana l . 
Found : C ,  6 6 . 78 ;  H ,  8 . 9 5 ;  N ,  7 . 07 .  
Meth  yl 1 - [p- (1- Tet razo 1 y 1 ) phen yl ] cyc 1 opentaneca rboxyl ate (120) . 
To a s t i rred so l ut i on of  2 . 1  g ( 9 . 6  mmo l ) of 1 1 8a i n  20 mL of g l ac i a l 
acet i c  ac i d ,  at  70 - 7 5  C under n i trogen , was added 1 . 42 g ( 9 . 6  mmol ) 
of  fresh l y  d i s t i l l ed ethyl  orthoformate i n  5 mL of g l ac i a l acet i c  
ac i d .  The m i xture was s t i rred for 4 h at 70 - 7 5  C .  Then , 1 . 87 g 
( 28 . 8  mmo l ) of  s od i um az i de was added port i onwi se , and the react i on 
was  con t i nued for an add i t i o na l  24 h .  After cool i ng to room tempera­
ture , the  so l ut i on was poured i n to 2 50 mL of  i ce wate r .  The prec i p i ­
t ate  was col l ected by f i l trat i on and recrysta l l i zed from methanol , 
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y i e l d i ng 1 . 7  g ( 6 5%) of 1 20 as l i ght  yel l ow needl e s ,  mp 1 1 5 - 1 1 8 C .  
I R  ( n ujo l ) :  1 7 1 0  cm- 1  ( C=O ) . I H NMR ( CDC 1 3 ) :  � 1 . 7 ( broad s ,  6 ,  
cpentyl ) ;  2 . 3 - 2 . 6  ( comp l ex m ,  2 ,  cyc l opentyl ) ;  3 . 5  ( s ,  3 ,  - OCH3 ) ;  
7 . 2 - 7 . 8  ( compl ex m ,  4 ,  Ar - H ) ; 9 . 7  ( s ,  1 ,  Tet - H ) . Anal . Ca l cul ated 
for C 1 4 H 1 6 N4 02 : C ,  6 1 . 74 ;  H ,  5 . 9 2 ;  N ,  20 . 58 .  Found : C ,  6 1 . 64 ;  H ,  
6 . 1 3 ;  N ,  2 0 . 53 .  
l - (p-Am i nophenyl )cyc l opentanecarboxyl i c  ac i d  ( 1 2 1 ) .  A methanol  
so l ut i on ( 60 mL ) of  5 . 1  g ( 22 . 4  mmol ) of 1 1 4  was cata l yt i ca l l y  
reduced w i t h  1 0% p l at i n um o n  carbon under a hydrogen atmo sphere o n  a 
Parr apparatu s . When the  t heoret i ca  1 quan t i ty of hydrogen had been 
absorbed , t h e  cata l y s t  was removed by f i l trat i on .  The so l vent was 
removed under reduced pre s s ure . Recrysta l l i zat i on of  the  re s i due 
from methano l  y i e l ded 4 . 2  g ( 9 1%)  of  1 2 1  a s  l i gh t  tan need l e s ,  mp 
1 9 5 - 1 98 C (L  i t 1 8 4 mp 1 96 - 1 9 9  C ) . I H  NMR ( CDC 1 3  - C F3 COOD ) : b 1 . 85 
( broad s ,  6 ,  - CH2 - ) ; 2 . 4 - 2 . 7  ( comp l ex m, 2 ,  cyc l openty l ) ;  3 . 2  ( broad 
fl at , 2 ,  - NH2 ) ;  7 . 5 5 ( d ,  2 ,  Ar- H ) ; 7 . 9  ( d ,  2 ,  Ar-H ) ; 1 1 . 6 ( broad , 1 ,  
- COOH ) . 
2 - (D i e t hyl am i n o ) e t hyl l - [p-( l - Tetrazolyl )phenyl lcyc l opent ane 
carboxyl ate  Hyd roch l o r i de (57b) . To a s t i rred so l u t i on of  3 . 8  g 
( 1 1 . 2  mmo l ) of  57a  i n  40 mL of g l ac i a l acet i c  ac i d ,  at 7 0 - 7 5  C under 
n i t rogen , was  added 1 . 7 g ( 1 1 . 2  mmo l ) of fre s h l y  d i s t i l l ed ethyl 
orthoformate i n  10 mL of g l ac i a l acet i c  ac i d .  The m i xture was 
s t i rred for 4 h .  Then 2 . 2  g ( 3 3 . 6  mmo l ) of  so l i d  NaN3 wa s added 
port i onwi s e ,  and the  reac t i on was con t i nued for 48 h .  After cool i ng 
the  so l u t i on on an i ce bath , the  m i xture was f i l tered . The col l ected 
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so l i d  was  washed w i t h  20  mL of  ether . The so l vents  were removed 
under reduced pre s sure to  y i el d  an orange o i l . Th i s  o i l was d i s ­
s o l ved i n  5 0  mL o f  d i ethyl ether and extracted w i t h  three 50 -mL 
port i on s  of  water . The ether l ayer was dr i ed over anhydrous magne s i -
um s u l fate . The dry i ng agent was removed by fi l trat i on .  The 
hydroc h l or i de s a l t was prepared by treat i ng an ether  so l ut i on of the  
base  w i t h  g a seous  HC1 . Recrysta l l i z at i on from ch l oroform - d i ethyl 
ether  y i e l ded a crude yel l ow so l i d .  The crude product  was  twi ce 
chromatographed on a co l umn of s i l i ca gel , CHC1 3 : methanol , 9 : 1 ,  a s  
e l uen t , t o  g i ve a yel l ow compound , mp  1 54 - 1 56 C .  I R  ( n ujol ) :  1 7 20  
cm- 1 ( C=O )  no NH abs . l H  NMR  ( Oz O ) : b 1 . 1 - 1 . 4  ( m ,  6H ) ; 1 . 6 - 2 . 2  
( broad m ,  8H ) ; 2 . 5 - 3 . 5  ( m ,  6H ) ; 4 . 3 - 4 . 5  ( m ,  2H ) ;  7 . 3  ( d ,  2 H ) ; 8 . 0  ( d ,  
2 H ) . Ana l . Ca l cu l ated for C 1 9 Hz 8 Ns Oz C l  
. Hz O :  C ,  55 . 4 0 ;  H ,  7 . 34 ; N ,  
1 7 . 00 .  Found : C ,  5 5 . 1 4 ;  H ,  7 . 4 1 ; N ,  1 7 . 04 .  
p- (Tr i fl uoromethyl )benzyl Brom ide  ( 1 23) . F i ve grams ( 28 . 4  mmol ) 
of  4 - ( t r i fl uoromethyl ) benzyl a l cohol  i n  1 0  mL of  48% HBr was s t i rred 
at refl ux for 1 2  h .  The so l ut i on was cool ed to room temperat ure , 
poured over 50 mL of  crushed i ce and extracted w i t h  three 50 mL 
port i on s  of  ethe r .  T h e  ether l ayer was dr i ed over anhydrous magne­
s i um s u l fate . The dry i  ng agent was removed by f i  l t rat i on and the 
so l vent  concentrated at  reduced pres sure to y i e l d  an o i l . The o i l  
was d i st i l l ed under reduced pres sure to y i e l d  6 . 4 2 g ( 96%) o f  lZl as 
a c l ear  o i l ,  bp 3 5 - 38 C/0 . 5  mm ( L i t 1 8 9 bp 6 5 - 66 C/5 mm ) . IR  ( n eat ) 
cm- 1 no OH abs . l H  NMR ( COC 1 3 ) :  b 4 . 6  ( s ,  2 ,  CHz ) ;  7 . 2  ( d ,  2 ,  ArH ) ; 
7 . 9  ( d ,  2 ,  ArH ) . 
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p- (Tri fl uoromethyl)phenyl aceton i tr i l e  (124) . To a so l ut i on of 
6 . 8  9 ( 28 . 4  mmo l ) of  ill in  40 mL of  7 5% ethanol  was added 4 . 2  9 
( 85 . 6  mmo l ) of  NaCN i n  1 0  mL of 7 5% ethanol . The react i on mi xture 
was  s t i rred for 1 2  h at  room temperature , poured i nto  about 200  mL of 
i ce water and extracted w i t h  three 50 mL port i on s  of  CHC1 3 .  The 
CHC 1 3  l ayer was  dr i ed over anhydrous magnes i um s u l fat e .  The dry i ng 
agent was  removed by f i l trat i on .  The so l vent was removed at  reduced 
pre s s ure to  y i e l d  a crude so l i d .  Recrysta l l i zat i on o f  the  product 
from petrol eum ether y i e l ded 4 . 8  9 ( 92%) of 1 24 a s  a wh i te so l i d ,  �p 
4 0 - 4 2  C ( L i t 1 9 0 mp 4 0 - 4 1  C ) . IR  ( n ujo l ) :  2220 cm- 1 ( C=N ) . l H  NMR 
( CDC 1 3 ) : � 3 . 8  ( s ,  2 ,  - CH2 ) j  7 . 4  ( d ,  2 ,  Ar - H ) j  8 . 0  ( d ,  2 ,  ArH ) . 
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